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Trypanosoma brucei undergoes developmentally regulated morphological 
and biochemical changes during its life cycle, being transmitted between the 
mammalian host and the tsetse fly. It is generally recognized that cellular 
responses to environmental changes are mediated through signalling 
pathways, but our understanding of trypanosome signal transduction during 
differentiation is limited.   
Protein Tyrosine Phosphatase 1 (TbPTP1) is the one of the few factors 
identified to be responsible for differentiation from stumpy to procyclic form 
parasite, whereby TbPTP1 inhibition stimulates transition to insect-form cells 
(Szoor et al., 2006).  
In order to characterize the TbPTP1 signalling pathway, a substrate-
trapping approach was used, which identified a phosphatase TbPIP39 as 
substrate of TbPTP1. TbPIP39 interacts with, and is dephosphorylated by 
TbPTP1 in stumpy form cells. Additionally, it has been shown that upon 
citrate/cis-aconitate (CCA) treatment, phosphorylated TbPIP39 localizes to 
the parasite glycosomes, the organelles responsible for bloodstream forms 
metabolism, thereby promoting cellular differentiation to procyclic forms 
(Szoor et al., 2010). With the aim of further dissecting the TbPTP1 signalling 
pathway, the substrate-trapping approach was used, which identified one 
novel TbPTP1 substrate candidate, potentially involved in regulation of 
differentiation.  
In addition, the effect of other differentiation triggers, namely protease 
treatment or mild acid exposure, on the level of TbPIP39 phosphorylation 
was analyzed, to determine whether these stimuli operate via the same 
TbPIP39–dependent pathway as CCA signalling. Specifically, changes in the 
phosphorylation status of TbPIP39 were visualized and quantitated by the 
use of antibodies detecting either TbPIP39 or the Y278 phosphorylated form 
of TbPIP39 generated during CCA-dependent differentiation. Both protease 
treatment and mild acid exposure generated a different pattern of TbPIP39 
phosphorylation, thus suggesting a different mechanism of action than CCA. 
Finally, the possibility of using piggyback strategies targeting TbPTP1 was 
investigated, as a means to decrease the number of the fly-transmissible 
 IX 
stumpy form cells in the bloodstream, thereby controlling parasite 
transmission. For this purpose, natural and synthetic inhibitors of human 
PTP1B were tested against the parasite enzyme, since they are being 
developed by pharmaceutical companies for the treatment of diabetes and 
obesity. The compounds tested showed a moderate in vitro inhibitory activity 
against recombinant TbPTP1 and mainly a non-competitive type of 
inhibition, similarly to that observed for human PTP1B. However, none of 
the compounds showed in vivo specificity for TbPTP1, indicating that further 
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1- Introduction 2 
1.1. Trypanosoma brucei sp. classification and evolution 
 
Trypanosoma brucei is a unicellular eukaryote belonging to the genus 
Trypanosoma, family Trypanosomatidae, order Kinetoplastida and phylum 












Species Trypanosoma brucei 
  
Sub-species T. brucei brucei 
 
Table 1.1 Trypanosoma brucei classification. Schematic diagram showing the scientific 
classification of Trypanosoma brucei spieces. 
 
All the species belonging to the genus Trypanosoma are parasites of vertebrate 
bloodstream and are transmitted by bloodsucking invertebrates, such as 
tsetse flies, fleas or leeches. Trypanosomes can be divided into two groups, 
according to their mode of transmission: by inoculation (Salivaria) or by 
contamination through feces of the insect vector (Stercoraria)  (Haag et al., 
1998). Salivarian trypanosomes comprise, among others, T. brucei, T. 
equiperdum, T. evansi, whereas stercorarian trypanosomes include several 
clades: T. cruzi (transmitted by triatomine bugs), the rodent  (T. musculi and 
T. lewisi, transmitted by fleas), the avian (transmitted by black flies and 
hippoboscid flies), the amphibian (transmitted by leeches), the reptilian and 
the fish trypanosomes (Haag et al., 1998; Simpson et al., 2006). 
 
 
1- Introduction 3 
1.2. Burden and epidemiology of African Trypanosomiasis 
 
 
The Trypanosoma brucei (T. b.) species include the subspecies of T. b. brucei, T. 
b. gambiense and T.b. rhodesiense, and are transmitted by different subspecies 
of tsetse fly (of the Glossina genus), which are found only in sub-Saharan 
Africa, between 14°N and 20°S (from Senegal in the west, to Somalia in the 
east) (WHO, 1998). T. b. brucei, as well as T. congolense and T. vivax, infect 
wild and game animals, particularly affecting African cattle with a wasting 
disease called nagana (or n’gana), which is estimated to cost livestock 
producers and consumers  US $ 340 million/year in Africa (Mulumba, 2003). 
Such loss of food, manure and transport has a serious impact on the rural 
poor in Africa, whose income is often based exclusively on livestock.  
T. b. gambiense and T. b. rhodesiense infect animals and humans, causing 
Human African Trypanosomiasis (HAT) or sleeping sickness; HAT, together 
with leishmaniasis, represent the major protozoan infections of sub-Saharan 
Africa, accounting for 1.5 million of disability-adjusted life years 
(DALYs)(Hotez et al., 2009), a measure of diseases burden, defined as the loss 
of the equivalent of one year of full health (Murray, 1994). Sleeping sickness 
is found in 36 African countries, with more than 250 discrete foci detected, 
particularly in rural areas. In 2006 an incidence of 50,000-70,000 new cases 
per year was estimated from detected cases (calculated using a ratio of 
detected over actual cases of 1:3-4) (WHO, 2006a), but a drop to 10,000 
detected new cases, the lowest level in the last 50 years, has been reported in 
2010, due to the strengthening of the control and surveillance efforts of the 
national sleeping sickness programmes (WHO, 2010). Consequently, 
elimination is nowadays considered a reasonable aim in countries reporting 
less than 100 cases per year (Welburn et al., 2009).  
HAT describes not one but two separate diseases: Gambiense and 
Rhodesiense HAT, which are characterized by different geographical 
distribution, epidemiology and clinical features (Fevre et al., 2006a). 
Gambiense sleeping sickness represents 90% of HAT cases and it is found in 
west and central Africa, particularly in the war-torn countries of Angola, 
Central African Republic, Democratic Republic of Congo, southern Sudan 
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and western part of Uganda, with most of the new cases occurring in DRC 
(Figure 1.1). In contrast, the rest of Uganda and the eastern African states of 
Kenya, Tanzania, Zambia, Malawi and Mozambique, are afflicted by 

























Figure 1.1 Prevalence of HAT. The African countries mainly affected by HAT are listed, 
according to the data reported (WHO, 2006a); the corresponding map is showing beneath 
(from Fevre et al., 2006) where red, orange, yellow and green indicate countries with very 
high, high, low and sporadic HAT frequencies, respectively 
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1.3. Trypanosomiasis control strategies 
 
Several control strategies exist for the control of African trypanosomiasis: 
from animal and human-targeted interventions to vector control methods. 
These different approaches are complementary and their use is dictated by 
the epidemiology of the disease and by the local ecological and social 
environment (Torr et al., 2005; Fevre et al., 2006a).  
Nowadays, animal-targeted interventions and vector control are the main 
strategies adopted for the control of Rhodesiense HAT (Welburn et al., 2001). 
Several drugs, such as diminazene aceturate, homidium bromide and 
isometamidium chloride, are currently widely employed in Africa for 
curative or prophylactic animal chemotherapy, but their availability and 
improper use has caused cases of resistance, which might become a serious 
issue in the near future (Geerts et al., 2001). For gambiense HAT, human-
targeted activities are more important, with active case finding combined 
with drug treatment of positive cases, being the cornerstone of disease 
control (Ekwanzala et al., 1996) 
 
1.4. HAT pathology  
 
The clinical signs and symptoms of gambiense and rhodesiense HAT are 
classified according to the stage of the disease: first or heamatolymphatic 
stage, when the parasite is found only in the blood, and second or 
meningoencephalitic stage, when the parasite is found also in the 
cerebrospinal fluid. Signs and symptoms of the two forms of HAT are 
generally the same, but T. b. rhodesiense form causes an acute infection, 
developing within days and leading to death after 6-8 months if untreated; 
by contrast Gambiense HAT is a chronic infection, which can take months or 
even years before the appearance of any sign or symptoms.  
In the first stage of sleeping sickness patients develop mainly common 
complaints such as fever, muscle ache, headache, joint pain and other signs 
of inflammation, which only partly correlate to the level of parasiteamia 
(WHO, 1998).  
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More specific signs are visible in patients in the second stage of the disease, 
particularly sleep disturbances caused by the disappearance of the circadian 
rhythm; alteration of mental state and abnormal reflexes, as well as 
coordination disorder are also typical of the meningoencephalitic stage. Most 
organs, but especially the heart and brain show sign of inflammation, which 
can lead to coma and death if untreated. Although the molecular 
mechanisms of cerebral damage are not completely understood, studies on 
infected mice seem to indicate that cytokines play an important role 
(Lundkvist et al., 2004).  
 
1.5. HAT treatment 
1.5.1.  Naphthylamine derivatives 
  
The first compound found to be effective against trypanosomes came from 
the synthetic dyestuff industry, with its most influential protagonist being 
Paul Ehrlich, the father of modern chemotherapy (Bosch et al., 2008). In 1901 
Ehrlich identified a sulphated naphthylamine derivative named Nagana Red, 
as a dye displaying trypanocidal activity, which was then further modified 
into Trypan Red and then in Trypan Blue (Figure 1.2 A) by others, including  
the German pharmaceutical company Bayer. Trypan Blue was found to be  
particularly effective against the parasite but had the limitation of staining 
the skin of the infected animal, and thus was unusable to treat humans.  
Only in 1917, Bayer identified a colourless but effective compound (Bayer 
205), named Germanin (Dressel et al., 1961) and later renamed suramin 
(Figure 1.2 A), which is still in use today for the treatment of early stage 
rhodesiense HAT.  
The mode of action of suramin has not been definitely proven. Indeed, 
although it has been shown to inhibit glycerolphosphate oxidase and other 
glycolytic enzymes (Fairlamb et al., 1977), it is believed to have additional 
targets due to its six negative charges, which can easily form strong 
electrostatic interactions with a variety of enzymes (Fairlamb et al., 1977; 
Wierenga et al., 1987; Barrett et al., 2007). 
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1.5.2. Arsenical drugs 
 
In parallel to the development of naphthlylamine derivatives, arsenical drugs 
were also found to be effective against trypanosomes, particularly Atoxyl® 
(Figure 1.2 B)  (Thomas, 1905), which was used in clinical practice in 1905 to 
treat sleeping sickness; however, the treatment required high doses of the 
compound and often resulted in blindness due to atrophy of the optic nerve 
(Bosch et al., 2008). In 1938 the compound melarsen (Figure 1.2 B) was 
synthetized from Atoxyl® by addition of a melamine moiety, which resulted 
in increased trypanocidal activity but increased and retained toxicity against 
the optic nerve. In order to limit the severe side effects of melarsen, the drug 
was combined with dimercaprol, an arsenic antidote developed during 
World War II to protect against poisoning by arsenic gas (Friedheim, 1949); 
the resulting product was melarsoprol (Figure 1.2 B), the only drug for the 
treatment of second stage of T. b. rhodesiense HAT (Table 1.2), which, 
although lacking melarsen’s toxic effect on the optic nerve, results in reactive 
encephalopathy in 5-10 % of the patients (WHO, 1998).   
Melarsoprol has been shown to cause parasite lysis (Meshnick et al., 1978), 
likely due to inhibition of glycolysis (Van Schaftingen et al., 1987) and to 
interact with trypanothione (Fairlamb et al., 1989), however how these 
interaction affect the trypanocidal activity is not clear.  
 
1.5.3.  Diamidines 
 
In the 1940s the hypoglycaemic drug synthalin (Figure 1.2 C) was found to 
cure trypanosome infection from mice and rats, and it was believed to do so 
by lowering the glucose levels in the blood. It was later noticed that the 
compound had a direct effect on the parasite itself, thus discovering the 
trypanocidal effect of diamidines (Lourie et al., 1937; Steverding, 2010). 
Among the different diamidine derivatives, pentamidine (Figure 1.2 C) was 
found to have more limited side effects, and thus employed for the treatment 
of first stage T. b. gambiense and it is nowadays still in use (Soeiro et al., 2005).  
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Pentamidine enters the cell through the P2 amino-purine transporter, also 
used by melarsoprol, and the low and high affinity pentamidine transporters 
(De Koning, 2001). Although the drug preferentially accumulates in the 
kinetoplast in Leishmania, where it interacts electrostatically with the 
mitochondrial DNA (Basselin et al., 1998), its definite mode of action has not 
been characterized. However, it has been suggested that pentamidine is 
likely to exert its effect from inhibition of multiple cellular targets, due to its 
high positive charge and concentration (Denise et al., 2001). 
The trypanocidal activity of pentamidine is high, with an in vitro IC50 of 1-10 
nM (Miezan et al., 1994), however it is not readily absorbed  and thus 
requires intramuscular injections. 
Another diamidine derivative was also identified as having good 
trypanocidal activity (Das et al., 1977) but was not pursued further at that 
time.  More recently, the same compound was synthesized as the prodrug, 
pafuramidine maleate (or compound DB289) (Figure 1.2 C), in order to 
increase its intestinal absorption, and in 2007 it was the first oral drug for 
HAT to ever enter clinical trials; however, it then failed phase I studies due 




Nifurtimox (Figure 1.2 D) was developed in the 1960s by the German 
company Bayer and was then discovered to be effective for the treatment of 
Chagas disease (Van den Bossche, 1978), caused by Trypanosoma cruzi, by 
causing oxidative damage to the parasite (Docampo et al., 1986). It was then 
found to be effective also against Trypanosoma brucei, although at high doses, 
and it has been used for the treatment of melarsoprol-refractory sleeping 
sickness cases (Pepin et al., 1989).  
More recently, oral nifurtimox has been used in combination with 
eflornithine, resulting in a shorter and easier to administer treatment for 
second stage T. b. gambiense (Priotto et al., 2006; Priotto et al., 2009). 
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1.5.5.  Eflornithine (DFMO) 
 
 Eflornitine (α-difluoromethylornithine or DFMO) (Figure 1.2 E) is the only 
drug for the treatment of sleeping sickness that has been registered in the last 
50 years (Table 1.2). It was initially developed for the treatment of cancer 
and other hyperproliferative diseases in the 1970s (Bey et al., 1978) and 
specifically designed to target the amino acid decarboxylase, ornithine 
decarboxylase (ODC).  
In parallel, DFMO was discovered to be effective against T. b. brucei (Bacchi et 
al., 1980) and treat gambiense sleeping sickness (Van Nieuwenhove et al., 
1985). DFMO was found not to be effective against T. b. rhodesiense, due to an 
almost 5 fold higher turnover rate of the ODC of this species (Iten et al., 
1997). In addition to ODC, DMFO has been reported to target the parasite 
trypanothione, rendering the cells more susceptible to oxidative stress 
(Fairlamb et al., 1987). In 1990 eflornithine was registered for the treatment of 
gambiense sleeping sickness but its expensiveness and lack of market in 
higher income countries caused its manufacturing to cease in 1995. Five years 
later, DMFO was relaunched by the pharmaceutical company Bristol-Myers 
Squibb, as a topical formulation to suppress the growth of facial hair, and a 
donation of the drug to treat sleeping sickness was agreed with the WHO 
(TDRnews, 2001).  
Although DMFO is less toxic than melarsoprol, its relatively poor in vitro 
activity (IC50 of 81-693 µM (Zweygarth et al., 1991)) and pharmacokinetic 
profile, render it far from ideal for the use in tropical environments (Barrett et 
al., 2007). However, until a better substitute will be identified, eflornithine is 
currently the only cure for melarsoprol-refractory HAT cases and used in 
combination with nifurtimox (NECT: “nifurtimox-eflornithine combination 
therapy”, i.e. 7 days of eflornithine followed by 10 days of oral nifurtimox) 
has been shown to decrease by half the length of the treatment and to render 
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1.5.6. Future directions in drug discovery 
 
In the last ten years several new initiatives for drug discovery for sleeping 
sickness and other neglected tropical diseases have been established (Barrett 
et al., 2007), such as the Drug Discovery Unit in Dundee 
(http://www.drugdiscovery.dundee.ac.uk/) and the Drug for Neglected 
Diseases Initiative (DNDi) in Geneva (http://www.dndi.org/index.php), 
which work in partnership with industry and academia to facilitate the 
identification of new lead compounds.  
The first priority set by the DNDi is the development of a safe, effective, 
cheap and practical stage 2 HAT treatment (for both gambiense and 
rhodesiense disease) (DNDi et al., 2009). A new drug, fexinidazole, a 
nitroimidazole compound similar to nifurtimox, which was initially 
discovered in the 1980s (Raether et al., 1983), is currently undergoing clinical 
trials (http://www.dndi.org/portfolio/fexinidazole.html). 


























Figure 1.2 Chemical structure of the different drugs effective against HAT (modified 
from Steverding, 2010). The chemical structures of the main compounds found to be 
effective against Human African Trypanosomiasis are shown, and the family of compounds 
are highlighted: Trypan blue, Suramin, together with Nagana Red and Trypan Red (not 
shown) belong to the sulphated naphthylamine family (A); atoxyl, melarsen and melarsoprol 
belong to the arsenicals group (B); Synthalin, Pentamidine and DB289 (pafuramidine 
maleate) are diamidine derivatives (C); Nifurtimox is a nitrofuran (D) and Eflornithine is 
analogue to the amino acid ornithine (E).  
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1.6.  Trypanosomes cell architecture 
 
1.6.1 The cytoskeleton, flagellum and flagellar pocket 
 
Trypanosomes are unicellular flagellated protozoa about 20 µm long and 
with a diameter of 2 µm (Cross, 1984). Their shape and form are maintained 
by the cellular cytoskeleton which is made up of subpellicular microtubules, 
that are cross linked to each other and to the plasma membrane, forming a 
corset that extends throughout the cell, with the exception of the flagellar 
pocket (Hemphill et al., 1991) (Figure 1.3 number 10). An important 
component of the trypanosome structure is the flagellum, which serves as a 
locomotory organ in bloodstream forms and is essential for parasite 
attachment to the tsetse fly salivary glands (Sherwin et al., 1989). The 
flagellum runs in a left-handed spiral from the posterior to the anterior pole 
along the length of the cell and is attached to the plasma membrane through 
the flagellum attachment zone (FAZ) (Kohl et al., 1999). Two different types 
of structure make up the flagellum: the classical 9+2 microtubule structure 
(axoneme) and the kinetoplastid and euglenoids-specific paraflagellar rod 
(PFR) (Vaughan et al., 2003). 












Figure 1.3 The trypanosome cell architecture. Simplified diagram showing a section of 
the trypanosome cell with the main features highlighted (from Matthews K. R., 2005). 
 
1- Introduction 13 
The axoneme is necessary to allow the correct orientation and directionality 
of the flagellum movements (Branche et al., 2006), similarly the PFR has been 
shown to play a central role in flagellar and cellular motility (Bastin et al., 
1998; Bastin et al., 1999).  
The flagellum enters the cytoplasm of the cell in a small invagination of the 
plasma membrane called the flagellar pocket (FP) (Webster et al., 1993) 
(Figure 1.3 number 3). The FP proximal end is represented by the basal body, 
the nucleation site of the axoneme microtubules, which is physically linked 
to the mitochondrial DNA via the tripartite attachment complex (Ogbadoyi 
et al., 2003); distal to the basal body the collarette can be identified, which is 
represented by the area where the flagellum enters the FP; distal to the 
collarette, the neck of the FP, an electron-dense ring structure, is found, 
which is called flagellar pocket collar (Lacomble et al., 2009).  
The flagellar pocket represents the only site of endo and exocytosis, as the 
subpellicular microtubules are too closely spaced to allow transport vesicles 
to access the plasma membrane (Overath et al., 2004). Importantly, the 
variable surface glycoprotein (VSG), that is recognized by the host IgG, is 
rapidly recycled through the FP and the bound antibodies are concomitantly 
degraded, thus allowing the parasite to evade the immune system (Ferrante 
et al., 1983; Engstler et al., 2007). Endocytosis of the VSGs and of other 
molecules is clathrin-dependent (Allen et al., 2003), as seen in higher 
eukaryotes, however in trypanosomes this process is particularly fast, with  
the whole VSG pool being turned over  in 15 min (Bangs et al., 1997).  
Apart from the FP, the rest of the vesicle trafficking machinery of 
trypanosomes resemble that of other eukaryotes, comprising of endosomes, 
lysosomes, the endoplasmic reticulum (ER) and the Golgi complex. 
However, the secretory and endocytic organelles display a more compact 
localization compared to higher eukaryotes, being found between the 
nucleus and the kinetoplast, with the exception of the ER, which is 
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1.6.2. The mitochondrion and the glycosomes 
 
The biggest and one of the most developmentally regulated intracellular 
structure found in trypanosomes is the mitochondrion (Figure 1.3 number 9). 
The mitochodrion is a single elongated organelle that runs the entire length 
of the cell, in contrast to mammalian cells, which contain thousands of them 
(Vickerman et al., 1988).  
In bloodstream form trypanosomes, the mitochondrion is underdeveloped 
and devoid of cristae, whereas in the insect stage cells this organelle is fully 
functional and it is used to metabolize amino acids, the main energy source 
found in the fly (Durieux et al., 1991).  
The main energy source of the bloodstream is glucose, which is metabolized 
in the kinetoplastid-specific organelles called glycosomes (Opperdoes et al., 
1977) (Figure 1.3 number 11). There are around 65-250 glycosomes per cell in 
bloodstream forms (Opperdoes et al., 1984) and during parasite development 
the abundance of most of their glycolytic enzymes decreases (Hart et al., 
1987; Parsons, 2004).  
In addition to glycolysis, glycosomes also contain enzymes involved in 
pyrimidine synthesis, purine salvage, ether-lipid biosynthesis and β-
oxidation (Michels, 1989). 
 
1.6.3.  The metabolism of bloodstream and procyclic forms 
 
The mitochondrion and the glycosomes play different but complementary 
roles during parasite development (Figure 1.4) (Vickerman, 1965; Vickerman 
et al., 1988). In the bloodstream glucose is found in millimolar concentrations 
and thus represents the main energy source for the cell, which uses the 
glycolytic enzymes of the glycosomes to convert glucose into 3-
phosphoglycerate. Then 3-phosphoglycerate is converted into pyruvate and 
ATP in the cytosol, which represents the main location of energy production 
for bloodstream form trypanosomes (Besteiro et al., 2005). The pyruvate 
produced from glycolysis is excreted outside the cell (Vickerman, 1965), 
unlike  what happens in mammalian cells, where glucose is metabolized into 
pyruvate in the cytosol and then further transformed into acetyl CoA in the 
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mitochondria (Figure 1.4) (Alberts et al., 2002). As a consequently of their 
active metabolism, glycosomes of bloodstream forms appear spherical in 
shape, in contrast to the less active and rodshaped glycosomes of insect-form 
parasites (Vickerman, 1985).  
The mitochondrion of bloodstream form cells, although lacking the enzymes 
of Krebs cycle, does possess the nucleus-encoded alternative oxidase (TAO), 
which is important to maintain the glycosomal and glycolytic redox balance, 
together with the glycerol-3-phosphate dehydrogenase (GP-DH), which 
reduces FAD to FADH2 (Clarkson et al., 1989). TAO is the only terminal 
oxidase of the mitochondrial electron transport chain in bloodstream forms 
and is considered to be essential in this life cycle form (Chaudhuri et al., 
2006). Indeed most of the cytochrome oxidase complex is absent in 
bloodstream forms, with the exception of the ATP synthase. Interestingly, the 
ATP synthase of bloodstream forms hydrolyzes ATP, thus working in the 
opposite manner to procyclic forms, and its function is essential to maintain 
mitochondrial membrane potential and parasite survival (Schnaufer et al., 
2005). 
Inside the tsetse fly, glucose found in the bloodmeal disappears within 15 
min of ingestion, and in the insect midgut exist mainly amino acids, 
particularly proline and threonine, which are metabolized in the fully active 
mitochondrion of procyclic forms (Vickerman, 1985). However, insect-stage 
cells can adjust their metabolism in response to the prevailing metabolic 
condition, indeed they still retain some degree of glycosomal activity, with 
some enzymes being expressed only in procyclic forms, such as the NADH-
dependent fumarate reductase, which is responsible for the convertion of 
phosphoenolpyruvate into succinate (Besteiro et al., 2002).  
Moreover, procyclic forms still possess a phosphoglycerate kinase (PGK), the 
enzyme responsible for one of the last steps of glycolysis, but its localization 
is mainly cytosolic, compared to the glycosomal form found in bloodstream 
parasites, thereby creating an additional site of ATP production (Besteiro et 
al., 2005). In addition, the end product of glycolysis, pyruvate, that was 
excreted in bloodstream forms, is imported into the mitochondrion in insect-
form cells, where it is degraded to acetyl CoA and then to acetate, through 
the Krebs cycle (Tielens et al., 1998).  
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In contrast to what happens in mammalian cells, the trypanosomes Krebs 
cycle does not degrade acetyl CoA or amino acids to CO2 but to acetate, 
succinate and alanine. Consequently, the main site of energy generation in 
procyclic forms is the mitochondrial respiratory chain, which is essential for 
parasite survival and growth, in a glucose-depleted environment (Figure 1.4) 
(van Weelden et al., 2003). Acetyl CoA is also converted into acetate through 
a trypanosome-specific cycle comprising an acetate:succinate CoA 
transferase and a succinyl-CoA synthetase (ASCT cycle), which generates 
extra ATP (Van Hellemond et al., 1998).  
The mitochondrial electron transport chain of procyclic forms is composed of 
two terminal oxidases, TAO and the cytochrome oxidase complex (COX), 
although TAO is expressed at lower levels. The presence of both of these 
enzymes seems to be beneficial to the parasite in order to adjust itself to the 
different availability of nutrients and oxygen (Chaudhuri et al., 2006). The 
cytochrome oxidase complex of procyclic forms is similar to the electron 
transport system of mammalian cells, which generates a proton gradient that 
is exploited by the ATP synthase to produce ATP (van Weelden et al., 2003). 
Oxidative phosphorylation is essential for procyclic forms in a glucose-
depleted environment; in contrast, in the presence of glucose, insect-form 
parasites rely mainly on substrate level phosphorylation to produce ATP 


















Figure 1.4 Schematic representation of T. brucei bloodstream and procyclic form 
metabolism.  The main pathways and sites of cellular metabolism are shown in a schematic 
diagram to allow comparison between mammalian cells and T. brucei bloodstream and 
procyclic forms. In mammalian cells glycolysis is carried out in the cytosol, whereas it is 
compartimentalized in the glycosomes in trypanosomes; the Krebs Cycle (TCA) of higher 
eukaryotes is found in the mitochondrion (Mit.) of procyclic forms, although it does not 
convert acetyl CoA into CO2 but only into acetate, succinate or alanine; procylic forms also 
metabolize acetyl CoA into acetate using the trypanosome-specific acetate: succinate CoA 
transferase and a succinyl-CoA synthetase (ASCT cycle). In bloodstream forms the TCA 
cycle is absent, and the mitochondrial respiratory chain lacks most of the components, with 
the exception of the glycerol-3-p dehydrogenase (GP-DH), the alternative oxidase (TAO) and 
the ATP synthase; however, the ATP synthase functions only to maintain the membrane 
potential (Δψm), whereas the main site of ATP production is the cytosol, from the 
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1.6.4. The nucleus and gene regulation 
 
The Trypanosoma brucei nucleus (Figure 1.4 number 1) is estimated to contain 
approximately 3.5 x 107 bp (35 Mb) per haploid genome (Borst et al., 1982), 
harbouring about 9,000 protein coding genes (El-Sayed et al., 2000; Berriman 
et al., 2005). The chromosomes are divided into three classes according to 
their relative mobility on pulsed-field gel electrophoresis: mini-, 
intermediate- and megabase-chromosomes.  
Mini chromosomes are 50-150 Kb, linear DNA sequences, which are about 
100 per cell and consist mainly of  177-bp repeats (Van der Ploeg et al., 1984). 
In addition, many minichromosomes contain a silent copy of the variable 
surface glycoprotein (VSG) genes and are thus highly susceptible to 
recombination events leading to translocation of the VSG gene to an 
expression site (Van der Ploeg et al., 1984; Ersfeld et al., 1999). Intermediate 
chromosomes range from 200 to 900 Kb, lack the repeats found in 
minichromosomes, they seem to serve mainly as a reservoir of VSG 
expression sites (Ersfeld et al., 1999).  The megabase chromosomes are 
diploid (Tait et al., 1989) in the nucleus (whereas the mini- and intermediate 
chromosomes are of uncertain ploidy) and are 11 in number, ranging from 1 
Mb to 6 Mb; they contain protein-coding genes with conserved synteny 
between different stocks but with DNA content varying up to 33% (Melville 
et al., 1998). 
 
Unlike in mammalian cells, in Trypanosoma brucei the majority of gene 
expression is not controlled by transcription initiation, but rather by RNA 
processing. Specifically genes that are next to each other and share a 
common orientation, are co-transcribed and subjected to a trans-splicing 
reaction, which adds a capped RNA of 40 ntd (called splice leader) to the 5’-
end, and are then polyadenylated at the 3’-end (Johnson et al., 1987; Ullu et 
al., 1993). Moreover trypanosomes lack polymerase II promoters for protein 
coding genes, although most protein coding genes are transcribed by 
polymerase II (Clayton, 2002), with the exception of the major surface 
proteins of bloodstream and procyclic forms, VSGs and EPs, which are 
transcribed by polymerase I (Rudenko et al., 1989). RNA polymerase III 
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transcribes most U RNAs (RNAs involved in splicing) and tRNAs (Nakaar et 
al., 1997). 
 
1.6.5.  Surface glycoproteins 
 
Bloodstream form T. brucei possess a thick surface coat made up of a variable 
surface glycoprotein (VSG), which are homodimers attached to the plasma 
membrane through C-terminal GPI (glycosylphosphatidylinositol) anchors 
(Cross, 1984). VSGs are synthesised in the ER and then sorted to the flagellar 
pocket by hydrodynamic forces on the swimming parasite (Engstler et al., 
2007). Once on the surface they are able to bind immunoglobulins of the host, 
which are then constantly internalised to the cell interior through the 
flagellar pocket (Webster et al., 1990). By binding host immuneglobulins, 
VSGs prevent complement-mediated lysis of the parasite (Ferrante et al., 
1983). In addition, these surface coat proteins protect trypanosomes from 
antibody detection; indeed, the VSG coat allows penetration of small 
molecules but restricts the access of the antibodies to the buried VSG epitope, 
found at the C-terminal end of the protein (Cross, 1978; Overath et al., 1994). 
During chronic infections trypanosomes keep changing their VSGs, in a 
process termed antigenic variation, whereby parasites expressing the 
dominant antigen type are killed by the immune response, but some 
trypanosomes survive and proliferate, having switched their VSG. The 
consequence of antigenic variation is the formation of repeated fluctuations 
of parasitaemia in the host (Vickerman, 1978).  
Importantly, antigenic variation is responsible for trypanosome evasion of 
the mammalian immune response and for the inability to develop a vaccine 
against African trypanosomiasis (Vickerman, 1978). The stimulus inducing 
antigenic variation has not been identified, but it is known that the immune 
response plays only a selective and not an inductive role, since VSG 
switching can occur in the absence of an immune response (Myler et al., 
1985).  
 
During parasite development from the bloodstream to the insect form stage, 
the VSG coat is shed and substituted by procyclin proteins, which are 
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detectable around 12-16 hr after differentiation (Roditi et al., 1989). 
Procyclins, or PARPs (Procyclin Acidic Repetitive Proteins) are grouped into 
two classes, according to amino acid repeat motifs of their C-terminal 
domains (Roditi et al., 1987).  
EP-procyclin is characterized by the presence of a glutamic acid and proline 
dipeptide repeat (E-P), whereas GPEET-procyclin contains a pentapeptide 
repeat motif (gly-pro-glu-glu-thr) (Mowatt et al., 1989). The function of these 
coat proteins was believed to be mainly protection from the proteases found 
in the tsetse fly midgut, conferred by their C-terminal domains containing 
the amino acid repeats (Ruepp et al., 1997; Acosta-Serrano et al., 2001). 
However, procyclin null mutant parasites were able to complete the life cycle 
in the tsetse fly and infect mice, thus proving that procyclins are not essential 
for cyclical transmission, although they do seem to provide a competitive 
advantage for the parasite (Vassella et al., 2009). 
 
1.7.  The Trypanosoma brucei cell cycle 
 
The events of the cell division cycle in trypanosomes are timely and orderly 
regulated in order to ensure proper duplication and segregation of the single 
copy organelles: the nucleus, the mitochondrion, the kinetoplast and the 
flagellum (Sherwin et al., 1989). The trypanosome cell cycle can be divided in 
the typical four phases of the eukaryotic cell cycle: G1, S, G2 and M (Figure 
1.5 a).  
During G1 phase the parasite possesses a single nucleus, kinetoplast and 
flagellum (Figure 1.5 b i), and it is this latter one which is first duplicated 
when the cell progresses through S phase, resulting in a cell showing a single 
kinetoplast and nucleus but two flagella (1K1N2F) (Figure 1.5 b ii). 
After the flagellum, the nucleus and kinetoplast are duplicated, and although 
their replication starts at approximately the same time, the kinetoplast DNA 
segregates before the nuclear DNA, thus giving rise to cells with two 
kinetoplasts, one nucleus and two flagella (2K1N2F) (Figure 1.5 b iii) 
(Woodward et al., 1990; McKean, 2003). 
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In early G2 the basal bodies, the site where the flagellum originates, move 
apart causing the segregation of the two flagella and simultaneously of the 
kinetoplasts (Ogbadoyi et al., 2003). 
After G2, nuclear mitosis occurs, during which chromosomes are segregated 
in a microtubule-independent manner, unlike what is observed for higher 
eukaryotes, with maxichromosomes following a different pattern compared 
to minichromosomes (Ersfeld et al., 1997). Nuclear mitosis results in the 
generation of cells possessing two kinetoplasts and two nuclei (2K2N2F) 
(Figure 1.5 b v). Finally, cytokinesis occurs through the formation of a 
cleavage furrow along the longitudinal axis, from the anterior to the 
posterior of the cell, passing between the two flagella, whose FAZs 
(flagellum attachment zones) provide the structural information required to 
position the cleavage furrow (Robinson et al., 1995). At the end of cytokinesis 
the cells possess a single kinetoplast, nucleus and flagellum (1K1N1F) 
(Figure 1.5 b i). The completion of the cycle takes 6 hr in bloodstream forms 
(Vickerman, 1985) and 8.5 hr in procyclic forms (Figure 1.5 a). 
 
Trypanosomes undergo proliferation in most of their life cycle stages 
(slender, procyclic and epimastigote forms) with the exception of 
transmissible stages (stumpy, mesocyclic and metacyclic forms), in which the 
parasites are cell-cycle arrested. Such observations suggested the presence of 
an interplay between the cell cycle progression and initiation of 
differentiation (Matthews et al., 1994). This was supported by the fact that 
stumpy form cells were able to differentiate synchronously, whereas slender 
form cells were not (Ziegelbauer et al., 1990; Matthews et al., 1994). In 
addition, the first cell cycle event after differentiation was found to be S-
phase, which suggested that only parasites in G0/G1 were competent to 
perceive the differentiation signal (Shapiro et al., 1984; Matthews K R, 2004). 
However, once the parasites have initiated differentiation, their cell cycle 
position does not affect the completion of the developmental step, indeed 
inhibition of S-phase did not alter the stumpy transition to procyclic forms 
(Matthews K R, 2004). 
 
 




Figure 1.5 Diagram showing Trypanosoma brucei  (procyclic form) cell cycle (from 
McKean, 2003). Schematic representation of the nuclear and kinetoplast cell cycle stages 
highlighting the timing of the different phases: gap phase 1 (G1), nuclear/kinetoplast 
synthetic phase (SN/SK), gap phase 2 (G2), kinetoplast segregation (D), nuclear mitosis (M), 
apportioning phase (A) –phase during which the basal bodies move apart-, and cytokinesis 
(C)   (a). Diagram of the main morphological changes taking place during the cell cycle (b); 
the number of flagella (F), kinetoplasts (K) and nuclei (N) during the different stages (i-v) is 
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1.8. The Life Cycle 
 
In order to adapt to different environments, being transmitted between 
mammalian hosts by the tsetse fly, African trypanosomes undergo a series of 
programmed morphological and biochemical changes, referred to as the life 
cycle (Vickerman, 1965). The Trypanosoma brucei life cycle includes two 
bloodstream form stages (slender and stumpy forms) and four main insect 
form stages (procyclic, mesocyclic, epimastigote and metacyclic) (Figure 1.6 
and Table 1.2).  
The need to adjust to different energy sources available in the bloodstream 
and fly environments, together with the necessity to evade the host’s 
defence, are the main factors influencing the parasite metabolic and 
morphological changes (Vickerman, 1985). In addition, the transition to a 
different environment affects the cell cycle state, as cell proliferation is 
required to establish the parasite in a new environment, whereas cell cycle 
arrest enables a synchronous differentiation, which helps to protect the 
parasite when they are vulnerable, during transition between environments 
(Table 1.2).   
 
1.8.1. Life in the bloodstream 
 
When a tsetse fly bites the skin of a mammalian host, metacyclic form 
parasites are injected into the dermal connective tissue, pass to the lymphatic 
system and then enter the bloodstream.  
In the bloodstream, long slender forms possess a post nuclear kinetoplast 
(trypomastigote arrangement) positioned towards the posterior of the cell, 
and a flagellum that extends to the anterior of the cell and then becomes free 
(Vickerman, 1985) (Figure 1.6). Slender forms proliferate causing an 
ascending parasiteamia, which peaks when the host develops an immune 
response against the dominant VSG type. After that, most of the slender form 
cells are killed, and are replaced by the non-dividing stumpy forms, thereby 
causing the parasitaemia to decline (Ferrante et al., 1983).  
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Figure 1.6 Schematic diagram showing the trypanosomes life cycle in the mammalian 
bloodstream and tsetse fly, modified from Vickerman, 1985. The main life cycle stages 
are highlighted: slender and stumpy forms in the bloodstream, procyclic and mesocyclic 
forms in the fly midgut, epimastigote, premetacyclic, nascent and mature metacyclic forms in 
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As previously mentioned, slender form cells obtain their energy from glycolysis 
(Vickerman et al., 1988), utilizing the glucose present in the host’s body fluids. 
However, when slender forms become stumpy forms, they start to switch to an 
amino acid-based energy metabolism through the elaboration of some 
mitochondrial activity, particularly NADH2 oxidation (NAD diaphorase 
activity), with the first changes being detectable as soon as 12 hr post 
differentiation (Brown et al., 1973). In addition, the mitochondrion acquires the 
ability to utilize Krebs cycle intermediates, thus metabolizing pyruvate. Overall, 
all these metabolic changes enable stumpy forms to pre-adapt to survive in the 
fly environment (Vickerman, 1965). Moreover, it has been shown that stumpy 
forms are more resistant than slender forms to acidic and proteolytic stress 
(Nolan et al., 2000).  
In parallel to the biochemical changes, the mitochondrion modifies its 
morphology by increasing its tube diameter and by developing well-defined 
cristae in its lumen (Vickerman, 1965) (Figure 1.6).  At the same time, stumpy 
form cells become shorter, broader, they loose the free flagellum and increase 
the distance between their kinetoplast and the posterior end of the cell (Brown 
et al., 1973).  
Stumpy cells are important for the overall success of the parasite infection, as 
they limit the host parasitaemia by being non-proliferative (Shapiro et al., 1984), 
and increase the chance of disease transmission by being capable to 
differentiate into insect form cells. Indeed, the expression of stumpy 
characteristics has proven to be a key event in regulating the ability of the 
parasite to differentiate (Tasker et al., 2000).  
 
The concomitant presence of stumpy and slender form cells in the mammalian 
bloodstream has lead to the use of the adjective “pleomorphic”, when referring 
to these life cycle forms (Vickerman, 1965). However, pleomorphic lines can 
become “monomorphic” (i.e. showing only slender morphology) by long term 
passage in laboratory animals (Fairbairn et al., 1947). These monomorphic lines, 
which are widely used in laboratories, have lost the capacity to become stumpy 
and thus are able to differentiate to procyclic forms only asynchronously 
(Overath et al., 1986). The fact that pleomorphic and monomorphic lines are 
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able to differentiate to procyclic forms, although with different kinetics and 
efficiencies, suggests that both populations possess differentiation-competent 
cells (termed stumpy*), which are morphologically slender cells but are able to 
continue the life cycle (Tasker et al., 2000) (Figure 1.7). The requirement for 
intermediate/stumpy* forms during the in vitro differentiation of a 
pleomorphic population has been contested by others, who reported as 
supportive evidence the fact that similar kinetics of VSG loss and procyclins 
expression exist, between monomorphic and pleomorphic cells (Bass et al., 
1991), although this argument was subsequently disputed (Matthews et al., 
1994). However, despite these controversial in vitro observations, the presence 
of intermediate/stumpy* and stumpy forms, in the course of a natural in vivo 












 Figure 1.7 Model for the ability of pleomorphic and monomorphic trypanosomes to 
differentiate to procyclic forms (from Tasker, et al. 2000). In a pleomorphic population, 
slender form cells that are found in the G0/G1 window are able to progress to a transitional 
form, stumpy* (ST*), which possess some stumpy characteristics essential for differentiation, 
although are not morphologically stumpy; ST* can then differentiate to procyclic forms (Pc) 
either directly or through stumpy forms. In contrast, in a monomorphic population slender forms 
are able to achieve the differentiation competent state (ST*), but are less able to undergo 
morphological transformation to the stumpy form; consequently they cause very high 
parasitaemia that kills the host.  
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1.8.2.  Life in the tsetse fly 
 
In the tsetse fly, the bloodmeal enters the crop, and then the midgut, where 
further digestion is carried out (FAO, 1982). The trypanosomes ingested with 
the bloodmeal are transported into the lumen of the fly midgut, within the 
peritrophic matrix, a thick extracellular sheath that surrounds the bloodmeal 
(Figure 1.8, number 1).  
In the anterior midgut, slender forms are killed, probably after glucose 
deprivation or of acidic/proteolytic stress, whereas stumpy forms continue 
swimming to the posterior midgut; here they start to lose the VSG coat and stop 
endocytosis from the flagellar pocket, thereby becoming procylic forms 
(Vickerman et al., 1988).  
The release of the VSG coat is partly achieved through the activation of the GPI-
specific phospholipase C (GPI-PLC), (Bulow et al., 1985) and in part through the 
action of a metalloprotease (Gruszynski et al., 2003). In place of the VSG coat, EP 
protein  is expressed at 4-6 hr after initiation of synchronous differentiation in 
vitro (Ziegelbauer et al., 1990), and at 6-12 hr GPEET procyclin is also present 
(Vassella et al., 2000). During this transition several metabolic and 
morphological changes also take place, some of which follow the differentiation 
events started in stumpy forms. Indeed the mitochondrial metabolism that was 
activated in stumpy forms, fully develops in procyclic forms, expanding into a 
branched network with discoid cristae. 
In addition, glycosomes change from spherical to rod-shape (Vickerman et al., 
1988) and the posterior portion of the cell elongates, causing the kinetoplast to 
reposition further away from the posterior end of the cell and closer to the 
nucleus (Vickerman, 1985; Matthews et al., 1995).  
After four days from the infection, the proliferative procyclic form parasites 
invade the ectoperitrophic space, passing through the membrane over the 
anterior midgut (Ellis et al., 1977). Inside the ectoperitrophic space, the 
trypanosomes migrate towards the proventriculus, a specialized muscular 
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Figure 1.8 Trypanosoma brucei life cycle in the tsetse fly (modified from Vickerman, 
1988). The location of the different life cycle stages within the tsetse fly is shown (1: posterior 
midgut, 2: proventriculus; 3: salivary gland; Nascent met.: nascent metacyclic).  
 
On the way towards the proventriculus, procyclic forms become elongated 
mesocyclic (Sharma et al., 2008b) and they arrest in G2 phase of the cell cycle. 
Once these mesocyclic parasites reach the proventriculus they further increase 
their length and retraverse the peritrophic membrane migrating towards the 
hypopharynx, reaching the salivary glands (Vickerman et al., 1988) (Figure 1.8 
number 3). 
During this migration, mesocyclic trypomastigote trypanosomes become short 
epimastigotes (the kinetoplast is now prenuclear), which are created by an 
asymmetric cell division of the long trypomastigote (Sharma et al., 2008b). This 
asymmetric division gives rise to one short and one long daughter epimatigote, 
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and the latter appears to die, whereas the short epimastigote colonizes the 
salivary glands.  
In the salivary glands four different forms of the parasite exist: attached 
epimastigote, premetacyclics, nascent metacyclics and mature free metacyclics 
(Vickerman, 1985) (Figure 1.8 number 3).  
The epimastigote forms are characterized by their attachment to the epithelium 
through a branched outgrowth of the flagellum (“flagellipodia”), which shows 
punctuate focal cup-like plaques at regular intervals. In addition, they possess a 
well developed mitochondrion and bacilliform glycosomes (Tetley et al., 1985) 
and multiply still attached to the epithelium. Furthermore, epimastigote forms 
express a different surface protein, called BARP (brucei alanine rich protein), 
which is specific for this life cycle stage (Urwyler et al., 2007). 
Scattered among epimastigotes, premetacyclic forms are recognizable by their 
postnuclear kinetoplast and flagellar origin (trypomastigote configuration) and 
a reduced flagellar outgrowth, although they are still attached to the 
epithelium.  
Premetacyclic forms then differentiate to nascent metacyclic forms, which 
further reduce their surface of attachment to the salivary gland, stop dividing 
and express VSG on their surface coat. In addition, nascent metacyclic forms 
already show a single stranded mitochondrion and spherical glycosomes, 
characteristic of mature metacyclic forms (Tetley et al., 1985).  
The complete coating of nascent metacyclic causes their release from the 
epithelium as free mature metacyclic forms. Metacyclic forms possess a blunt 
posterior end, in contrast to the pointed extremity of epimastigote and 
premetacyclic forms, and are heterogeneous with respect to the VSG expressed, 
which enables them to be infective to mammalian hosts (Tetley et al., 1985). 
Metacyclic forms are produced after 3-5 weeks from the initial infection and in 
only 2-5 % of the flies (Vickerman et al., 1988). 
During T. brucei life cycle stages present in the fly salivary glands, before the 
development of metacyclic forms (Tait et al., 2007), genetic exchange has been 
reported (Jenni et al., 1986), with both cross- and self-fertilization taking place 
(Tait et al., 1990). Observations have suggested that a meiotic division would be 
required, but a haploid stage has not been detected so far (Gibson, 2001). 
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However, sexual division is not an obligatory part of the life cycle, since it 
occurs only in a proportion of the parasites (Jenni et al., 1986).  
 
1.9. Molecular aspects of T. brucei differentiation 
 
1.9.1.  Slender to Stumpy transition 
 
The first factor reported to induce differentiation of slender to stumpy forms 
was cell density (Black et al., 1985); indeed it was noted that pleomorphic 
slender cells grown in culture became stumpy after reaching stationary phase, 
with no need of additional factors, and with the timing of differentiation 
dependent upon the initial cell density (Reuner et al., 1997).  
Further studies showed that density-dependent differentiation required a 
soluble factor released by the cell, which would cause cell cycle arrest and 
subsequent differentiation. Such a factor, termed “stumpy induction factor” 
(SIF), was found to be heat stable and with molecular weight lower than 500 
Da, but has not been identified so far. Moreover SIF was suggested to act 
through the cAMP pathway, since a cell permeable analog of cAMP, 
successfully induced cellular differentiation. In addition, measurement of 
intracellular cAMP levels in differentiating cells detected a 2-fold increase 15 
min after addition of conditioned media, reaching baseline levels after 30 min 
(Vassella et al., 1997). Additional work identified the adenosine/5’-AMP 
product of cAMP hydrolysis as the triggering factor, thus suggesting that cAMP 
is not acting directly to induce differentiation but through its metabolic 
products (Laxman et al., 2006). The mechanism of action of these products have 
not been identified, but potential molecular targets suggested are AMP kinases, 
cyclin-dependent kinases or mitogen-activated protein kinases (Laxman et al., 
2006).  
Population density is a widespread parameter controlling initiation of 
differentiation or development in several prokaryotic and eukaryotic systems, 
however it is usually starvation that induces cell cycle arrest and the next 
developmental step is then triggered by a minimum number of cells (minimum 
density sensing)(Kaiser et al., 1993). In contrast, T. brucei possesses a maximal 
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density sensing, thereby cell cycle arrest and transition to stumpy forms is 
induced when reaching high cell density. The choice of this mechanism is 
dictated by the environment, that once again plays a key role in the parasite 
development; indeed in the bloodstream, where glucose is abundant, the 
limiting factor is not energy source but host survival, and thus trypanosomes 
require to sense maximal rather than minimal cell density in order to survive 
(Vassella et al., 1997), a phenomenon also observed in many bacterial 
populations.  
 
1.9.2. Stimuli causing stumpy to procyclic form transition 
1.9.2.1. Temperature shift and citrate/cis-aconitate 
 
A temperature shift from 37° to 27°-25°C was the first stimulus identified to 
cause the transition from stumpy to procyclic forms in vitro, with the whole 
population showing procyclic morphology at 72 hr (Bienen et al., 1980). Such a 
stimulus has been readily correlated to the natural tsetse feeding environment 
and habits, indeed they preferentially feed at dusk (Makumi et al., 1998), when 
the temperature can drop significantly.  
It was then found that the tricarboxylate Krebs cycle intermediates, citrate and 
cis-aconitate, also induced procyclic formation, in the presence of a temperature 
reduction to 27°C (Brun et al., 1981). Specifically, cis-aconitate concentrations 
between 2 and 16 mM were found to be effective, resulting in 91 % of procyclic 
form cells after 48 hr of 3 mM cis-aconitate treatment; 3 mM citrate was found 
to be less effective than 3 mM cis-aconitate, resulting in a 1/5 and 1/3 lower 
absolute number of differentiated cells at 48 and 72 hr, respectively (Brun et al., 
1981).   
It was postulated that incubation of cells with citrate/cis-aconitate (CCA) 
would cause an increased concentration of citrate, cis-aconitate and isocitrate 
inside the mitochondrion, through the action of the enzyme aconitase, which 
converts the first two compounds into isocitrate. Hence, a certain level of 
isocitrate would have then activated the Krebs cycle, triggering metabolic and 
morphological transformation (Brun et al., 1981). The apparently contradictory 
observation that isocitrate alone did not induce differentiation was explained 
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by the fact that it did not cross the inner mitochondrial membrane (Brun et al., 
1981).  
However, the millimolar concentrations of citrate/cis-aconitate required were 
considered unphysiological, since citrate levels in the mammalian bloodstream, 
where trypanosomes are bathed during transition to the fly midgut, reaches 
only 0.1 mM (Brun et al., 1981) and in tsetse fly body fluids about 15 µM (Hunt 
et al., 1994).  
A major turning point in understanding the physiological role of CCA in 
trypanosome differentiation from stumpy to procyclic was the discovery by 
Engstler et al., that a bigger temperature shift (cold shock) from 37° to 20°C, 
rather than 27°C, resulted in the acquisition of greater sensitivity to micromolar 
concentrations of CCA (Engstler et al., 2004). This observation indicated that 
citrate/cis-aconitate is likely to play a key role in trypanosomes differentiation 
in vivo, as tsetse fly will experience cold temperatures after feeding (Rogers, 
2000). Interestingly, it was also noticed that cold shock caused bloodstream 
form cells to express the insect-stage procyclin proteins, although not on the cell 
surface (Engstler et al., 2004), suggesting that differential trafficking might be 
important during differentiation to procyclic forms. 
More recently the genes encoding for CCA transporters have been identified as 
members of the transmembrane-spanning proteins of the major facilitator 
superfamily, called PAD (“proteins associated with differentiation”) (Dean et 
al., 2009). Specifically PAD1 and PAD2 were shown to be responsible for the 
sensitization of stumpy form cells to low physiological CCA concentrations, 
particularly under cold shock conditions (Dean et al., 2009).   
 
1.9.2.2. Mild acid and proteinase treatment  
 
In addition to temperature reduction and CCA addition, treatment of 
bloodstream form cells with mild acid (Rolin et al., 1998) or proteinases (Yabu et 
al., 1988), in the presence of temperature reduction, have been reported to 
induce transformation to procyclic forms.  
Mild acid was initially investigated because of its role in the development of 
Leishmania (Zilberstein et al., 1991) and Trypanosoma cruzi (Tomlinson et al., 
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1995), where a lower pH is characteristic of the extracellular environment 
encountered during the developmental steps. In Trypanosoma brucei, 
preincubation at pH 5.5, for 2 hr prior to incubation at 27°C, resulted in cellular 
differentiation in the absence of CCA. However, only 10% of the cells showed 
procyclic morphology, EP expression and mitochodrial activity after 72 hr, 
compared to 100% of transformation for CCA-treated cells (Rolin et al., 1998). 
Mild acid treatment seemed to induce differentiation by causing death of 
slender forms but it was not clear whether that was the only mechanism 
responsible (Rolin et al., 1998). Since the slower kinetics observed after mild acid 
treatment is probably unlikely to mirror the in vivo differentiation, and since the 
tsetse midgut pH has been shown to be alkaline (Van Den Abbeele et al., 1999), 
the importance of this treatment during trypanosomes development  is 
questionable. However, it cannot be excluded, that  mild acid conditions are 
potentially encountered in the extracellular environment before reaching the 
midgut, acting together with other stimuli, such as CCA and cold shock to 
induce differentiation to procyclic forms in vivo.  
 
Similarly to mild acid treatment, proteolytic stress has been shown to cause 
stumpy to procyclic form transition (Yabu et al., 1988). Specifically trypsin 
treatment, coupled to temperature shift (37° to 27°C) of monomorphic 
Trypanosoma brucei gambiense induced the cells to become procyclics, with 
similar efficiency as CCA treatment (Yabu et al., 1988) .  
In contrast, other studies, performed on pleomorphic cells, reported different 
kinetics, with proteinase-treated cells differentiating faster than CCA-treated 
ones (Hunt et al., 1994; Sbicego et al., 1999). Furthermore, it was noticed that 
there was a high degree of slender cells death caused by trypsin or pronase (a 
mixture of bacterial proteases) treatment; however, it was demonstrated that 
trypsin did not cause differentiation solely by enriching for stumpy forms, but 
acted as a trigger itself (Sbicego et al., 1999). The mechanism underlying 
proteolytic stress-induced differentiation is unknown, since it appears to 
include VSG release but also other morphological rearrangements, such as 
flagellar internalization and membrane fusion (Frevert et al., 1986).  
The physiological role of proteolytic stress is easy to envisage, as stumpy forms 
are found in the fly midgut, the site of bloodmeal digestion (FAO, 1982), where 
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trypsin-like enzymes have been implicated in the differentiation process 
(Imbuga et al., 1992). Moreover, there has been a report showing that 
bloodstream form trypanosomes, from peak parasiteamia, release proteases  
into the external medium, perhaps in order to assis the penetration of the 
peritrophic membrane (Nwagwu et al., 1988), but also potentially influencing 
cellular development. 
 
1.9.3. Molecular events during transition to procyclic forms 
 
The first detectable cytological event of pleomorphic lines of Trypanosoma brucei 
CCA-induced differentiation at 27°C to procyclic forms is expression of 
procyclin transcript, as early as 15 minutes after induction of differentiation, 
followed by gain of procyclin protein at 2 hr (Roditi et al., 1989) (Figure 1.9).  
Between 4 and 6 hr the bloodstream form surface protein VSG is lost, which is 
partly achieved through the activation of the GPI-specific phospholipase C 
(GPI-PLC), (Bulow et al., 1985) and in part through the action of a 











Figure 1.9.  Summary the timing of the major event following induction of differentiation 
from stumpy to procyclic forms (from Matthews and Gull, 1994). The timing of the 
molecular events and cell cycle changes following initiation of differentiation (time zero) are 
highlighted as bars. 
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After VSG loss an increase in intracellular cAMP has been described at 6-10 
hr and a second one after the first cell division (20-40 hr) (Rolin et al., 1993). 
Together with the first cAMP increase, a pulse of RNA synthesis has been 
detected (Pays et al., 1993), followed by expression of the cytoskeletal-
associated protein CAP 5.5 (Matthews et al., 1994). The cell-cycle arrested 
stumpy form cells start to differentiate between 6 and 12 hr after addition of 
citrate/cis-aconitate; entry into S-phase is then followed by daughter 
kinetoplast separation, mitosis and ultimately cytokinesis (Matthews et al., 
1994) (Figure 1.9).  
Several factors controlling the events linked to differentiation have been 
identified, which include members of the phosphorylation signalling 
pathways, such as phosphatases and kinases. 
 
1.9.1.1. Protein phosphatases involved in differentiation to procyclic 
forms  
 
A protein tyrosine phosphatase, TbPTP1, has been shown to negatively 
control transition to procyclic forms (Szoor et al., 2006) by inactivating its 
tyrosine-phosphorylated substrate, TbPIP39 (TbPTP1 interacting protein of 39 
kDa). Indeed, TbPTP1 inhibition resulted in induction of differentiation 
through the increased level of phosphorylated and active TbPIP39, which 
transduced the developmental signal to the glycosomes (Szoor et al., 2010) 
(for a more detailed analysis of TbPTP1 see paragraph 1.17). 
 
1.9.1.2. Kinases involved in differentiation to procyclic form 
 
In addition to protein phosphatases, a few protein kinases have been linked 
to the control of different aspects of differentiation to procyclic forms. 
Particularly, several homologues to the mammalian mitogen-activated 
protein kinases (MAPKs) have been shown to be involved in growth or 
differentiation processes. For example, TbMAPK2 was found to control 
procyclic form proliferation, with null mutant stumpy form parasites 
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showing delayed differentiation kinetics, followed by cell-cycle arrest in 
insect form cells (Muller et al., 2002).  
In addition to MAPKs, a member of the AGC family of eukaryotic kinases 
(cAMP-dependent, cGMP-dependent and protein kinase C), PKC, has been 
shown to negatively regulate VSG shedding and cAMP production, this 
being observed soon after the initiation of differentiation. Indeed treatment 
of bloodstream forms with specific PKC inhibitors caused significant VSG 
release and stimulated adenylate cyclase activity (Rolin et al., 1996) (For a 
more detailed analysis of T. brucei protein kinases see paragraph 1.13).   
  
1.10. Trypanosoma brucei signalling  
 
Trypanosoma brucei adaptation to changes in the extracellular environment is 
an essential requirement to ensure parasite survival. Since responses to 
environmental changes are mediated through signalling pathways, the 
factors involved in signal transduction are key components for 
understanding the cellular biology of these protozoan organisms, as well as 
for finding ways to compromise their ability to survive.  
Homologues of mammalian receptors, protein kinases, protein phosphatases 
and second messengers have been found in T. brucei, although many of the 
components and connections have not yet been established (Parsons et al., 
2000). For example, the activating and deactivating phosphorylation sites of 
mammalian kinases, such as of ERK1, have been found to be conserved in T. 
brucei, but the canonical upstream receptors and downstream effectors are 
absent (Nett et al., 2009b).  
Interestingly, several differences between trypanosomes and higher 
eukaryotes can be ascribed to the peculiar biology of the parasite, as 
highlighted by the identification of signalling pathways involving RNA 
binding proteins (Chou et al., 2010) and RNA processing (Nett et al., 2009b) in 
trypanosomes, which were distinct to most mammalian pathways, that 
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1.10.1.   Surface receptors 
 
Mammalian cells possess mainly three classes of surface receptors: ion-
channel linked receptors (such as neurotransmitter receptors), G-protein 
coupled receptors (or serpentine receptors, such as β2-adrenergic receptors) 
and enzyme-linked receptors (such as receptor kinases). 
In trypanosomatids most of the genes encoding for serpentine and enzyme-
linked receptors are missing or the extent of homology is not convincing 
(Parsons et al., 2000) (Table 1.3).  
An exception is represented by T. brucei adenylate cyclases (AC), which are 
membrane-bound enzymes that catalyze the formation of cAMP from ATP 
and, in mammalian cells, are regulated by G-protein coupled receptors. In T. 
brucei four AC genes have been found, ESAG4 and GRESAG 4.1, 4.2 and 4.3, 
which belong to the family of VSG expression site-associated genes and 
related genes (ESAGs and GRESAGs, respectively) (Paindavoine et al., 1992).  
Interestingly, T. brucei ACs possess a large extracellular N-terminal domain, 
in contrast to mammalian cells, whose adenylate cyclases do not have 
extracellular domains since they act as effectors of G-protein coupled 
receptors. Such differences indicate that the parasite enzymes probably serve 
as extracellular receptors, as also suggested by the variety of their N-terminal 
domains (Paindavoine et al., 1992). In this regard, the structure of 
trypanosome adenylate cyclases is more reminiscent of mammalian guanylyl 
cyclases or of the receptor adenylate cyclase found in Dictyostelium (Pitt et al., 
1992), which possess both receptor and effector function. This one-step signal 
amplification, compared to the two-step system typical of mammalian cells, 
likely provides the advantage of eliciting and quenching the signal very 
rapidly, and it is coupled to a more limited magnification, which probably 
does not affect trypanosomes because of their smaller size (Seebeck T, 2001).  
In bloodstream forms adenylate cyclase activity has been detected soon after 
VSG release, as previously mentioned, and is also found to occur in response 
to cellular stress. They are not to be obligatory coupled, however, as certain 
stimuli causing VSG shedding do not cause increased cAMP levels (Rolin et 
al., 1996).   
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1.10.2. Second messengers 
 
Second messengers are small molecules that are formed in or released into 
the cytosol in response to an extracellular signal and which transduce the 
signal to the interior of the cell, such as cAMP, IP3 (inositol tri-phosphate), 
and Ca2 + (Berridge, 1993). Trypanosoma brucei possess all the main second 
messengers found in mammalian cells, but they sometimes show peculiar 
features and interactions, as seen in the case of surface receptors (Table 1.3). 
 
1.10.2.1. The cAMP signalling 
 
The second messenger cAMP is highly conserved among different 
organisms, while other upstream and downstream components are variable. 
In T. brucei cAMP is involved in the differentiation from slender to stumpy 
(Vassella et al., 1997) and from stumpy to procyclic forms (Reed et al., 1985), 
and involves the activity of four adenylate cyclases (Paindavoine et al., 1992), 
as previously mentioned.  
The levels of cAMP are controlled also by the action of phosphodiesterases 
(PDEs), of which two families are found in trypanosomes, compared to 11 
groups in mammalian cells (Aravind et al., 1997). Some members of class 2 
PDEs were shown to be essential in bloodstream forms and thus are being 
pursued as drug targets (Oberholzer et al., 2007). 
In T. brucei the downstream signalling of cAMP is not known, since protein 
kinase A (PKA), which is the main cAMP effector in mammalian cells, has 
been shown to be activated by cGMP and not cAMP (Shalaby et al., 2001).  
 
1.10.2.2. Calcium signalling 
 
Calcium is another highly conserved second messenger, which is found also 
in trypanosomes, although its role in the parasite biology and development 
has not been well characterized (Parsons et al., 2000). However, some studies 
have highlighted its potential involvement in a variety of cellular processes, 
such as cell division (Dolan et al., 1986), motility (Wu et al., 1994), cell death 
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induced by reactive oxygen species (Ridgley et al., 1999) and parasite 
differentiation (Ruben et al., 1990).  
Supporting the existence of Ca2+ signalling in trypanosomes is the presence 
of numerous downstream effectors, such as the calcium-binding protein 
calmodulin (CaM) (Ruben et al., 1987). In addition to calmodulin, T. brucei 
possess several CaM-binding proteins, which include Ca2+-ATPase in the 
plasma membrane (Benaim et al., 1993) and the elongation factor 1α (Kaur et 
al., 1994). Moreover, other EF-hand calcium binding proteins have been 
detected in the flagellum proteome, thus suggesting a possible role of Ca2+ in 
motility or environmental sensing (Wu et al., 1994).  
 
 
1.10.2.3. Phosphatidylinositol signalling 
 
Phosphatidylinositol (PI) is a unique membrane lipid that can undergo 
reversible phosphorylation generating different inositol phospholipids, 
which represent important second messengers in mammalian cells. PI 
phosphorylation is regulated by PI3K (phosphatidylinositol 3-kinase), which 
generates PIP, PIP2, PIP3 (mono-, di- or tri-phosphorylated PI) and by PLC 
(phospholipase C), which gives rise to soluble IP3 (inositoltriphosphate) and 
membrane bound DAG (diacylglycerol) (Berridge, 1993).  
In Trypanosoma brucei GPI (glycophosphatidylinositol) is a glycolipid that 
anchors the VSG to the membrane of the parasite but the action of GPI-PLC 
(GPI phospholipase C) can release the GPI, which can be found free 
intracellualrly, as a mediator of signalling pathways (Table 1.3). For 
example, GPI-PLC has been found to increase endocytosis of transferrin, a 
mammalian plasma protein that transports iron, essential for parasite growth 
(Subramanya et al., 2009). In addition to its intracellular effect, the GPI 
moiety has been shown to act extracellularly, causing host macrophages to 
release proinflammatory cytokines (Tachado et al., 1994).  
Nothing is known about GPI-PLC mediated IP3 production in T. brucei, 
except the fact that IP3 does not induce Ca2+ release from the ER (Nolan et al., 
1994), in contrast to what seen in mammalian cells.  
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One of the members of the PIK (phosphatidylinositol kinase) family has been 
identified in T. brucei which showed conserved functions with yeast and 
mammalian homologues, as a major regulator of vesicular trafficking 
endocytosis and Golgi complex segregation (Hall et al., 2006). Other T. brucei 
PIK members, TbTOR1 and TbTOR2, are involved in cell growth control, 
cytokinesis and cytoskeletal remodeling (Barquilla et al., 2008).  
The PIK products PIP, PIP2 and PIP3 have not been characterized, however 
PH domains have been identified on several parasite protein kinases, such as 
in Nrk, a kinase potentially involved in differentiation to stumpy forms (Gale 
et al., 1994), suggesting a possible role of PI signalling in the regulation of 
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1.11. T. brucei protein phosphorylation 
 
Protein phosphorylation is one of the main components of signalling 
pathways, controlling a variety of aspects of cellular physiology (Hunter, 
1987). In Trypanosoma brucei, protein phosphorylation has been documented 
and showed to change during parasite development (Parsons et al., 1990; 
Aboagye-Kwarteng T, 1991; Bakalara et al., 1995). Particularly, two 30-45 kDa 
proteins were initially identified as showing increased tyrosine 
phosphorylation upon transition from slender to procyclic forms (Parsons M, 
1991), and two proteins with similar size were also reported to increase 
serine and threonine phosphorylation levels during the same stages 
(Aboagye-Kwarteng T, 1991). Further studies have then revealed that the two 
phosphorylated proteins were nucleolar RNA binding proteins, Nopp44/46 
(Das et al., 1996; Das et al., 1998), phosphorylated on serine by CK2 (Park et 
al., 2002), tyrosine dephosphorylated by TbPTP1 (Chou et al., 2010) and 
important for ribosome biogenesis (Jensen et al., 2005).  
Moreover, analysis of protein phosphatase activity on cell extracts 
highlighted a different level of activity between bloodstream and procyclic 
form, with the former showing up to twice the activity of the latter (Bakalara 
et al., 1995).  
In addition to T. brucei development, protein phosphorylation has been 
found to play a role in the bloodstream parasite growth, as shown by the 
decrease in cell multiplication after treatment with the tyrosine kinase 
inhibitor genistein, which caused the alteration of tyrosine phosphorylation 
levels of a dozen proteins detectable by Western blot analysis (Wheeler-Alm 
et al., 1992). Recently, more sensitive phosphoproteomic techniques have 
identified 491 cytosolic phosphoproteins in bloodstream form T. brucei, 
involved in several biological processes, such as DNA and RNA processing, 
protein synthesis and degradation, and metabolism (Nett et al., 2009b)  
(Figure 1.10). 
Moreover, some tyrosine phosphorylated proteins were found to localize in 
the flagellum basal body and axoneme in procyclic forms, thus suggesting 
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that tyrosine phosphorylation might be involved in flagellum formation and 
basal body segregation in this life cycle stage (Nett et al., 2009a). 
Among the 491 phosphorylated proteins identified, 44 were kinases, the 
majority of which showed multiple phosphorylation sites on the MAP kinase 
activation loop, similarly to that observed for mammalian MAP kinases, thus 
suggesting some segments of higher eukaryotes signal transduction are 














1.10 Role of phosphorylated proteins in bloodstream form T. brucei, as predicted by 
their genome annotation (modified from Nett et al., 2009a). The biological processes 
potentially regulated by protein phosphorylation include signal transduction, DNA/RNA 
processing, protein synthesis and degradation, etc.; most of the phosphorylated proteins 
were found to be hypothetical proteins, with no homology to known proteins.  
 
In contrast, trypanosomes are more similar to prokaryotes than to eukaryotes 
when analysing the ratio of phosphoserine/threonine/tyrosine present, 
being 75/21.5/3.5% in T. brucei, 70/20/10% in prokaryotes and 86/12/2% in 
eukaryotes (Nett et al., 2009b).  
In addition to MAP kinases, the other phosphorylated kinases detected 
belong to different families, such as the cdc2-related protein kinases (CRK1, 
2, and 3), which control the cell cycle (Mottram et al., 1995), the dual 
specificity kinases (DYRKs), which are involved in cell proliferation and 
development in Drosophila (Lochhead et al., 2003), GSK3β, which controls 
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glucose homeostasis in mammalian cells (Rayasam et al., 2009) and the STE 
family, which regulate MAP kinases. 
 Similarly, several tyrosine-phosphorylated proteins detected in procyclic 
form T. brucei were kinases, of which two were metabolic kinases 
(phospoenolpyruvate carboxykinase and 6-phospho-1-fructokinase) and 19 
protein kinases belonging mainly to the MAP kinase and cdc-2 related 
protein kinase families (Nett et al., 2009a). Interestingly the tyrosine-
phosphorylated proteins were found to be concentrated at the cytoskeleton, 
basal body, axoneme and nucleolar compartment in procyclic forms, in 
marked contrast with the localization of tyrosine-phosphorylated proteins in 
mammalian cells, which localize on the plasma membrane (Vuori, 1998). 
 
1.12. T. brucei protein kinases 
 
The analysis of the T. brucei genome reported the presence of 156 eukaryotic 
protein kinases (ePKs) and 20 atypical protein kinases (aPKs), which is 
approximately 30% of the number of kinases in humans (Parsons et al., 2005), 
but twice the number of kinases found in other unicellular organism, such as 
S. cerevisiae or P. falciparum, thereby suggesting a more central role of protein 
phosphorylation in trypanosomes compared to other protozoa (Nett et al., 
2009b).  
Moreover, the analysis of the different groups of ePKs, highlighted 
differences in the relative number of trypanosomatid kinases found in each 
group compared to the human counterpart (Table 1.4). One of the main 
differences in the kinome of T. brucei, and of other kinetoplastid parasite, was 
the complete absence of the PTK family (protein tyrosine kinases), which 
includes the enzyme-linked receptor family of receptor tyrosine kinases (Nett 
et al., 2009b). The lack of tyrosine kinases indicates that tyrosine 
phosphorylation is probably performed by dual specificity kinases, which 
are able to phosphorylate serine/threonine and tyrosine residues 
(Dhanasekaran et al., 1998), such as the MAP kinase kinases (STE7), and the 
CLK family, which are present in the T. brucei kinome (Parsons, 2005).  
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Furthermore, trypanosomes possess a smaller  amount of kinases belonging 
to the AGC (cyclic nucleotide-regulated protein kinases) and CAMK 
(Ca2+/Calmodulin-regulated protein kinases and AMP-activated protein 
kinases) groups, compared to the same groups in humans (Table 1.5). 
However, several important kinases that respond to second messengers are 
found in T. brucei, such as PKA, PKG and PKC. The CMGC kinase family 
(cyclin-dependent kinases) is better represented than other groups in 
mammalian cells, and includes 10 MAP kinases and 11 cyclin-dependent 
kinases. Similarly, the NEK family of “other” ePKs contains more kinases 
than the corresponding group in humans, and it also appears to possess a 
slightly bigger variety of accessory domains, which could indicate its 
involvement in parasite-specific signalling mechanisms (Parsons, 2005). 
Interestingly one member of this family has been characterized and shown to 
be upregulated during parasite differentiation from slender to stumpy forms 
(Gale et al., 1994).  
Among the 156 ePKs, 19 protein kinases were not found to be significantly 
similar to any enzyme of any other organisms, and were thus classified as 
“unique” PKs (Parsons, 2005). 
The comparative analysis of the T. brucei kinome identified differences not 
only in the size of the different kinase families but also in the presence and 
combination of certain accessory domains, for example the lack of SH2 (Src 
kinase homolgy domain) and SH3 domains that bind phosphotyrosine and 
proline-rich sequences, respectively, thus suggesting, for the former, the 
evolution of different motifs interacting with parasite-specific tyrosine 
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1.13. T. brucei Protein Phosphatases 
 
Protein phosphatases are classified according to their substrate specificity 
into five main categories: serine/threonine phosphatases (STPs), protein 
tyrosine phosphatases (PTPs) and lipid phosphatases. The PTP family also 
includes the dual specificity phosphatases (DSPs), which dephosphorylate 
tyrosine and serine/threonine residues, and the family of smaller and 
simpler low molecular weight phosphatases (LMW-PTPs), which are specific 
for phosphorylated tyrosine (Fauman et al., 1996).  
An ontology based classification (Wolstencroft et al., 2006) of T. brucei 
phosphatases highlighted the presence of the main classical families of 
phosphatases, but differences in their composition and in the type of 
accessory domains present, and the existence of parasite enzymes with no 
orthologues in other organisms, thus suggesting the evolution of parasite-
specific signalling pathways (Brenchley et al., 2007) (Table 1.4).  The first 
difference observed was the small proportion of kinetoplastids PTPs, 
compared with humans, with 2.6% of T. brucei phosphatases being PTPs 
(2/78), and 30% in humans  (43/140). The low proportion of PTPs seems to 
be compensated by the higher number of STPs detected, with 69% (54/78) 
present in T. brucei compared to 24% (33/140) in the human genome.  
Moreover, a significant number of atypical phosphatases and kinetoplastid-
specific enzymes were identified, belonging especially to the DSP family, 
whose members also were found to be significantly longer compared to their 
human counterparts (Brenchley et al., 2007). 
One subfamily of atypical DSP were shown  to possess peculiar Leucine Rich 
Repeats (LRRs), found in some receptor-like kinases (RLKs) of A. thaliana 
(Shiu et al., 2001), or in human phosphatase PHLPP. However, no enzyme 
has been identified which contains LRRs in a DSP domain, making this 
combination of domains kinetoplastid-specific. Interestingly, the LRRs 
sequences contained in kinetoplastid DSPs resulted to be similar to LRR 
proteins involved in Ras-mediated signalling, an important mammalian 
pathway that controls cell growth via the activation of the GTP-binding 
protein Ras and of the downstream Raf kinase (Alberts et al., 2002), thus 
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suggesting a similar scaffolding role for this group of phosphatases 
(Brenchley et al., 2007). 
In addition to the LRRs, a second subfamily of atypical DSPs, were found to 
be composed of two pseudokinase domains, thus named “kinatases”, from 
the union of kinase and phosphatase domains. Similar enzymes containing 
both kinase and phosphatase domains are present only in other protozoan 
organisms, indicating an evolutionarily conserved function of this group of 
DSPs (Brenchley et al., 2007). 
Another group of kinetoplastid DSPs that showed no orthologues with 
human enzymes, was the MAP kinase phosphatases (MKPs), which resemble 
MKPs of Arabidopsis, particularly AtMKP1, involved in the control of stress 
response (Ulm et al., 2002), indicating, once again, the close evolutionary 
relationship of certain features of trypanosomes to plants. The same was also 
found to be true for some of the serine/threonine phosphatases, the 
kinetoplastid-specific phospho protein phosphatases (kPPP), whose 
sequences were mostly similar to plant and fungal phosphatases. However, 
not all the phosphatase families followed this trend, for example the PPM 
group (protein phosphatase, magnesium or manganese-dependent) of 
serine/threonine phosphatases showed closer homology to yeast and 
mammalian rather than plant enzymes (Brenchley et al., 2007).  
 
1.13.1 Characterized T. brucei Protein Phosphatases 
 
The identification of the T. brucei phosphatome has given an insight into the 
composition and size of the different families of enzymes, as well as of their 
structural differences and similarities to other organisms. However, the 
function of most of these phosphatases is not known yet. Indeed only about 
10 % (8/78) of T. brucei phosphatases have been characterized so far, five 
serine/threonine phosphatases and three tyrosine phosphatases (Szoor, 
2010) (Table 1.4).  
T. brucei PP1 and PP2A (TbPP1 and TbPP2A), belonging to the STP family, 
were found to be important for kinetoplast segregation and cellular 
cytokinesis (Das et al., 1994), possibly regulating the kinetoplast cycle with 
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the cell cycle (Li et al., 2006) and they were also shown to control the amount 
of β tubulin mRNA (Li et al., 1995).  
Another member of the serine/threonine phosphatases, TbPP5, is involved in 
the regulation of Hsp90, an essential heat shock protein for parasite survival 
during stress, by promoting protein folding and maturation, particularly at 
37°C (Jones et al., 2008). 
The fourth member of the STP family characterized in T. brucei is PP7 or 
PPEF (protein phosphatase with EF hands), whose gene does not possess the 
classical calmodulin binding and EF-hand motifs, and thus is likely not to be 
regulated by Ca2+ and which is involved in cell growth (Mills et al., 2007).  
The fifth STP characterized belongs to the subfamily of FCPs (TFIIF-
stimulated CTD phosphatases), which in higher eukaryotic cells are 
responsible for the regulation of the carboxyl terminal domain of RNA 
polymerase II, thereby promoting enzyme recycling after transcription 
(Kobor et al., 1999). In T. brucei one member of the FCPs has been identified, 
as TbPIP39, a glycosomal phosphatase essential for parasite development 
(Szoor et al., 2010). 
One gene coding for a protein tyrosine phosphatase (PTP) has been 
identified in T. brucei: Tb10.70.0070 (TbPTP1). TbPTP1 has been shown to 
control parasite development (Szoor et al., 2006) (see paragraph 1.17).  Two 
dual specificity phosphatases (DSPs) were also identified, TbPTP2 and 
TbPTP3, which were found to be involved in cell cycle regulation 


























Phosphatase N°  Characterized Function 
PP1 8 TbPP1 Kinet. segregation  
PP2A 2 TbPP2A Kinet. segregation  
PP2B 2 TbPP2B n.d 
PP4 1 TbPP4 n.d 
PP5 1 TbPP5 Heat shock response 
PP6 0 TbPP6 - 
PP7 2 TbPP7 Parasite growth 
FCPs 14 TbPIP39 Development St to Pcf 
PTPs 1 TbPTP1 Development St to Pcf 
DSPs 19 TbPTP2, TbPTP3 Cell cycle regulation 
 
 
Table 1.4 Summary of the main features of the T. brucei Kinome and Phosphatome 
and  the list of Protein Phosphatases. The main differences of the T. brucei kinome 
(Parsons et al., 2005) and the phosphatome (Brenchley et al., 2007) compared to higher 
eukaryotes are highlighted in the table of the upper panel. In the table of the lower panel the 
classes of Ser/Thr Protein Phosphatases (PP1-PP7 and FCPs) and Protein Tyrosine 
Phosphatases (PTPs and DSPs) are listed, together with the number of genes identified in 
the T. brucei phosphatome, the names of the characterized enzymes and their function 
(Kinet. segregation: kinetoplast segregation; n.d: not determined; St: stumpy; Pcf: procyclic). 
 
Kinome  Phosphatome 
156 Total ePKs  78 Total  
20 atypical PKs  54 STPs (11 kinet-sp PPPs) 
19 unique PKs  19 DSPs (6 atypical DSPs) 
  2 PTPs 
   
absence of PTKs  smaller PTPs 
smaller AGC, CAMK   
bigger CMGC  bigger STPs 
   
absence of SH2 and SH3 
domains  
presence of plant LRRs 
domains 
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1.14. Mammalian Protein Tyrosine Phosphatases 
 
In mammalian cells 81 active Protein Tyrosine Phosphatases (PTPs) have 
been identified, which are classified into four families according to their 
substrate specificity (Alonso et al., 2004) (Figure 1.11 A). 
Class I PTPs possess a cysteine-based catalytic mechanism and include 
classical PTPs, which are specific for phosphorylated tyrosine residues, and 
dual specific PTPs (DSPs), which can act on phosphorylated tyrosine as well 
as serine/threonine residues. Class II enzymes are low molecular weight 
phosphatases (LMPTP) that are characterized by a smaller and simpler 
structure and act on phosphorylated tyrosine residues. Class III PTPs are the 
cell cycle regulators CDC25s, which dephosphorylate cyclin-dependent 
kinases (CDKs) on tyrosine or threonine residues. The last family comprises 
PTPs possessing an aspartic acid as catalytic residue, instead of the cysteine 
found in the other three classes. Examples of enzymes belonging to this 
group are the transcription factors Eya, involved in Drosophila development 
(Jemc et al., 2007). 
  
Classical PTPs possess a catalytic site characterized by the active-site 
signature motif or “PTP loop” [I/V]HCX5R[S/T], where X is any amino acid, 
and C is the cysteine residue essential for catalysis (Tonks, 2003). This family 
of enzymes is further divided into receptor-like (RPTPs) and non-
transmembrane, cytoplasmic PTPs (NRPTPs) (Tonks, 2006).  
Cytoplasmic classical PTPs comprise a large family of heterogeneous 
enzymes, particularly rich in protein-protein interaction domains that 
function in regulating the enzyme activity, substrate specificity and 
localization, for example, the SH2, found in the phosphatase SHP1 (Pei et al., 
1996). In addition, some cytoplasmic PTPs possess targeting domains such as 
the PDZ binding motif, which binds to the PDZ motif, typically found on 
synapse and junction-associated molecules (Kim et al., 1995) (Figure 1.11 B).  
1- Introduction 52 
     
Figure 1.11. Classification of mammalian protein tyrosine phosphatases (PTPs) (from 
Alonso et al., 2004). (A) The four classes of mammalian PTPs are shown (A to D: Class I to 
III of cysteine-based PTPs and the class of aspartic acid-based PTPs), together with their 
corresponding numbers (in parenthesis). (B) Schematic diagram of the domain structure of 
mammalian cytosolic PTPs. PTP: PTP catalytic domain; FERM: band 
4.1/ezrin/radixin/moesin homology; PDZ: postsynaptic density-95/disc large/ZO1 homolgy; 
KIND: kinase N lobe-like domain; SH2: src homolgy 2; Sec 14 p: sec homolgy; KIM: kinase 
interaction motif; Pro-rich: proline rich; BRO: baculavirus BRO homolgy. 
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1.14.1 Structure and catalytic mechanism of mammalian   protein tyrosine 
phosphatases  
 
The characterization of the X-ray crystallographic structures of several 
classical PTPs has highlighted the presence of ten conserved motifs (M1 to 
M10) within the common PTP catalytic domain, which comprise 
approximately 280 aa (Andersen et al., 2001).  
Two of these domains (M4 and M9) are highly conserved among different 
classical PTPs: M9 is the PTP loop, which characterizes the PTP family, and 
M4 forms the core structure surrounding the catalytic site.  
In addition to the PTP loop, the active site is structurally defined by three 
other motifs: the P loop, the WPD loop and the Q loop (M1, M8 and M10, 
respectively), which have been first characterized for the cytoplasmic PTP, 
PTP1B (Tonks, 2003) (Figure 1.12).  
The phosphotyrosine recognition loop, or P loop (M1), defines the depth of 
the active site, thereby creating the selectivity for phosphotyrosine.  
The WPD loop (M8) is critical for the dynamics of the catalytic site, since, by 
interacting with the PTP loop, it closes around the side chain of the 
phosphorylated tyrosine of the substrate thus positioning the aspartic acid 
residue (the D in the WPD loop) close to the tyrosyl group. This 
conformational change is essential to carry out the catalytic reaction initiated 
by the cysteine residue of the PTP loop. Indeed, the aspartic acid is 
responsible for the protonation of the substrate that follows the nucleophilic 
attack of the cysteine residue in the first step of catalysis (Figure 1.13, step 1). 
In addition, the aspartic acid of the WPD loop is important for the hydrolysis 
of the substrate in the second part of the reaction (Tonks, 2003) (Figure 1.13, 
step 2). 
Finally the Q loop (M10) contains a glutamine residue (Q) that is responsible 
for the hydrolysis and release of the substrate, together with the aspartic acid 






























Figure 1.12 Structure of the PTP catalytic site (modified from Tonks, 2003). The 
structure and location of the active site of mammalian PTPs in the presence of a peptide 
substrate is shown in the upper and lower panel, respectively. The four motifs creating the 
structure of the catalytic cleft are highlighted: the phosphotyrosine-selectivity motif (PTyr-
loop or P loop), the PTP signature motif containing the nucleophilic cysteine residue (PTP-
loop), the motif containing the important aspartic acid (WPD-loop) and the glutamine 




























Figure 1.13. PTP catalytic mechanism (modified from Tonks, 2003). A schematic 
representation of the two-step catalytic mechanism of PTPs; in step 1 the sulphur atom of 
the catalytic cysteine attacks the phosphate of the substrate (arrow) and the side chain of the 
conserved aspartic acid of the WPD loop protonates the tyrosyl-leaving group of the 
substrate; in step 2 the same aspartic acid residue hydrolyses the catalytic intermediate 
(thick line), together with the glutamine residue of the Q loop. Residues of the enzyme are 
circled, whereas the phosphate of the substrate is highlighted by a yellow square. Residues 
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1.15. The “substrate-trapping” mutant approach 
 
The substitution of one of the amino acids required for catalysis has been 
used as a strategy to identify substrates of mammalian PTPs, and is known 
as the “substrate-trapping” approach (Garton et al., 1996). Initially, two 
substrate-trapping mutant PTPs were created: one possessing a serine 
residue instead of the catalytic cysteine (Cys→Ser)(Guan et al., 1991) and one 
possessing an alanine instead of the aspartic acid residue (Glu→Ala)(Flint et 
al., 1997) required for catalysis. The Cys→Ser mutant enzyme was shown to 
retain some substrate binding ability, although it was not found to be an 
inactive enzyme. The Glu→Ala mutant phosphatase was also not completely 
inactive but was shown to interact more strongly with the substrates (Flint et 
al., 1997). Indeed, mutation of the aspartic acid residue, found in the WPD 
loop, produces an enzyme that is not able to finish the first step of catalysis. 
Therefore the mutant enzyme maintains a high affinity for the substrate, 
provided by the catalytic cysteine, but it traps the substrate inside its  
catalytic cleft, without dephosphorylating it. This ability is clearly useful to 
facilitate the isolation and identification of substrates, which would 
otherwise be missed, due to the transient nature of the enzyme-substrate 
interaction.  
 
1.16. T. brucei protein tyrosine phosphatases 
 
Sequence analysis has classified kinetoplastid PTPs into three groups, based 
on the conservation of the ten hallmark PTP motifs (M1 to M10) (see 
paragraph 1.14.1) (Andersen et al., 2001) (Figure 1.14). 
Group 1 contains parasite PTPs most similar to human enzymes and includes 
one Leishmania major enzyme (LmPTP1) and one Trypanosoma cruzi enzyme 
(TcPTP1)(Brenchley et al., 2007). The only characterized PTP of this group is  
Leishmania donovani PTP1 (LdPTP1), which has been implicated in the 
regulation of parasite virulence in vivo (Nascimento et al., 2006; Brenchley et 
al., 2007)  (Figure 1.14, Group 1). 
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 Group 2 PTPs lack motif 2 (M2) and possess up to six kinetoplastid-specific 
regions in both the pre-catalytic and catalytic domain of the proteins. This 
group contains three phosphatases: TbPTP1 (which, despite its name, is not a 
homologue of LmPTP1 or TcPTP1), LmPTP2 and TcPTP2 (Figure 1.14, Group 
2). The function of the kinetoplastid-specific regions is unknown but might 
be important in substrate recognition or regulation (Brenchley et al., 2007). 
The only characterized enzyme of the second group is TbPTP1(Szoor et al., 
2006), which will be talked about in detail in the next paragraph. 
Group 3 PTPs show the most interesting variations from higher eukaryote 
enzymes, with substitutions and deletions in several motifs and includes two 
enzymes: LmjF32.0640 and Tb11.01.5450 (TbPTP2)(Brenchley et al., 2007; 
Szoor, 2010) (Figure 1.14, Group 3).  
Overall the main difference between mammalian protein tyrosine 
phosphatases and the homologues found in T. brucei and in other 
kinetoplastid parasites, lies in the lack of extracellular and trans-membrane 
regions or of any additional recognisable regulatory or targeting domains.  
This low homology suggests that kinetoplastid PTPs may be suitable targets 
for the design of specific and selective inhibitors against parasitic infection 
and transmission (Brenchley et al., 2007).  
Figure 1.14. Phylogenetic tree of protozoan protein tyrosine phosphatases (PTPs) 
(modified from Andreeva et al., 2008). The three groups of kinetoplastid PTPs are 
highlighted (Group 1, 2 and 3) and their relationship to mammalian PTPs are shown.  
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1.17. T. brucei protein tyrosine phosphatase 1 
 
As previously mentioned, the only characterized kinetoplastid PTP 
belonging to group 2 is T. brucei protein tyrosine phosphatase (TbPTP1) 
(Szoor et al., 2006; Szoor et al., 2010). TbPTP1 is a 34 kD protein (306 aa) 
containing 9 of the 10 landmark motifs (M1-M10) present in classical 
tyrosine-specific phosphatases (see paragraph 1.14)(Andersen et al., 2001) 
(Figure 1.15). The only motif missing is the less conserved motif 2 (M2), 
which is replaced by a trypanosome-specific motif (T1). In addition to T1, 
three other trypanosome-specific motifs are present in the enzyme sequence, 
two found in the catalytic region (aa 43-306) which were named T1 to T4, and 
two in the pre-catalytic region (aa 1-43), which were called PcT1 and PcT2 
(Szoor et al., 2006) (Figure 1.15).  
Figure 1.15. TbPTP1 structure. Schematic diagram of TbPTP1 highlighting the PTP motifs 
(M1-10) and the trypanosome-specific motifs (PcT1-2, T1-4). The ten conserved PTP motifs 
are shown (M1-M10) and coloured according to the degree of conservation among PTPs 
(red: high, orange: medium, blue: low); the trypanosome-specific motifs are coloured in pink 
(PcT1, PcT1, T1-T4). Numbers correspond to amino acid sequence of TbPTP1 (Szoor et al., 
2006). 
 
Beyond the pre-catalytic region, the TbPTP1 catalytic domain is more 
homologous to the human protein tyrosine phosphatase 1B (PTP1B)(Tonks et 
al., 1988) and to another human PTP upregulated in quiescent B cells 
(PTPROt) (Aguiar et al., 1999), with 24% and 23% of identity, respectively 
(Szoor et al., 2006).  
Functionally, recombinant TbPTP1 was shown to be active in vitro, with its 
activity being tyrosine-specific and sensitive to the general PTP inhibitor, 
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sodium vanadate, oxidation and pH changes (Szoor et al., 2006). Importantly, 
TbPTP1 inactivation by RNAi or by a PTP1B-specific pharmacological 
inhibitor resulted in the spontaneous transition from bloodstream to 
procyclic forms, showing the same kinetics as cis-aconitate treatment. 
Overall the data suggested that TbPTP1 is kept active in bloodstream forms 
cells and upon induction of differentiation to procyclic forms the enzyme is 
inhibited thereby activating downstream signalling events (Szoor et al., 2006).  
More recently a TbPTP1 target has been identified, as a glycosomal 
serine/threonine phosphatase (TbPTP1-interacting protein, 39 kDa or 
TbPIP39), which was shown to be dephosphorylated by TbPTP1 (Szoor et al., 
2010). TbPIP39 was also shown to be responsible for the downstream events 
leading to procyclic form transition, as demonstrated by the fact that its 
down-regulation by RNAi resulted in inhibition of differentiation. In 
addition, TbPIP39 glycosomal localization was found to be essential for its 
role in the parasite life cycle, since the RNAi phenotype was not rescued by 
the ectopic expresssion of the protein lacking the C-terminal sequence 
responsible for its localization (Szoor et al., 2010). 
Very recently, a second TbPTP1 substrate has been identified in procyclic 
form cells, as the RNA-binding protein Nopp44/46 (Chou et al., 2010). 
Nopp44/46 is a nucleolar protein important for ribosome biogenesis (Jensen 
et al., 2005), whose tyrosine phosphorylation was shown to increase upon 
transition from slender to procyclic forms (Parsons M, 1991). However, the 
effect of the interaction between TbPTP1 and Nopp44/46 is not clear, nor it is 
known whether this interaction is part of the events involved in 
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1.18. Human PTP1B 
 
Human protein tyrosine phosphatase 1B (PTP1B), was one of the first 
tyrosine-specific phosphatases identified and named after its elution 
properties during purification from human placenta (Tonks et al., 1988). 
PTP1B is a ubiquitously expressed protein, composed of 435 aa, which plays 
a role in several pathways: from cellular transformation, where it 
antagonizes the oncogenic kinases neu (Brown-Shimer et al., 1992) and vSrc 
(Woodford-Thomas et al., 1992), to cell adhesion (Liu et al., 1998) and insulin 
signalling (Tonks et al., 1990). Therefore, PTP1B is involved in a variety of 
pathologies, like leukemia or other cancers (LaMontagne et al., 1998b; 
Lessard et al., 2010), diabetes and obesity (Elchebly et al., 1999). It was 
particularly this last observation that attracted the attention of 
pharmaceutical companies, as diabetes and obesity represent one of the main 
health challenges of the 21st century, with the WHO estimating that more 
than 700 million people will be obese by 2015 (WHO, 2006b). As a 
consequence, numerous PTP1B inhibitors have been developed, with the aim 
of finding a potent selective and highly specific compound (Zhang et al., 
2007). 
 
1.18.1 The PTP1B inhibitor BZ3 
 
Among the different PTP1B inhibitors developed, a group of benzbromarone 
derivatives (Wrobel et al., 1999) were found to be particularly interesting, as 
they were bound to an allosteric site of the enzyme (Wiesmann et al., 2004). A 
compound of this family, 3-(3,5-Di-bromo-4-hydroxy-benzoyl)-2-ethyl-
benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide), was 
then successfully commercialized as PTP1B inhibitor (Calbiochem®), which 
will be referred to as BZ3, in the course of this work (Szoor et al., 2006).  
The crystallographic analysis of PTP1B bound to this compound showed that 
its binding to the allosteric site caused the phosphatase to adopt the “open” 
conformation. In the “open” conformation the catalytic site is accessible to 
the substrate, whereas in the “closed” conformation the catalytic WPD loop 
closes over the binding pocket to facilitate catalysis (Barford D et al., 1994). 
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Importantly, BZ3 showed selectivity for PTP1B in vivo, as judged by the 
stimulation of insulin phosphorylation (Wiesmann et al., 2004). In agreement 




As evident from its complex life cycle, Trypanosoma brucei undergoes 
developmentally regulated morphological and biochemical changes in 
response to environmental cues, which are mediated through signalling 
pathways. However, our understanding of trypanosome signal transduction 
during differentiation is limited.  
 Protein Tyrosine Phosphatase 1 (TbPTP1) is the one of the few factors 
identified to be responsible for differentiation from stumpy to procyclic form 
parasite (Szoor et al., 2006), acting through the novel substrate TbPIP39 
(Szoor et al., 2010). However the stimulus and the mechanism responsible for 
the physiological inhibition of TbPTP1 upon initiation of differentiation is not 
known and only two TbPTP1 substrates have been identified (Chou et al., 
2010; Szoor et al., 2010). 
The aims of this work were the validation of TbPTP1-TbPIP39 interaction, 
and the identification of novel substrates of TbPTP1. In addition, it was 
interesting to characterize the stimulus and the mechanism responsible for 
TbPTP1 inactivation upon differentiation to procyclic forms, in order to gain 
a deeper understanding of the role of the TbPTP1-TbPIP39 signalling 
pathway during this life cycle transition. Finally a part of this project 
investigated piggyback strategies targeting TbPTP1, as a means to decrease 
the number of the fly-transmissible stumpy form cells in the bloodstream, 
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2.1. Trypanosomes cultures 
2.1.1 Cell lines 
 
Most of the cell lines used in this project were derived from Trypanosoma 
brucei brucei Lister 427  (427), which probably originated from the Shinyanga 
IIII strain, isolated in 1965 from cattle in Tanganiyka 
(http://tryps.rockefeller.edu).  
For RNAi experiments “Single marker cells 16” or SMC 16 were used, which 
are cells originated from 427 cells and expressing the bacteriophage T7 RNA 
polymerase and tetracycline repressor protein (Wirtz et al., 1999). These cells 
need to be grown in 2.5 µg/ml of G418 (Gentamicin) to retain the T7 RNA 
polymerase gene. The Tb10.389.0310 and Tb11.02.2090 SMC16 RNAi cell lines 
were grown in 2.5 µg/ml of G418 and 2.5 µg/ml phleomycin (to select for 
cells containing the p2T7 RNAi plasmid) and the induction of the RNAi was 
performed by addition of 1 µg/ml of tetracycline.   
For stumpy form cells the pleomorphic Trypanosoma brucei brucei Antat 1.1, 
originally isolated in Uganda in 1966 (http://tryps.rockefeller.edu), were 
inoculated in mice, which were then sacrificed 5-6 days after infection. 
The procyclic form cells, used mainly as positive control for EP protein 
expression, were the procyclic PTT, which express the T7 RNA polymerase 
and the tetracycline repressor protein.   
 
2.1.2 Cell Media 
 
For bloodstream form cells HMI-9 media (Sigma), supplemented with 20 % 
FCS and 1 mg/ml of penicillin/streptomycin (GIBCO), was used; cells were 
grown at 37°C with 5% CO2 (Hirumi et al., 1989) using vented flasks. Procylic 
form parasites were grown at 27° C in SDM-79 supplemented with 10 % FCS, 
1 mg/ml penicillin/streptomycin and 7.5 mg/ml of sterile bovine haemin 
(Cross et al., 1973). 
Bloodstream or procyclic form cells were counted using a Z2 Coulter 
Counter Analyzer (Beckam Coulter) set to sample size range of 2.5-7 µm.  
When needed, cells were frozen by centrifuging 10 ml of logarithmic-phase 
culture at 2,000 rpm for 10 min; then the pellet was resuspended in 0.5-1 ml 
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of media and an equal amount of freezing mix (HMI-9/14% glycerol for 
bloodstream form or SDM-79/14 % glycerol for procyclic forms) was added 
drop wise in order to slowly equilibrate the cells to the glycerol. Cryovials 
were then gently mixed and left standing for 2 minutes before being placed 
at -80° C, in a polystyrene box, to allow slow freezing; after about 2 days the 
vials were transferred to a normal freezing box or to liquid nitrogen (-196°C).   
 
2.1.3 Purification of trypanosomes from blood 
 
When stumpy form cells were needed, infected mice were sacrificed by heart 
puncture, (performed by Deborah Hall or Keith Matthews) and the blood 
was loaded on DEAE-cellulose (DE-52) pre-settled in a glass column, in order 
to absorb the particulate component of the blood (Lanham et al., 1970); 
trypanosomes were eluted by addition of PSG buffer (3 mM NaH2PO4-2H2O, 
43.6 mM NaCl, 57 mM Na2HPO4 and 83 mM D-glucose, pH 7.8) on the top of 
the column. Cells were usually allow to recover a few hours in HMI-9 at 
37°C, before starting any experiment.   
 
2.1.4 Inducing differentiation of stumpy to procyclic forms 
 
Stumpy form cells (2x106/ml) were induced to differentiate by addition of 6 
mM cis-aconitate (Sigma 43412 , 0.6 M stock, in PBS, pH 7.6) to the HMI-9, 
then transferring the flasks into the 27° C incubator and substituting the 
vented lids with unvented ones. Similarly, 10 mM citrate was sometimes 
used to induce transformation to procyclic forms. 
For BZ3-induced differentiation, the compound (PTP1B inhibitor, 3-(3,5-
Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-
2-ylsulfamyl)-phenyl)-amide) was purchased from Calbiochem (cat# 539741); 
a stock solution of 67 mM in DMSO was used and aliquoted at -80°C; freshly 
thawed aliquots were always used, to a final concentration of 150 µM in 
HMI-9.   
When pronase was used to trigger differentiation (Hunt et al., 1994), 4 units 
of pronase (from Streptomyces griseus, Biochemika 81748, 5 unit/mg) were 
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added to 1 ml of cells (approximately 2x107) in PSG buffer; cells were left 10 
minutes at 25°C then spun and washed twice with PSG before being 
resuspended in HMI-9. 
Cold shock of stumpy form cells was also used to induce differentiation 
(Engstler et al., 2004), by placing the un-vented flasks containing cells in an 
incubator set at 20° C overnight.  
 
2.1.5 Transfection of bloodstream form cells 
 
The Amaxa nucleofector® device (Lonza) was used for transfection of 
bloodstream forms Trypanosoma b. b. (Burkard et al., 2007). Plasmid DNA for 
transfection was digested overnight and purified using a Nucleospin column 
(Macherey-Nagel); it was then precipitated by addition of 70% ethanol and 
resuspended in 5 µl of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). 
Approximately 4x107 cells were centrifuged at 2,000 rpm for 10 min and 100 
µl of Amaxa T cell buffer or Ingenio™ electroporator solution (Mirus) was 
added to the pellet, which was resuspended and transferred into the 
provided cuvettes, together with the linearized DNA plasmid. The 
electroporation was perfomed placing the cuvette in the Amaxa 
nucleofector® device and selecting progamme X001. Immediately after that, 
the cells were transferred to a 10 ml flask containing HMI-9 and left to 
recover in the 37°C incubator overnight. The next day the cells were serially 
diluted 1:10 in a 24-well plate in HMI-9 supplemented with the antibiotic of 
choice, to select for cell containing the transfected plasmid. The selection was 
carried out over  10-12 days.  
 
2.2. DNA manipulation 
2.2.1 Polymerase chain reaction 
 
For a standard polymerase chain reaction (PCR) a mixture was used 
containing the following: approximately 1 µg of template DNA, 0.1-1 µM of 
primers, 0.2 mM of deoxynucleotides, 1-4 mM of MgCl2, 2 units of GoTaq® 
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DNA polymerase, autoclaved H2O and 1X of the GoTaq® flexi buffer 
supplied (Promega M8305) to a final volume of 50 µl. 
Reaction conditions were usually: 95°C for 4-6 min (initial denaturation step) 
for 1 cycle, then for 30 cycles at 94°C for 1 min (denaturation step) followed 
by the annealing step (1 min at 5°C lower than the Tm of the primers) and by 
72°C for 2 min (elongation step, approximately 1 min per kb of DNA). At the 
end of the 30 cycles a final elongation step of 72°C for 2-3 min was added.  
When primers containing restriction sites were designed, the chosen 
restriction site was added at the 5’ end of the forward and reverse primer, 
usually including a 4 bp sequence at the 5’ end to increase digestion 
efficiency. Primers were generally designed to be 18-30 bp long, with GC 
content between 40% and 60 %, containing G or C at the 3’ end to allow 
stronger binding to the DNA template. The absence of self-complementarity 
and of palindromic sequences was checked by using the online server 
OligoCalc (http://www.basic.northwestern.edu/biotools/oligocalc.html).  
 
 
2.2.2 Agarose gel electrophoresis 
 
DNA was visualised in a 1% agarose gel in 1x TAE buffer (0.4 mM Tris-HCl, 
0.1 mM EDTA, pH 7.7). Usually 100 ml of buffer was used for a small gel, 
with addition of 0.5 µg/ml of ethidium bromide or 5 µl of SafeView Nucleic 
Acid stain (NBS Biologicals). The gel was cast in a Fisher Brand DNA gel 
apparatus and run in TAE buffer at 120 Volts for approximately 20 min. 
DNA samples were added to a 1X DNA loading buffer (0.25% Bromophenol 
blue, 0.25 % Xylene cyanol FF and 15% Ficoll). 
 
2.2.3 DNA purification 
 
DNA purification from PCR reaction or from agarose gel was performed 
using a NucleoSpin Extract II kit (Machery-Nagel), according to 
manufacturer’s instructions. 
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2.2.4 DNA digestion 
 
DNA digestions were performed by incubating between 0.2 and 2 µg of 
DNA with 10 units of restriction enzyme, and 1X of the buffer required, in a 
final volume of 20 µl. The reactions were incubated at the suggested 
temperature for the enzyme of choice, for 2 hr. Restriction enzymes were 
purchased mainly from Promega, and New England Biolabs.  
 
2.2.5 DNA ligation  
 
Ligations were set up using a 5-10:1 insert:vector ratio with the 
corresponding quantities calculated using the formula ((ng vector x size 
insert in kb)/(size of vector in kb) x 5-10). Insert and vector, together with 10-
20 units of T4 DNA ligase (Promega) were incubated overnight at 4°C in the 
buffer provided. Sometimes ligations were preceded by calf intestine alkaline 
phosphatase (CIAP, Sigma M182A) treatment of the linearized vector; CIAP 
causes the dephosphorylation of the 5’ phosphate groups of the DNA, useful 
to prevent recircularization and religation of linerized DNA. For this 
purpose, the DNA was incubated with 0.05 units of CIAP in 1x CIAP buffer 
provided at 37°C for 30 minutes. 
 
2.2.6 Bacteria transformation  
 
Following ligation, the DNA was transformed by heat shock into competent 
E. coli XL-1 blue cells (Stratagene), for simple cloning; when transformation 
was needed for expression of recombinant protein the BL21-CodonPlus 
(DE3)-RIPL competent E. coli (Stratagene) were used, which are cells that 
contain extra copies of rare E. coli argU, ileY, leuW, proL tRNA genes to 
correct for codon bias and to improve expression.  
For the transformation, 60 µl of bacteria per sample were gently thawed on 
ice and transferred to new 1.5 ml eppendorf tubes, where 10 µl of ligation 
were added. Bacteria containing the DNA to transform were kept on ice for 
20 min and then heat shocked 90 seconds at 42°C. After that the tubes were 
left on ice for 2 min and 750 µl of LB broth (Luria Broth: 1% bactotryptone, 
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0.5% bacto-yeast extract, 1% NaCl, pH 7.0 (Gibco)) was added to allow the 
bacteria to recover. In addition, the tubes were placed in the 37°C shaking 
incubator for 1 hr. Finally, the bacteria were plated in plates containing LB 
agar (1.2% agar, 2.5 % LB) and ampicillin (100 µg/ml) or kanamycin (30 
µg/ml), according to the resistance contained in the DNA plasmid used. 
 
2.2.7 Mini-scale DNA preparation 
 
For mini-scale DNA preparations one colony of bacteria was inoculated into 
2 ml of LB broth containing the appropriate antibiotic (ampicillin (100 
µg/ml) or kanamycin (30 µg/ml)), and left in the 37°C shaking incubator 
overnight. The next day, 1.5 ml of bacteria culture were harvested by 
centrifugation in an eppendorf tube. The pellet was resuspended in 100 µl of 
solution I (50 mM glucose, 25 mM Tris-HCl pH 8.0 and 10 mM EDTA pH 
8.0); 200 µl of solution II (0.2 N NaOH and 1% SDS) were then added and the 
tube mixed by inversion several times. To allow separation of plasmid DNA 
from the rest, 150 µl of solution III (3 M KAc and 40% of Glacial Acetic acid) 
were added, the tube was kept on ice for 5 min and then centrifuged 10 min 
at 13,000 rpm. The resulting white precipitate consisted of chromosomal 
DNA, high-molecular-weight RNA and potassium/SDS/protein/cell wall 
complexes, whereas the supernatant contained the plasmid DNA. The 
supernatant was then transferred to a new tube and the DNA was 
precipitated by addition of 0.6 volume of 100% ethanol (900 µl for 450 µl of 
supernatant) and by incubation at -80°C for at least 20 minutes. The tube was 
centrifuged 15 min at 13,000 rpm, the resulting DNA pellet was washed once 
with 70% ethanol, centrifuged again for 5 min and allowed to dry on the 
bench. Finally the DNA pellet was resuspended into 40 µl of H2O or of TE 
buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA).      
 
2.2.8 Large-scale DNA preparation 
 
Large-scale DNA preparations were performed using the QIAGEN Plasmid 
Purification Kit for Maxi, which requires the 1/100 dilution of a starter 
bacteria culture in 200 ml of LB supplemented with the appropriate 
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antibiotic. After an overnight growth in the 37°C shaking incubator, the 
bacteria were harvested by centrifugation 15 min at 6,000 g and the pellet 
was resuspended in 10 ml of ice-cold buffer P1 (50 mM Tris-HCl, pH 8.0, 10 
mM EDTA and 100 µg/ml RNase A). Bacteria were then lysed by addition of 
buffer P2 (200 mM NaOH and 1% SDS) and cell debris, genomic DNA and 
proteins were precipitated by addition of 10 ml of buffer P3 (3 M KAc, pH 
5.5). After 20 minutes on ice, the tube was centrifuged at 20,000 g for 30 
minutes at 4°C and the resulting supernatant, containing plasmid DNA, was 
transferred in a new tube and centrifuged again at 20,000 g for 15 minutes, at 
4°C. The plasmid DNA was then purified through the application of the 
supernatant to a QIAGEN column, which contains an anion-exchange resin. 
After three washes with buffer QC (1 M NaCl, 50 mM MOPS pH 7.0 and 15% 
isopropanol) the DNA was eluted by addition of 15 ml of elution buffer (1.25 
M NaCl, 50 mM Tris-HCl pH 8.5 and 15% isopropanol). The DNA was then 
precipitated using 0.7 volumes of isopropanol, followed by a 30 minutes spin 
at 15,000 g at 4°C. The resulting pellet was washed with 70 % ethanol, 
centrifuged again 10 minutes at 15,000 g and air-dried on the bench. Finally 
the pellet was resuspended in 600 µl of TE buffer and the DNA concentration 
was quantitated using an Eppendorf Biophotometer and single use 
Eppendorf UVettes®.  
 
2.3. Northern blot analysis 
2.3.1 Probe preparation 
 
The Northern blot probe was generated by PCR of the chosen sequence 
inserted in pGEM plasmid. The PCR was performed as previously described 
(see paragraph 2.2.1), using the M13 forward and reverse primers, and 
annealing temperature of 50°C. After visualization of the product on a DNA 
gel and its purification, the riboprobe reaction was carried out using the DIG 
RNA labeling kit (SP6/T7) (Roche). In the reaction 1 µg of DNA was 
incubated with 2 µl of 10 x NTP labeling mixture (10 mM ATP, 10 mM CTP, 
10 mM GTP, 6.5 mM UTP, 3.5 mM DIG-11-UTP, pH 7.5),  5 mM DTT, 20 
units of Protector RNase inhibitor to prevent RNA degradation during the 
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labeling reaction, 1x transcription buffer and 40 units of T7 RNA polymerase, 
which synthesizes RNA from a DNA template.  The reaction was incubated 
at 37°C for 2 hr, after which the DNA template was degraded by addition of 
20 units of DNase I, RNAase-free, for further 15 min at 37°C. In order to stop 
the reaction 2 µl of 200 mM EDTA (ethylene-diamino-tetraacetic acid, pH 8.0) 
were added. Finally, the probe was precipitated by incubation in 100 mM 
LiCl and 3 volumes of cold 100% ethanol at -70°C for 30 minutes. The tube 
was centrifuged 15 minutes at 12,000 g, the resulting pellet was washed once 
with 70% ethanol, air-dried and resuspended in 50 µl of water supplemented 
with 20 units of RNase inhibitor. 
 
2.3.2 RNA sample and gel preparation 
 
The RNA was extracted from 10-50 ml of bloodstream form cells using the 
RNeasy Mini kit (Qiagen), according to manifacturer’s instructions. Cells 
were harvested by centrifugation and the resulting pellet was resuspended in 
600 µl of lysis RLT buffer containing guanidine thiocyanate, which 
immediately inactivates RNases to ensure purification of intact RNA. One 
volume of 70% ethanol was then added to provide appropriate binding 
conditions of the RNA in the sample to the RNeasy spin column. The column 
is centrifuged for 15 seconds at 8,000 g to allow the binding, washed once 
with buffer containing ethanol and then eluted in 30-50 µl of RNase-free 
water.  
The RNA agarose gel was prepared by heating 1.2 g of agarose in 80 ml of 
distilled water and by addition of 10 ml of 10 x MOPS (40 mM 4-
morpholinepropanesulfonic acid, 10 mM sodium acetate, pH 7.0 and 1 mM 
EDTA). After allowing the solution to cool down, 3 ml of 37% formaldehyde 
were added, under the chemical hood, and the gel was poured into a Fisher 
brand DNA gel apparatus. The RNA samples were prepared firstly by the 
spectrophotometric (absorbance at 260 nm) quantification of the RNA using 
a NanoDrop device (Thermo Scientific). After that, 2 µg of RNA were 
transferred to a new 1.5 ml eppendorf tube, where 9 µl of 99.5% formamide, 3 
µl of 37% formaldehyde, 2 µl of 10x MOPS and 2 µl of RNA loading buffer (6 
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% formaldehyde, 30 % formamide, 1x MOPS, 10% glycerol and 0.01% 
bromophenol blue) were added. The samples were heated at 60°C for 5 
minutes and then loaded on the gel, which was run 90 minutes at 150 Volts. 
In order to visualize the RNA, the gel was stained by incubation in 1x MOPS 
with 1 µg/ml of ethidium bromide for 15 minutes, followed by three 40-
minutes washes in distilled water. The visualization and quantification of the 
RNA loaded was performed using the Syngene G:Box apparatus and the 
GeneSnap (for pictures acquisition) and GeneTools (for picture analysis) 
softwares.  
 
2.3.3 Blotting the RNA gel 
 
A capillary blotting system was used to transfer the RNA from the gel to a 
positively charged nylon membrane (Roche). In order to do so, a plastic tray, 
properly cleaned with soap, 70 % ethanol and washed with water, was filled 
with 10 x SSC (1.5 M NaCl, 0.15 M Tri Na Citrate) up to 2 cm. After that, the 
nylon membrane of appropriate size to cover the gel was cut, and wetted in 
10 X SSC, together with a long piece of filter paper (Fisher brand) covering 
the tray. Similarly, two pieces of filter paper of the same size of the gel were 
also cut and wetted in 2 X SSC. Inside the tray, one lunchbox was placed as 
to create a raised platform; on top of the box, the long piece of filter paper 
was positioned so that its extremities touch the solution in the tray. On top of 
the filter paper, a layer of parafilm was placed to cover the whole tray, in 
order to avoid evaporation of the SSC solution. The parafilm was cut in the 
area above the lunch box, where the gel was placed facing down, followed 
by the two pieces of pre-wetted nylon membrane and by two pieces of filter 
paper of the same size of the gel. A layer of paper towels covering the whole 
tray was then added to allow absorption of the SSC solution from the tray 
towards the gel. Finally, on top of the paper towels a weight was placed, as 
to create pressure evenly over the tray. The whole capillary blotting system 
was left at room temperature overnight. The next morning, the system was 
disassembled and the RNA was cross-linked to the nylon membrane by UV 
light, by placing the membrane in a Uvitec machine set at 0.125 Joules, for a 
couple of minutes.  
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2.3.4 Northern blot hybridization and detection 
 
Initially the membrane was blocked in hybridisation buffer (5x SSC, 50% 
formamide, 0.02% SDS and 2% blocking solution) 1 hour at 68°C. After that, 
the membrane was incubated with 2 µl of boiled probe in 7 ml of prewarmed 
hybridisation solution, overnight at 68°C, in a rotating tube. The next day the 
blot was washed twice with 70 ml of 2x SSC/0.1% SDS at 68°C and once with 
0.5 x SSC/0.1% SDS for further 40 minutes at 68°C. The membrane was then 
briefly washed with wash buffer (100 mM maleic acid, 150 mM NaCl, pH 7.4 
and 0.3 % Tween 20) before blocking it with maleic acid buffer (100 mM 
maleic acid, 150 mM NaCl, pH 7.4) supplemented with 1% DIG (Blocking 
Reagent, Roche) block for 1 hr at room temperature. Detection of the DIG-
labeled probe was performed using anti-Digoxigenin-Alkaline Phosphatase 
Fab fragment antibody (1:25,000 Roche) in maleic acid buffer/ 1% DIG block 
for 30 minutes at room temperature, followed by 3 washes for 5 minutes with 
wash buffer. The membrane was then soaked in detection buffer (100 mM 
Tris-HCl pH 9.5, 100 mM NaCl), before addition of the chemiluminescence 
substrate CDP-Star (1:100, Roche) for 2 minutes. The enzymatic reaction of 
CDP-Star reagent with alkaline phosphatase produces a light signal which 
can be detected by film or chemiluminescent-compatible instruments, 
specifically the quantification was performed using the Syngene G:Box 
apparatus and the GeneSnap and GeneTools softwares.  
 
2.4. Western blot analysis 
2.4.1 Protein extraction 
 
Cells were harvested by centrifugation at 2,000 g for 10 min, washed once 
with PBS (137 mM NaCl, 3 mM KCl, 16 mM Na2HPO4, 3 mM KH2PO4, pH 
7.6), centrifuged again and the resulting pellet was either frozen in liquid 
nitrogen or resuspended directly in Laemmli sample buffer (62.5 mM Tris-
HCl, pH6.8, 2% SDS, 10% glycerol and traces of bromophenol blue). 
Alternatively, the cell pellet stored at -80°C was resuspended in cell lysis 
buffer (such as His-purification lysis buffer, see paragraph 2.7.2 or TbPTP1 
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activity buffer, see paragraph 6.7.3) and subjected to 2 or 3 cycles of freezing-
thawing to lyse the cells thoroughly. 
Protein quantification was performed by the Bradford method, using the 
Bradford Reagent (Sigma), specifically 20 µl of sample was mixed with 600 µl 
of reagent in a disposable uvette (Eppendorf), for 10 minutes and absorption 
at 595 nm was measured using a spectrophotometer; the quantity 
corresponding to the absorbance measured was determined using a standard 




Proteins were resolved in 12%/13% or 15% polyacrylamide gels by mixing 
1.86 ml of running buffer (1.5M Tris-HCl, pH8.8, 0.4% SDS) with 3 ml/3.25 
ml or 3.75 ml of acrylamide solution (30% w/v acrylamide/bisacrylamide 
ratio 37.5:1), respectively, and adding water to a final volume of 7.49 ml; 
polymerisation was started by addition of 50 µl of 10% APS (ammonium 
persulphate, to a final concentration of 0.06%) and 7.5 µl of TEMED (N’,N’, 
N, N’-Tetramethylethylene-diamine, to a final concentration of 0.001%). After 
letting the running gel set, the stacking gel was cast by mixing 375 µl of 
stacking buffer (0.5 M Tris-HCl pH 6.8, 0.4% SDS) with 625 µl of acrylamide 
solution to a final volume of 2.5 ml. Polymerisation was started by addition 
of 0.05% APS and 0.001% TEMED. Gels were prepared and run in a Bio-Rad 
PROTEAN II apparatus at 150 Volts in running buffer (25 mM Tris-HCl, pH 
8.3, 192 mM Glycine, 0.1% SDS). Between 5 and 50 x106 cells were loaded per 
lane, according to the type of experiment. 
When needed gels were stained with SimplyBlue™ Safestain (Invitrogen) for 
1 hr and destained in water for a further hour.  
 
2.4.3 Proteins transfer  
 
For Western blot analysis the gels were blotted onto nitrocellulose (Whatman 
Schleicher and Schuell, PROTRAN, 0.45 µm pore size) or PVDF membrane 
(Immobilon-P, Millipore) using either a semi-dry or a wet blot system, the 
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latter was always used for the detection of tyrosine phosphorylated proteins, 
whereas the former was used with the other antibodies, such as anti-TbPIP39 
or anti p-TbPIP39. 
Before blotting, the PVDF membrane was activated by a brief incubation in 
methanol, as suggested by the manufacturer’s instructions.  
For the wet blot, the gel, the membrane, two pieces of filter paper of the size 
of the gel and the two fiber pads provided were assembled in a Mini Trans 
Blot apparatus (Biorad). The gel sandwich was prepared by placing the 
provided cassette on a small tray containing blotting buffer (2.5 mM Tris, 192 
mM Glycine and 20% methanol) with the black side facing down. On top of 
the black side of the cassette the other components were assembled in the 
following order: one of the fiber pads, one piece of filter paper, the gel, the 
membrane, the other piece of filter paper and the other fiber pad. The 
cassette was then closed and placed in the apparatus, with the black side 
facing the black side of the blotting device. Finally, a cooling unit containing 
ice was added and the apparatus was set running at 30 Volts overnight. 
For the semi-dry transfer, the membranes and gels were soaked in transfer 
buffer (2.5 mM Tris, 15 mM Glycine, 0.02% SDS, 20% methanol), together 
with two sheets of extra thick filter paper; they were then assembled in the 
semidry blotter (Biorad, Trans-blot SD), placing one sheet of filter paper 
towards the bottom (towards the anode) then adding the membrane on top 
and the gel, followed by the second sheet of filter paper (towards the 
cathode). Air bubbles between each layer were then removed by gently 
rolling a pipette on the wet surface and the blotter was run at 15 Volts for 50 
min.   
To assess that the complete transfer had taken place, the membrane was 
stained with Ponceau Stain (0.4 % of Ponceau S and 3% tri-chloroacetic acid), 
for less than one minute, and destained with water. 
 
2.4.4 Western blot detection and quantification 
 
When analysing tyrosine phosphorylated proteins, the PVDF membrane was 
blocked by incubation for 1 hr at 37°C, according to the manufacturer’s 
instructions. The p-Tyr antibody used was the 4G10 clone (Millipore) at 
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1:1,000 dilution in TBS-BSA (2%) for 1 hr, followed by 20 min wash in TBS-
Tween (0.05%). The secondary antibody used was anti-mouse-HRP (Sigma) 
at 1:5,000 dilution, for 1 hr, followed by a 20 min wash with TBS-Tween 
(0.05%). Detection was carried out using the ECL Western blotting system 
(Amersham Biosciences) and by exposing the membrane on X-ray films 
(Kodak). Quantification was performed using the Syngene G:Box apparatus 
and the GeneSnap and GeneTools software.  
For western blot against tubulin, the Odessey® infrared imaging system 
(LICOR Biosciences) was used, therefore all the incubation were performed 
in 50% Odyssey® block in PBS and the secondary antibody used was the 
anti-mouse green (LICOR Biosciences product n°: 926-32210, in 1:7,000 
dilution).  
For the analysis of tyrosine-phosphorylated proteins in stumpy cell extract, 
approximately 6 µg of proteins were loaded in the gel, corresponding to 
about 4 x 107 cells/100 µl. When phenyl phosphate (Sigma) was used, 200 
mM of the compound were incubated 5-10 min with the primary antibody 
before proceeding with the Western blot.   
When using the anti p-PIP39 antibody, the dry blot was used, and the 
blocking and the incubation steps were performed in 2% BSA. When using 
the anti-PIP39 or other antibodies, the dry blot was also used but 2% BSA 
was replaced by 5% milk, as blocking reagent, and TBS was replaced by PBS 
for incubations and washes. 
The membrane was stripped by incubation in 0.2 N NaOH/ 1% SDS for 30-
60 minutes followed by extensive washes in water. In order to check the 
complete disappearance of the signal, the membrane was treated with ECL 
reagents and exposed on the Syngene G:Box.  
 
 
2.4.5 Primary antibody dilution 
 
As mentioned in the previous paragraph, the anti phosphorylated tyrosine 
antibody (4G10, Upstate) was used at 1:1,000 dilution; similarly, the anti-
TbPIP39 and the anti His-tag antibody were used at 1:1,000 dilution, whereas 
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the anti p-PIP39 antibody (against Y278 of TbPIP39) was used at 1:750 or 
1:500 dilution; the anti BB2 antibody (anti TY tag: EVHTNQDPLD peptide) 




Bloodstream form 427  overexpressing wild type TbPTP1 were treated with 
tetracycline for 24 hr and then induced to differentiate with 6 mM cis-
aconitate for 48 hr. After that, approximately 2x108 cells were harvested by 
centrifugation and the resulting pellet was frozen in liquid nitrogen and 
stored at -80°C. The day of the immunoprecipitation the pellet was 
resuspended in 500 µl of IP lysis buffer (10 mM Tirs-HCl, pH 8.0, 0.05 mM 
EDTA and 150 mM NaCl) supplemented with one tablet of protease inhibitor 
cocktail (Roche). Cell lysis was completed by subjecting the sample to 
sonication, in a water bath for 5 minutes. After that, the cell extract was 
centrifuged at 13,000 rpm at 4°C for 10 minutes and the supernatant was 
transferred to a new 1.5 ml eppendorf tube containing 70 µl of Protein G 
agarose beads (Sigma). Following a 30-min incubation on ice, to allow the 
aspecific binding of proteins to the resin, the tube was centrifuged 3 min at 
4°C to separate the agarose beads from the cell extract, which was 
transferred to two new tubes. The BB2 antibody, which recognizes the TY-tag 
(EVHTNQDPLD peptide) of TbPTP1, was added to both tubes containing the 
cell extract using a 1:10 dilution. In one of the two tubes, the BB2 antibody 
was added together with the corresponding BB2 peptide, as negative control 
for the immune-precipitation (antibody and peptide were pre-incubated 
together for 30-40 min before addition of cell extract). The two tubes were left 
rotating at 4°C for 1 hr, and then 100 µl/100 µl of Protein G agarose beads 
(pre-washed in IP lysis buffer 2-3 times) were added to the cell extracts in 
order to precipitate the antibody. For this aim, the tubes were incubated for a 
further hour, rotating at 4°C. Finally, the agarose beads were washed 6 times 
with IP lysis buffer and the immunoprecipitated proteins were eluted from 
the agarose beads by addition of 30 µl SDS sample buffer. 
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2.6. Cell extract dephosphorylation 
 
Stumpy cells from a mouse infection at 1 x 107/ml in HMI-9 were harvested 
and lysed in 100 µl of pNPP buffer plus protease inhibitor (Roche). Cell 
extracts were quantified using the Bradford method (see paragraph 2.4.1). A 
total of 32 µg of cell extract was used and incubated with 5 µg of recombinant 
TbPTP1 for each reaction. The dephosphorylation reaction was allowed to 
proceed for 1 hour at 37°C.   
 
2.7. Recombinant TbPTP1 
2.7.1 Creation of double mutants TbPTP1 by site-directed mutagenesis 
 
To produce the double mutants D199A/Q275A and D199A/C229S TbPTP1, 
the single mutant D199A and C229S were used as template and the 
additional mutation was inserted using the following primers: FW 5’- GCG 
ATT CGG TAT GGT TGC ACG GTT AGA GCA GTA TG- 5’ and Rev 5’- 
CAT ACT GCT CTA ACC GTG CAA CCA TAC CGA ATC GC-3’for Q275A 
and FW 5’- C GTC GGT TGG CCC GCT CAC GGT GTT CCA G-3’ and Rev 
5’- C TGG AAC ACC GTG AGC GGG CCA ACC GAC G-3’ for C229S 
(underlined bases indicate the inserted mutations). The in situ mutagenesis 
was performed following the manufacturer’s instructions (QuikChange XL 
Site-Directed mutagenesis kit, Stratagene).  
 
2.7.2 Expression and purification of the recombinant proteins 
 
The E. coli XL1 strain transformed with the appropriate expression plasmid 
were grown in 50 ml of LB plus kanamycin 30 µg/ml at 37°C, shaking 
overnight. The bacteria were then diluted 1:20 in fresh LB plus antibiotic and 
grown 2 hr at 37°C. The O.D. of the bacteria at 600 nm was checked every 
hour and 0.4 mM IPTG (isopropyl-β-D-thio-galactose) was added when the 
O.D. was between 0.6-0.8. The cells were then grown at 30°C for further 4 
hours. Cells were harvested by centrifugation, 20 min at 4,000 rpm and the 
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pellet resuspended in 5 ml of PBS plus 2-3 ml of His lysis buffer (20 mM Tris-
HCl, pH 7.5-8.0, 250 mM NaCl, 1% Trition X-100, 1 mM β mercapthoethanol 
and 5 mM imidazole). Lysis was performed by sonicating the samples on ice 
4 times for 30 seconds and debris were removed by centrifugation 20 min, 
10,000 rpm at 4°C. The supernatant was incubated with 100-200 µl of NiNTA 
agarose beads (QIAGEN) 1 hr at 4°C, on a rotating wheel, and washed 
extensively with His lysis buffer. For protein elution, the beads were 
incubated 30 min with 1.5 ml of Wash 1 (20 mM Tris-HCl, pH 8.0, 250 mM 
NaCl and 5 mM imidazole), spun, the supernantant discarded and incubated 
further 30 min with 1.5 ml of Wash 2 (20 mM Tris-HCl, pH 8.0, 250 mM NaCl 
and 20 mM imidazole). Elution was performed in two steps: by addition of 
200 µl of Elution 1 (20 mM Tris-HCl, pH 8.0, 250 mM NaCl and 250 mM 
imidazole) for 10 min at 4°C, and by addition of 200 µl of Elution 2 (20 mM 
Tris-HCl, pH 8.0, 250 mM NaCl, 500 mM imidazole and 1mM β 
mercapthoethanol) for 10 min at 4°C. 
 
2.7.3 Tyrosine phosphatase activity assay 
 
Phosphatase activity was assayed by measuring the ability of the 
phosphatase to catalyze the hydrolysis of p-nitrophenylphosphate (pNPP, 
Sigma N-2765), to p-nitrophenol, a chromogenic product with absorbance at 
405 nm. Reaction mixtures (50 µl) contained 2–5 µg of purified TbPTP1 with 
20 mM final concentration of pNPP in 50 mM Tris, 50 mM Bis-Tris and 100 
mM NaAc, pH 5.5. Reactions were incubated at 37°C for 15–30 min and 
quenched by addition of 100 µl of 0.2 M NaOH. The absorbance of the 
samples was measured at 405 nm in a microplate reader (ELx808 Absorbance 
Microplate Reader, BioTek). 
 
2.7.4 Enzyme kinetics assay 
 
TbPTP1 maximal velocity (Vmax) and KM were determined by monitoring the 
hydrolysis of serial dilutions of the synthetic substrate p-nitrophenyl 
phosphate (pNPP) in presence of a constant quantity of enzyme (0.4 µg per 
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reaction); enzyme and pNPP were incubated in pNPP buffer (50 mM Tris, 50 
mM Bis-Tris, 100 mM NaAc, pH 5.5) supplemented with 2 mM DTT in a final 
volume of 80 µl per reaction; the reactions were carried out in triplicate in 96-
well plates and always included a blank control lacking the enzyme. After 15 
min at 37°C, 0.1 ml of 2M NaOH was added, in order to detect the amount of 
hydrolysed substrate (pNP), which was then quantified by measuring the 
absorbance of the samples at 405 nm using a microplate reader (ELx808 
Absorbance Microplate Reader, BioTek).  
The velocity of pNPP hydrolysis was calculated dividing the average of O.D. 
measured minus the blank, by 18.8 x1x15, and multiplying the result by 1,000 
to obtain millimoles released per minute (according to the Beer’s law:  
A=εxcxI, where A is the absorbance measured, ε is the extinction coefficient 
of p-nitrophenolate: 18.8 mM-1cm-1 (Montalibet et al., 2005), c is the molar 
concentration of the substrate and I is the length through which the light 
passes (usually 1 cm) (Berg et al., 2002) in order to convert experimental units 
(i.e. absorbance) into molecules of product formed (c) over 15 min, the above 
equation is used, thus c= A/(18.8  mM-1cm-1 x1 cmx15 min). The velocity of 
hydrolysis obtained was plotted on the y-axis against the molar 
concentration of substrate on the x-axis and the graph was analysed with 
GraphPad Prism software using the Michaelis-Menten equation (Y= 
(VmaxxX)/(KM+X), where Y is the enzyme velocity and X is the substrate 
concentration) in order to derive the Vmax and KM of the enzyme. 
 
2.7.5 Enzyme inhibition assay 
 
For the determination of the IC50 against TbPTP1 (the amount of inhibitor 
required for 50% inhibition of enzyme activity) 0.3-0.4 µg of recombinant 
TbPTP1 was incubated in the presence of 2 mM DTT in pNPP activity buffer 
(50 mM Tris, 50 mM Bis-Tris, 100 mM NaAc, pH 5.5) to a final volume of 80 
µl per reaction, in a 96-well plate; the inhibitor to be tested was subsequently 
added to a final concentration of 200 µM, which was then serially diluted 1:2 
to obtain ten different concentrations ranging from 200 µM to 0 µM. In order 
to start the reaction the synthetic substrate p-nitrophenyl phosphate (pNPP) 
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was added to a final concentration of 0.175 mM (importantly lower than the 
KM determined for TbPTP1 alone, see previous paragraph), the reactions 
were carried out in triplicate in a 96-well plate and always included a blank 
lacking the enzyme. Absorbance was measured after addition of 0.1 ml of 2M 
NaOH at 405 nm using a microplate reader (ELx808 Absorbance Microplate 
Reader, BioTek). The absorbance of the blank was subtracted from the 
average absorbance of the triplicate samples and the percentage of 
hydrolysis over the control was calculated dividing the obtained O.D. of the 
enzyme in presence of inhibitor by the O.D. of the enzyme without inhibitor, 
multiplied by 100; the percentage of hydrolysis over the control was then 
plotted on the y-axis vs. the logarithmic of the molar concentration of the 
inhibitor tested. The dose-response curve was drawn using GraphPad Prism 
software, which calculates the corresponding IC50  (using the sigmoidal dose-
response equation: Y= Bottom+ (Top-Bottom)/(1+10 LogIC50-X)), only data with 
R2>0.9 was considered. When high 95% confidence intervals (95% CI) were 
obtained, the data were also fitted to a dose-response equation with fixed 
Top (=100) and Bottom (=0). 
For inhibition assays against human PTP1B, 40 ng of recombinant protein 
(Sigma, P6244-50UG) was used per reaction and incubated with 10 µM of 
DiFMUP substrate (6,8-difluoro-4-methylumbelliferyl phosphate, Invitrogen 
D6567, ε= 17 mM-1) in PTP1B buffer (25 mM Hepes pH 7.2, 50 mM NaCl, 2.5 
mM EDTA and BSA 0.01 mg/ml). PTP1B was first incubated with the 
inhibitor tested for 30 min at 37°C, then the substrate DiFMUP was added for 
10 min at 37°C. Changes in fluorescence were read at exc. 360 nm and em. 
460 nm, using the Flx800 Plate Reader (BioTek). Data was graphed as for 
TbPTP1. 
 
2.7.6 Enzyme competition assay 
 
For testing the nature of the inhibitor (competitive, non-competitive and 
mixed inhibitors) competition assays were carried out, in which a constant 
concentration of enzyme and inhibitor was tested in the presence of different 
concentrations of substrate (pNPP). TbPTP1 was used, as previously done, at 
0.3-0.4 µg per reaction, in the same buffer and 96-well plate format used for 
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enzyme kinetics and inhibition assays; the inhibitor to be tested was used at 
two or three different concentrations lower and higher than IC50 and added 
to the mix of enzyme and buffer. To start the reaction 40 µl of substrate was 
added to a final concentration of 33.3 mM for the first row of triplicate 
samples and then diluted 1:2 in the subsequent wells. The absorbance 
obtained was converted into velocity of hydrolysis, as done for the enzyme 
kinetics assay, and plotted against the linear molar concentration of 
substrate. The Vmax and KM were calculated by GraphPad Prism using the 
Michaelis-Menten equation (Y= (Vmaxx X)/(KM+X), where Y is the enzyme 
velocity and X is the substrate concentration); the Vmax and KM of the enzyme 
in presence of the inhibitor was compared with the ones obtained with 
enzyme and substrate alone. 
 
2.7.7 Compounds preparation  
 
All the DDP inhibitors tested were dissolved in DMSO (dimethyl sulfoxide) 
at 25 mM stock concentration of which aliquots were kept at -20°C in dark 
0.2 ml eppendorf tubes. Similarly, Oleanolic acid (Sigma O5504) was 
dissolved to have a 20 mM stock solution, of which aliquots were kept at        
-20°C.  
Sodium vanadate (Sigma) was activated by adjusting the pH of a 200 mM 
solution to pH 10 with 1 M NaOH or HCl (Gordon, 1991); the solution was 
then boiled until it turned colorless, cooled and adjusted to pH 10 again, 
followed by other cycles of boiling and setting the pH until the solution 
remained colorless with a stable pH of 10. 
The PTP1B inhibitor 3-(3,5-Di-bromo-4-hydroxy-benzoyl)-2-ethyl-
benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide), 
(Calbiochem®, product number 539741) was dissolved in DMSO to give a 67 
mM  stock solution.   
 
2.8. Cell extract selection using recombinant TbPTP1 
 
Approximately 1.4x109 stumpy form cells were treated with 150 µM BZ3 for 
1.5 hr in HMI-9. They were then harvested by centrifugation, washed once in 
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PSG, and frozen in liquid nitrogen. Cells were then lysed by addition of 500 
µl of His-purification lysis buffer (20 mM Tris, 250 mM NaCl, 1% Triton-X, 1 
mM β mercaptoethanol, 5 mM Imidazole, pH 7.5-8) supplemented with 
complete, EDTA-free protease inhibitor cocktail (Roche). The extract was 
lysed by two cycles of freezing-thawing at -80°C, centrifugated for 20 min at 
4°C 14,000 rpm and sonicated 3 min in a water bath. Quantification of 
cellular protein was performed by the Bradford method following the 
manufacturer’s instructions.  
A total of 15 mg of cell extract, in 800 µl of His-purification buffer, was first 
incubated with NiNTA agarose beads, 20 min at 4°C, in order to clear the cell 
extract from proteins that could aspecifically bind to the beads; then 3.8 mg 
and 11.6 mg of the cleared extract were incubated with 20 µl of beads alone 
or 40 µl of recombinant TbPTP1, respectively. The reaction was allowed to 
proceed for 1.5 hr at 4°C on a slowly shaking platform. After 2-3 washes with 
PBS the proteins were eluted by addition of 40 µl of SDS sample buffer and 
boiled.  
 
2.9. Mass spectrometry analysis 
 
The Mass spectrometry analysis was performed by Richard Burchmore, at 
the Sir Henry Wellcome Proteomics Facility (University of Glasgow), using 
the electrospray ionization technique on a QSTAR Pulsar Hybrid 
LC/MS/MS System. The resulting spectra were then compared against the 
complete T. brucei proteome using the Matrix Science Mascot search engine. 
More details of the protocol used can be found in Szoor et al., 2010. 
 
2.10. Cellular ROS detection 
 
For reactive oxygen species (ROS) detection using H2DCF-DA (2’, 7’-
dichlorofluorescin diacetate, Sigma D6883) cells were stained with 50 µM 
H2DCF-DA in HIM-9 for 20 min in the 37°C incubator then harvested by 
centrifugation 5-10 min at 2,000 rpm and washed once with PSG to remove 
excess dye. Cells were then resuspended in PSG and treated with cis-
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aconitate/citrate/isocitrate or H2O2. Cells were then analysed by flow 
cytometry with the FITC channel using FACSCalibur (BD Biosciences) 
machine and the BD Cell Quest Pro software.  
For quantification cells were analysed using a fluorimeter (Fluostar Galaxy, 
BMG Labtechnology and Fluostar Galaxy software) with excitation at 490 nm 
and emission at 520 nm and DCF (2’, 7’-dichlorofluorescein, Sigma 410217) 
dilutions as standard. When the cell-permeable ROS-scavenger NAC (N-
Acetyl-L-cysteine, Sigma A9165) was used, cells were grown in HMI-9 
supplemented with NAC (250, 400 or 800 µM) for 1 hr prior the addition of 
the dye and treated again when the dye was added.  
 
For ROS quantification using Ampliflu Red (Sigma 90101), cells were placed 
in HIM-9 containing 50 µM Ampliflu Red and 1unit/ml HRP before addition 
of cis-aconitate/citrate/isocitrate or H2O2. Fluorescence was measured in 
triplicate at excitation wavelength of 544 nm and emission at 590 nm in a 
black 96-well plate using Fluostar Galaxy, BMG Lab technology and Fluostar 
Galaxy software. 
 
2.11. Cell proliferation assay using Alamar Blue®  
 
Cells were grown in normal HMI-9, 20% FCS, in a 96-well plate with initial 
cell density of 1x105/ml and were treated with serial dilution of the drug to 
be tested for 48 hr in the 37°C incubator; after that 10% v/v Alamar Blue® 
(Abd Serotec) was added (20 µl in 200 µl) for further 24 hr and absorbance of 
the samples was read at 540 and 595 nm, using ELx808 Absorbance 
Microplate Reader, BioTek and the Gen5 software. Cells were tested in 
triplicate and included a blank with the drug in HMI-9 without cells; the 
average absorbance of the triplicate samples minus the blank was calculated 
for both the wavelengths and the percentage difference in Alamar Blue® 
reduction of the cells treated with the drug versus untreated was calculated 
using the following formula, as suggested by the manufacturer: [A540-
(A595xR0) for test well)/(A540-(A595xR0) for control well]x100 , where R0 is the 
correction factor for different filters obtained from: [(A540media+alamar)- 
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(A540media)/(A595media+alamar)-(A595media)]. The percentage of Alamar 
Blue® reduction was then plotted on the y-axis against the logarithmic 
concentration of the drug tested using GraphPad Prism and the LD50 was 
calculated analyzing the data using the sigmoidal dose-response equation: 
Y= Bottom+ (Top-Bottom)/(1+10 LogIC50-X)).  
 
2.12. Flow cytometry for EP-procyclin surface expression 
 
Approximately 2-4 x106 cells were centrifugated in FACS tube 5 min at 2,000 
g , washed once with PBS and fixed in 200 µl PBS 2 % formaldehyde/ 0.05 % 
gluteraldehyde, overnight at 4°C. The next day the cells were first washed 
with PBS, then blocked in PBS 2% BSA for 30 min at 4°C; the primary 
antibody (anti EP-procyclin, 1:1,000) was then added in PBS 2% BSA for 30 
min and secondary (anti mouse FITC, 1:1,000) was added for the same length 
of time after one wash with PBS. The samples were kept in PBS and analysed 
by flow cytometry using a FACSCalibur FACS machine (BD Biosciences). 
The percentage of EP-positive cells was counted by gating on the positive 





When needed the samples subjected to flow cytometry (see previous 
paragraph) were also used for immunofluorescence. After FACS analysis the 
same samples were briefly centrifuged, the pellet was resuspended in about 
100 µl of PBS and spread over a glass slide (Menzel-Glaser slides 76 x 26 
mm). After allowing the slides to air-dry, they were stained with 1 µg/ml of 
4,6-diamidino-2-phenylindole (DAPI) for 2 minutes to highlight the nucleus 
and kinetoplast of the cells. Afterwards the slides were covered with a cover 
slip (Scientific Laboratories Supplies) mounted using 10% PDA (p-
phenylenediamine) in MOWIOL (10% MOWIOL, 25% glycerol and 0.1 M 
Tri-HCl, pH 8.5). The slides were then analysed under a Zeiss Axioskop 2 
plus Microscope.   
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2.14. Bioinformatics 
 
TbPTP1 3-D structure model was predicted using the online application 
Swiss-Pdb Viewer (Arnold et al., 2006) (http://swissmodel.expasy.org/), 
selecting the “alignment mode” and as template PTP1B catalytic domain 
(PDB code: 1g7fA). The model (E value =0.00e-1) was then visualized using 
Swiss-Pdb Viewer application. 
 
2.15. Statistical analysis 
Statistical analysis was performed using General Linear Model of the 
statistical software MINITAB (version 1.4). The cut off for significance used 
was P<0.5. 
 
2.16. Plasmids used in this study 
2.16.1 The pGEM®-T Easy plasmid 
 
The pGEM®-T Easy plasmid (Promega) was used to clone PCR products. 
The vector is already linearized and contains 3’ thymidine overhangs that 
improve the efficiency of the ligation of PCR products by preventing 
recirculization of the plasmid.   
2.16.2 The pET-28a and pET-30a plasmids 
 
The pET-28a is a 5.3-kb plasmid (Novagen) containing an N-terminal His 
Tag® (a stretch of five His), a thrombin cleavage site and T7 Tag® coding 
sequence. It also contains the T7 promoter and terminator sequences and the 
kanamycin resistance gene. For the inducible expression of the tagged 
protein, the plasmid contains the E. coli lac operator and the lacI gene, coding 
for the lac repressor. The repressor is constitutively expressed and by binding 
to the lac operator, inhibits efficient transcription of the downstream 
sequence, containing the exogenous gene.  However, when lactose or other 
analogues, like IPTG (isopropyl-β-D-thio-galactose), are present, the 
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repressor is inactivated and the exogenous gene is expressed. This plasmid 
was used for the expression of wild type TbPTP1. 
 
The pET-30a plasmid is identical to the pET-28a, except that it contains the S 
Tag® instead of the T7 Tag® and a C-terminal His Tag®, in addition to the 
N-terminal one.  Consequently the pET-30a is slightly longer than the pET-
28a (5422 bp compared to 5369 bp). 
In both plasmids the TbPTP1 gene was cloned using the XhoI and BamHI 
restriction sites. The pET-30a was used for the wild type and all the mutants 
TbPTP1. 
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2.16.3 The p2T7 plasmid 
 
The p2T7 is a plasmid developed from the p2rRNAprom for RNA 
interference in T. brucei (LaCount et al., 2000), and it contains two 
bacteriophage T7 promoters on the opposite sides of the target gene. The 
primary advantage of this vector is that it allows the construct to be prepared 
in a single cloning step. In presence of G418 (1µg/ml), the sense and 
antisense RNAs, from the sequence located between the two promoters, are 
expressed and anneal to form dsRNA, which activate the RNAi pathways. 
The Tb10.389.0310 and Tb11.02.2090 gene fragments (688 bp and 525 bp, 
respectively) were both inserted in the p2T7 plasmid using the HindIII and 
BamHI restriction sites. 
 
2.17. Primers used for RNAi 
Tb10.389.0310 
 
Tb10.389.0310 FWD primer HindIII, BamHI: 5’-AAGCTT (Hind III) GGATCC 
(BamHI) TGT TGT GTC GCC GAT TAT GT; Tb10.389.0310 REV primer XhoI, 
NdeI: 5’-CAA CTG ACG CGA TAC CCG TAA AAG TG. 
Tb11.02.2090 
 
Tb11.02.2090 FWD primer HindIII and BamHI: 5’-ATA AAGCTT (Hind III) 
GGATCC (BamH) ACC GGA TGT GACT TGC ACC A; Tb11.02.2090 REV 
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3.1. Introduction 
 
Trypanosoma brucei Protein Tyrosine Phosphatase 1 (TbPTP1) represents a 
major regulator of trypanosome differentiation from stumpy to procyclic 
forms (Szoor B et al., 2006). In order to better characterize the TbPTP1 
signalling pathway responsible for this transition, the validation of the 
candidate interacting protein, TbPIP39, and the identification of novel 
substrates was essential. For this purpose, two complementary approaches 
were investigated, which are the topic of this chapter.  
The first approach involved the potential use of a TbPTP1 substrate 
consensus sequence in order to identify novel substrates of the phosphatase 
in silico, similarly to what has been done with human PTP1B (Myers et al., 
2001). For this aim, the PTP1B substrate consensus literature was reviewed, 
and the 3-D structures of PTP1B and TbPTP1 were compared.  
The second approach consisted of the in vitro selection of candidate 
substrates from stumpy form cell extracts, using a recombinant substrate-
trapping mutant TbPTP1, which was employed to both validate the 
candidate protein and identify novel substrates.   
 
3.2. Comparative analysis of PTP1B and TbPTP1 structures 
 
Published work on human PTP1B identified a specific motif in a group of 
substrates, required for their interaction with the phosphatase (Salmeen et al., 
2000); this motif was also successfully used to predict two novel 
physiological substrates for PTP1 (Myers et al., 2001). Therefore, the 
possibility of using a similar approach for the identification of substrates of 
TbPTP1 was examined.  
Before investigating the presence of a potential TbPTP1 substrate consensus 
sequence, it was essential to compare the primary sequence and 3-D 
conformation of TbPTP1 and PTP1B, in order to assess whether the two 
enzymes share a conserved structure. Since the TbPTP1 structure, which has 
been recently characterized (Chou et al., 2010), was not known at the time in 
which the project was conducted, a model of its 3-D fold was predicted using 
the online workspace Swiss Model (Arnold et al., 2006). It is worth noting 
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that the PTP1B C-terminal domain was missing in the 3D model as only the 
catalytic domain of the enzyme spanning aa 1-298 (Sun et al., 2003)  or 1-321 
(Jia et al., 1995) have been crystallized. 
 
3.2.1 The ten landmark PTP motifs 
 
 As previously described, the alignment of the amino acid sequence of PTP1B 
and TbPTP1 showed that all the ten landmark PTP motifs (M1 to M10) 
(Andersen et al., 2001), except for motif 2 (M2), are present in the parasite 
enzyme (Szoor et al., 2006).  
A more detailed analysis of the alignments of these motifs revealed that all 
the invariant residues of the ten landmark PTP motifs (underscored bold 
letters in Table 2.1) are perfectly conserved in TbPTP1 and that the overall 
identity of the motifs varies between 38 and 100%, with 7 out of 8 motifs 
scoring more than 50% (Table 3.1).  
 
3.2.2 Conserved residues outside the landmark motifs 
 
Outside the landmark motifs, seven residues have been reported to be 
conserved among PTPs (Andersen et al., 2001), five of which are not identical 
in TbPTP1, specifically Glu19, Arg156, Arg169, Leu192 and Arg254 of PTP1B 
are replaced by Phe25, Asp167, His188, Glu211 and Lys267 in the parasite 
enzyme (Table 3.2).  
Of these five PTP residues, four are considered to be important for the 
definition of certain helices/sheets (Andersen et al., 2001), all of which are 
predicted to fold into the same secondary structure in TbPTP1. Specifically 
Phe25 defines the conserved α’2 helix, Asp167 and His188 the β10 and β11-
sheet, and Glu211 the α3 helix.  
The fifth substitution Arg254→Lys267 is potentially interesting, indeed 
Arg254 has been shown to form hydrogen bonds with the PTP loop of 
PTP1B, and has been hypothesized to function in enhancing the interaction 
with the phosphorylated tyrosine (pTyr) of the substrate and/or in 
stabilizing the thiolate form of the nucleophilic cysteine (Andersen et al., 
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2001). Interestingly, mutations of Arg254 to Lys or Gln in PTP1B have been 
shown to have an inhibitory effect on the dephosphorylation of the artificial 
substrate pNPP (Salmeen et al., 2000), thus the presence in TbPTP1 of Lys267 
could indicate a weaker nucleophilic activity of the catalytic Cys residue.  
In addition, Arg254 has been shown to form the second phosphate-binding 
site, which has lower affinity for the substrate but that could be targeted, 
together with the main active site, to develop more specific inhibitors (Puius 
et al., 1997). Indeed a peptide possessing two adjacent phosphorylated 
tyrosine residues (tandem pTyr), which targets both sites, has been shown to 
have a 70-fold higher binding affinity for PTP1B compared to the mono 
phosphorylated tyrosine peptide (Salmeen et al., 2000).  
Therefore, the observation that Arg254 is substituted by Lys267 in TbPTP1 
has two potentially important implications: the fact that the parasite enzyme 
might not prefer substrates containing tandem pTyr over mono pTyr, and 









































Table 3.1. Comparative analysis of the residues conserved between TbPTP1 and 
mammalian PTPs. (A) TbPTP1 structure highlighting the ten conserved landmark PTP 
motifs (Andersen et al., 2001) and the trypanosome-specific ones. (B) The consensus 
sequences of the PTP motifs are compared to the residues found in TbPTP1 (Szoor et al., 
2006). The percentage of amino acid identity is also shown (identity); invariant amino acids 
are underscored and bold, bold letters are conserved >90% and non bold >80% (from 
Andersen at el., 2001).  























Table 3.2. Conservation of the important PTP residues outside the landmark motifs. 
The conserved residues in mammalian PTPs (Andersen et al., 2001) (numbered for PTP1B) 
are compared with the corresponding amino acids of TbPTP1; TbPTP1 residues that are not 
conserved with PTP1B, and other mammalian PTPs, are highlighted. The proposed function 
of each residue, according to Andersen et al., 2001 is also shown (H bond: hydrogen bond; 
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3.2.3 3-D structure prediction of the trypanosome-specific motifs 
 
As previously illustrated (see paragraph 1.17), other interesting differences 
were highlighted from the comparative analysis of the primary sequence of 
TbPTP1 and human PTP1B: the presence of six trypanosome-specific 
sequences, two pre-catalytic (PcT1 and PcT2) and four within the catalytic 
core (T1-T4) (Szoor et al., 2006)(Figure 3.1 A).  
Prediction of the secondary and 3-D structure for TbPTP1, using the online 
available Swiss Model server (Arnold et al., 2006; Bordoli et al., 2009), and 
their superimposition with the PTP1B structure showed that most of the 
trypanosome-specific motifs align with the PTP1B backbone. However, these 
motifs are often arranged in random coils or U-turns, rather than α-helices or 
β-sheets, and are positioned on the surface of the enzyme (Figure 3.1 B).  
The only exceptions are the motif T3, which is found within the core of the 
enzyme and motif T4, which is found outside in the 3-D structure prediction 
(aa 1-288).  
According to the TbPTP1 3-D model, the trypanosome-specific pre-catalytic 
motif PcT1 (aa 20-29) is found on the surface and folds into an α-helix, which 
aligns well with the corresponding PTP1B α2’ helix, a motif that is conserved 
structurally but not at sequence level among PTPs (Andersen et al., 2001).  
In contrast, PcT2 (aa 32-43), which is predicted to form a coil, partly deviates 
(residue 33-35) from the backbone structure of PTP1B and protrudes towards 
the outside of the enzyme.  
Similarly, the trypanosome-specific motif T1 (aa 55-63), which substitutes 
M2, is predicted to fold into a loop, in contrast to M2, which forms a β-sheet. 
Moreover Tyr62 of T1 is predicted to map on the edge of the loop, facing 
away from the central core of the enzyme. Similarly to T1, T2 (aa 164-166) 
also forms a U-turn on the surface of the enzyme (Figure 3.1 B). 
The most interesting trypanosome-specific motif is probably T3 (aa 239-244), 
as it is found in the vicinity of the active site of the enzyme, although none of 
the corresponding residues in PTP1B have been shown to participate in 
catalysis. Motif T3 aligns well with the PTP1B backbone and, similarly to the 
human sequence, is predicted to fold into an α-helix. The only difference 
between T3 and the corresponding region of PTP1B are two TbPTP1 residues, 
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Ala242 and Tyr243, which are not well conserved among PTPs, each of 
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Figure 3.1. TbPTP1 structure. (A) Schematic diagram of TbPTP1 highlighting the PTP 
motifs (M1-10) and the trypanosomes-specific motifs (PcT1-2, T1-4). The ten conserved PTP 
motifs are shown (M1-M10) and coloured according to the degree of conservation among 
PTPs (red: high, orange: medium, blue: low); the trypanosome-specific motifs are coloured in 
pink (PcT1, PcT1, T1-T4). The secondary structure prediction for TbPTP1 (α-helix, β-sheet 
and coil, predicted obtained using Swiss Model (Arnold et al., 2006) is also shown and 
labeled according to Andersen et al., 2001. (B) The 3-D structure of TbPTP1 and PTP1B are 
shown, as predicted by the Swiss Model server and visualized using Swiss pdb-Viewer. The 
PTP motifs are labeled and coloured as for A. 
3- TbPTP1 substrate identification 97 
3.3. TbPTP1 substrate consensus analysis 
 
The comparative analysis of the PTP1B and TbPTP1 structure showed that 
the two proteins share most of the residues involved in substrate binding 
(Table 3.1 and Figure 3.1). Consequently, it is possible that the two enzymes 
share the preference for certain types of amino acids surrounding the 
phosphorylated tyrosine.  
A review of the literature published regarding the PTP1B substrate 
consensus sequence (i.e., the most commonly occurring amino acids, at each 
position of an aligned series of substrate proteins (Berg et al., 2002)) revealed 
the existence of two groups of substrates. The first group includes the PTP1B 
targets that are phosphorylated in two adjacent tyrosine residues (tandem 
pTyr), such as the insulin receptor (Salmeen et al., 2000). The second group 
comprises the substrates presenting only one phosphorylated tyrosine 
residues (pTyr), like the EGF receptor (Zhang et al., 1993).  
 
3.3.1 Tandem phosphorylated tyrosine consensus sequence 
 
For the first group, a substrate consensus sequence was characterized (E/D-
pY-pY-R/K), which was successfully used for the identification of two novel 
PTP1B targets (Myers et al., 2001). The residue responsible for the binding to 
the second pTyr has been shown to be Arg254 (Puius et al., 1997), which is 
not conserved in TbPTP1 (see paragraph 3.2.2).  
This observation, together with the fact that no tandem pTyr were detected 
in the list of T. brucei tyrosine phosphorylated proteins (Nett et al., 2009b), 
suggested that the PTP1B substrate consensus E/D-pY-pY-R/K is probably 
not valid for TbPTP1.  
 
3.3.2 Mono phosphorylated tyrosine consensus sequence 
 
In addition to the PTP1B substrate consensus sequence containing tandem 
pTyr, a lot of work has also been done to try and identify the consensus 
containing one pTyr residue (Figure 3.2).  
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Initial studies that used the substrate peptide DADEpYL, modeled on the 
auto-phosphorylation site of EGFR, highlighted the importance of the acidic 
residue N-terminal to the pTyr (Zhang et al., 1993). Further crystallographic 
analysis of the PTP1B complex with the same peptide identified Arg47 as the 
major determinant of this preference (Sarmiento et al., 1998), due to the 
guanidinium group of Arg forming salt bridges with the carboxylate group 
at the -1 position of the substrate peptide. However, other studies, which 
used random peptides, for example generated from phage display libraries, 
showed a wider preference at the -1 position (N-terminal) to the pTyr (Vetter 
et al., 2000; Walchli et al., 2004).  
The observation that aromatic/aliphatic residues can also be accommodated 
at position -1 to the pTyr was then explained by the ability of the side chain 
of Arg47 to adopt two different conformations (Sarmiento et al., 2000). 
Interestingly, TbPTP1 possesses a Leu (Leu52) at the corresponding position 
of Arg47 of PTP1B, which suggests a possible preference for aliphatic or 
aromatic residues N-terminal to the pTyr (Figure 3.2).   
In the list of tyrosine-phosphorylated proteins of bloodstream form T. brucei, 
hits containing non-charged residues at the -1 position represented 15/41 
(36%), versus 6/41 (15%) proteins containing acidic residues in the same 
position. However, the confirmed TbPTP1 substrate, TbPIP39 possesses a 
glutamic acid (Glu278) N-terminal to the pTyr (DEpYTK) (Szoor et al., 2010). 
These contrasting observations probably suggest that the in silico selection of 
TbPTP1 substrates, based on the type of residue found in the vicinity of the 























Figure 3.2 Substrate consensus sequence analysis. The schematic diagram summarizes 
the literature cited in the text concerning the PTP1B substrate consensus sequence for mono 
pTyr; the peptide used in the studies analysed is shown on the left (modifications of the 
EGFR peptide: DADEpY), and the residues N-terminal to the pTyr are highlighted in bold 
together with the corresponding aa type (acidic/aromatic/aliphatic). Acidic residues were 
initially identified as preferentially selected, due to their interaction with the basic side  chain 
of Arg47 (Sarmiento et al., 1998); then a wider preference of aa N-terminal  to the pTyr was 
recognized, explained by the repositioning of the Arg side chain (Sarmiento et al., 2000). 
TbPTP1 possesses Leu52 in place of Arg47 of PTP1B, which might suggest a preference for 
aromatic or aliphatic aa N-terminal to the pTyr of its substrates. Red, green and blue colours 
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3.4. The TbPTP1 substrate-trapping mutant approach 
 
In order to identify novel TbPTP1 substrates, the method chosen was the use 
of a substrate-trapping mutant TbPTP1, coupled to mass spectrometry 
analysis. Such a procedure, using the single mutant D→A, has been 
employed successfully in the case of PTP1B (Flint et al., 1997; LaMontagne et 
al., 1998a) and it is based on the fact that the substitution of the catalytic 
aspartic acid of the WPD loop causes the enzyme to retain the substrate, thus 
allowing its selection and identification (Flint et al., 1997) (see paragraph 
1.15).  
The visualization of the trapped proteins is then possible by Western blot 
analysis against phosphorylated tyrosine residues. Therefore it was initially 
important to optimize the detection of tyrosine-phosphorylated proteins in T. 
brucei using Western blot.  
 
 
3.4.1 Profile of tyrosine-phosphorylated proteins in stumpy cell extract 
 
In order to optimize the detection of tyrosine-phosphorylated proteins 
several conditions of cell lysis and Western blot analysis were tested. 
Particularly important turned out to be the use of the more sensitive PVDF 
(polyvinylidene fluoride) membrane, compared to the normal nitrocellulose 
membrane, and the type of anti phosphorylated tyrosine antibody used (α-
pTyr).  
One example of a phosphorylated tyrosine profile, obtained from stumpy cell 
extracts is shown (Figure 3.3), together with a schematic comparison to the 
only published data available to date (Parsons et al., 1990). As can be seen, 
the profile obtained is not identical to the analysis conducted by Parsons et 
al., (compare Figure 3.3 A and Figure 3.3 B). In particular, proteins with a 
molecular weight of less than 30 kDa were not detected in the published 
profile. These discrepancies might be due to the different T. brucei strains, 
antibodies or blotting conditions used. Nevertheless it is possible to identify 
some proteins detected in both studies: two doublets at around 35 and 40 
kDa and a strong band at around 55 kDa (Figure 3.3 C).  
In order to test the specificity of the antibody for tyrosine-phosphorylated 
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proteins, the antibody itself was pre-incubated with phenyl phosphate, a 
phosphate analogue, which had been used for this purpose (Parsons et al., 
1990). In the presence of 200 mM phenyl phosphate (pp) most of the bands 
decreased in intensity, and the less abundant high molecular weight proteins 




Figure 3.3 Profile of tyrosine-phosphorylated proteins in stumpy form cell extracts. 
Example of a Western blot performed on stumpy form cell extracts probed with anti 
phosphorylated tyrosine antibody (α-pTyr), 4G10 (Upstate) (panel A) and its comparison with 
the only published profile by Parsons et al.,1990 (panel B); the apparently common bands 
(arrows) are shown in the diagram of panel C. The same extract was probed with the same 
antibody in absence or presence of 200 mM phenyl phosphate (pp); the ponceau stain of the 
membrane is included to show equal loading (Ponceau of panel D). All the numbers indicate 
molecular weight markers in kDa. 
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3.5. Selection of stumpy form cell extract using substrate-
trapping D199A/Q275A TbPTP1 
 
As previously mentioned, the substrate-trapping D181A mutant PTP1B has 
been extensively used for the identification of novel substrates of the 
phosphatase (Garton et al., 1996; LaMontagne et al., 1998a). However, more 
recent work has shown that the double mutant D181A/Q262A PTP1B 
displays a 6-fold greater substrate trapping ability compared to the D181A 
enzyme, as judged by in vitro binding assays to a substrate analogue and by 
in vivo immune-precipitations (Laiping et al., 2001).  
Therefore, in order to increase the substrate-trapping ability of the D199A 
TbPTP1, the double mutant D199A/Q275A enzyme was created (Figure 3.4). 
The Q275A mutation was introduced in the pET30a plasmid containing the 
His-tagged D199A protein sequence. In parallel, an additional double mutant 
D199A/ C229S TbPTP1 was also created (Figure 3.4), to be used as a negative 
control, since the corresponding PTP1B mutant has been shown to behave 
like the wild type protein (Laiping et al., 2001).  
 
Figure 3.4. Double mutants D199A/Q275A and D199A/C229S TbPTP1. The primary 
sequence of TbPTP1 is depicted, with trypanosome-specific motifs highlighted (PcT1, PcT2, 
T1 to T4). The domains important in catalysis (see paragraph 1.15.3) are labeled (WPD loop; 
P loop; Q loop). The residues substituted in the different mutant forms (D199, C229 and 
Q275) are indicated by asterisks (*).  
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Both D199A/Q275A and C229S/D1994A TbPTP1 mutants were expressed 
and purified in E. coli (Figure 3.5).  
After successful expression and purification, the double mutants were used, 
together with the single mutant D199A, to select potential TbPTP1 substrates 
from stumpy form cell extracts. Briefly, stumpy cells were harvested from a 
mouse infection and incubated with 150 µM BZ3, a commercially available 
PTP1B inhibitor (see paragraph 1.18.3), that is able to inhibit TbPTP1 (Szoor 
et al., 2006), for 1.5 hr at 37°C.  Cells were then lysed and incubated for 1 hr at 
4°C with the different His-tagged mutant versions of TbPTP1. After 2-3 PBS 
washes, the bound proteins were eluted with the addition of SDS sample 
buffer, boiled and subjected to SDS-PAGE and Western blot. 
Western blot was performed using the anti phosphorylated tyrosine 
antibody (α-pTyr), with the same conditions previously optimized (Figure 
2.3), since the substrates trapped by the enzyme are still phosphorylated. 
As expected the double mutant D199A/Q275A TbPTP1 trapped several 
tyrosine-phosphorylated proteins, whereas the D199A/C229S and the WT 
enzyme did not (Figure 3.5 B). 
In order to more specifically elute only the tyrosine phosphorylated proteins 
bound to the substrate-trapping enzyme, sodium vanadate was employed as 
a competitor. Indeed sodium vanadate is a powerful PTP inhibitor that binds 
the catalytic site of the enzyme and that has been used to elute proteins 
selected by substrate-trapping phosphatases (Blanchetot et al., 2005; Chang et 
al., 2008). However, vanadate did not elute tyrosine phosphorylated proteins 
bound to the D199A TbPTP1 (data not shown), even at 120 mM, a 
concentration 8-fold higher than published. This was despite the use of a  
buffer lacking imidazole and β-mercaptoethanol, which have been reported 
to inhibit vanadate action (Huyer et al., 1997). Since vanadate competition has 
been reported for only some PTPs, towards certain substrates and under 
specific conditions (Blanchetot et al., 2005), it is likely that, in the 
experimental conditions used, the compound did not compete strongly 
enough with recombinant D199A TbPTP1 to allow effective elution and 
visualization of the bound proteins. 
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Figure 3.5. Purification of the recombinant mutant forms of TbPTP1 and stumpy form 
cell extract selection. (A) Coomassie stain of purified His-tagged C229S/D199A mutant 
TbPTP1 (CD) and D199A/Q275A mutant TbPTP1 (DQ). (B) The same recombinant proteins 
of panel A were used to select potential TbPTP1 substrates from stumpy form cell extract. In 
the upper panel the Ponceau staining of the membrane shows the loadings of the 
recombinant proteins (Ponceau). In the lower panel is shown the Western blot of the 
selection using the different recombinant forms of the enzyme probed with anti 
phosphorylated tyrosine antibody (WB α-pTyr). DQ: D199A/Q275A mutant TbPTP1; D: 
D199A mutant TbPTP1; DC: D199A/C229S mutant TbPTP1, as negative control; WT: wild 
type TbPTP1 as negative control; Beads: nickel agarose beads incubated with cell extract; 
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3.6. TbPIP39 selection by TbPTP1 in stumpy form cell extracts 
 
TbPIP39 was identified by mass spectrometry analysis of stumpy form cell 
extract selected by the D199A mutant TbPTP1, before the start of this project. 
At that moment a specific antibody against TbPIP39 was not available, and 
thus it was not possible to visualize the two proteins by Western blot 
analysis, thus validating their interaction.  
Only during the course of this project, a specific antibody against TbPIP39 
was developed, which was then used to detect TbPIP39 in the cell extract 
selections (Figure 3.6). As expected, TbPIP39 was selected by the substrate-
trapping mutants D199A (“D”) and D199A/Q275A (“DQ”) TbPTP1 and not 
by wild type enzyme (“WT”) or by the agarose beads alone (“Beads”). 
However, the C229S/D199A mutant TbPTP1 (“DC”), which did not trap any 
tyrosine-phosphorylated proteins (Figure 3.5 B), did bind TbPIP39 (Figure 
3.6 A). This difference might be due to a lower sensitivity of the anti 
phosphorylated tyrosine antibody compared to the anti TbPIP39 antibody. 
The same selection was repeated using equal amounts of recombinant wild 
type (“WT”) and D199A (“D”) TbPTP1 (Figure 3.6 B). The Western blot was 
probed with anti His tag antibody (α-His), to obtain a more accurate 
quantification of the His-tagged recombinant protein compared to Ponceau 
staining, and with anti TbPIP39 antibody  (α-PIP39). TbPIP39 was found in 
the initial cell extract (“CE”), in the unbound cell extract (flow through, “FT”) 
and, importantly, in the lane corresponding to the substrate-trapping D199A 
TbPTP1 after incubation with the cell extract (arrowhead in “D + CE” lane of 
Figure 3.6 B). TbPIP39 was also selected by the wild type TbPTP1, after 
incubation with stumpy cell extract (arrowhead in “WT + CE” lane in Figure 
3.6 B). This observation suggested that, under certain experimental 
conditions, the interaction between wild type TbPTP1 and TbPIP39 was 
stable enough to be detected, as seen when the two proteins were immune-





















Figure 3.6 TbPIP39 selection by TbPTP1 in stumpy form cell extract. (A) The stumpy 
form cell extract selection of Figure 3.5 was probed with anti TbPIP39 antibody (α-PIP39); 
the recombinant TbPTP1 used are wild type (WT), C229S/D199A (DC), D199A (D), 
D199A/Q275A (DQ) and NiNTA agarose beads alone (Beads). All of them were incubated 
with stumpy form cell extract (+CE); cell extract prior incubation is also shown (lane CE). The 
Ponceau staining of the membrane is shown as loading control (Ponceau). (B) Western blot 
of another selection using wild type (WT), D199A (D) TbPTP1 and NiNTA agarose beads 
alone (Beads), in absence or presence of stumpy cell extract (-/+ CE). The membrane was 
probed against TbPIP39 (α-PIP39), and against His-tagged TbPTP1 (α-His). FT: flow 
through (cell extract after incubation with the recombinant proteins). Note that the white 
bands in the lower panel of B, are the recombinant proteins visible on the membrane, but not 
detected by the anti phosphorylated TbPIP39 antibody. 
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3.7. Selection of stumpy form cell extract using D199A TbPTP1 
and mass spectrometry analysis 
 
The stumpy form cell extract selection was then used in larger scale cell 
extract selection experiments.  The substrate-trapping mutant D199A TbPTP1 
was used, as it has been shown to trap more tyrosine phosphorylated 
proteins than the other mutants (Figure 3.5 B). 
For the larger scale selections, approximately 1x109 stumpy form cells were 
treated with BZ3 for 1.5 hr at 37°C. Subsequently the cells were lysed and the 
protein extract (11.6 mg) was incubated with the substrate-trapping D199A 
TbPTP1. After 2-3 PBS washes, the bound protein were eluted by addition of 
SDS sample buffer and half the amount of each sample was visualized by 
Coomassie staining of the gel (Figure 3.7).  
The substrate-trapping D199A TbPTP1 selected several proteins from the cell 
extract, as judged by the darker appearance of the gel (lane “D199A + CE” in 
Figure 3.7); among them, one band, of approximately 120 kDa, appeared to 
be clearly visible (arrow in Figure 3.7). This band, cut from the gel, together 
with the remaining half of the other samples were subjected to mass 
spectrometry analysis.  
The mass spectrometry (MS) analysis was carried out by Richard Burchmore 
(University of Glasgow), using the electrospray ionisation (ESI) technique on 
a QSTAR Pulsar Hybrid LC/MS/MS System. The resulting spectra were 
compared via Matrix Science Mascot search engine against the complete T. 
brucei proteome. The results of the mass spectrometry analysis are shown in 
Table 3.3, where the hits obtained from similar experiments to the one 
showed in Figure 3.7 are also included. A total of four cell extract selections 
were performed, two before the start of this project (experiment 1 and 2 of 
Table 3.3), and two performed during the course of this project (experiment 
3 and 4 of Table 3.3). The proteins listed have been selected by the D199A 
TbPTP1 mutant and not by the agarose beads alone (negative control) in any 
of the experiments. In addition, proteins very similar to hits found in the 
negative control (such as tryparedoxin peroxidase 1 and tryparedoxin 
peroxidase 2), were not considered to be specifically selected by TbPTP1. 
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Figure 3.7 Selection of stumpy form cell extract using the D199A TbPTP1. The 
Coomassie stained protein gel of stumpy cell extract selection showing the molecular weight 
marker (M, numbers are in kDa), approximately 5% of the extract used in the incubation with 
D199A TbPTP1 (CE), NiNTA agarose beads incubated with the cell extract (Beads) and 
recombinant D199A TbPTP1 in absence or presence of cell extract (D199A - and + CE). In 












Table 3.3. Summary of the proteins identified by MS analysis for the new and for the 
previous stumpy cell extract selection experiments. The experiments are numbered in 
chronological order: 1 and 2 (previously performed by B. Szoor on 27/10/06 and 16/05/07), 3 
and 4 (performed during the course of this project). Proteins are identified by GeneDB 
database accession number (GeneDB accession n°), a description of the corresponding 
function is given (hyp. prot.= hypothetical protein; ser/thr= serine/threonine; IQ CaM= IQ–
calmodulin binding domain), together with the predicted molecular weight in kDa (predicted 
MW). 
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The analysis of the MS hits identified four proteins common to more than 
one selection, corresponding to a putative CTD phosphatase (Tb09.160.4460), 
which was then characterized and named TbPIP39,(Szoor et al., 2010) (see 
paragraph 1.17), two dynein heavy chains (Tb11.01.3010 and Tb927.7.920), 
and one hypothetical protein (Tb11.02.2090) (Table 3.3, experiment 1 and 2). 
None of the proteins specifically selected by the D199A TbPTP1 in the two 
selections performed in the course of this project (experiment 3 and 4) were 
found in the two previous selections (experiment 1 and 2), although the 
protocol followed was the same.  
Four new hits were identified in the course of this project: two hypothetical 
proteins (Tb10.6K15.2800 and Tb927.7.5700) and one Ser/Thr kinase 
(Tb11.01.0400) (Table 3.3, experiment 3). In addition, another hypothetical 
protein (Tb10.389.0310), characterized by the presence of an IQ-calmodulin 
binding domain, was found when the band cut from the gel of selection 
number 4 (Figure 3.6, arrowhead) was analyzed (Table 3.3, experiment 4).  
In order to assess the potential relevance of these hits to the TbPTP1 pathway 
during differentiation to procyclic forms, the structural and functional role of 
the different candidate proteins was analyzed, with the exception of 
Tb09.160.4460 (TbPIP39), which has already been validated as TbPTP1 target 
(Szoor et al., 2010).  
 
Tb11.01.3010 and Tb927.7.920 
 
Two of the hits identified, Tb11.01.3010 and Tb927.7.920 were large dynein 
heavy chains, of predicted molecular weight of 480 and 468 kDa, respectively 
(www.genedb.org). 
Higher eukaryotes dyneins are multisubunit microtubule-dependent motor 
enzymes that act as the force-generating proteins of eukaryotic cilia and 
flagella. Specifically, dynein heavy chains exhibit ATPase activity and 
microtubule binding ability and are responsible for the movement of 
organelles and vesicles along the microtubules (Burgess et al., 2003).  
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In T. brucei some dyneins are part of the intraflagellar transport apparatus, 
where they aid the transport of protein particles from the distal tip of the 
flagellum back to the basal body. RNAi of one such protein, TbDHC1b 
(Tb11.02.0030), led to loss of the flagellum and to the disorganization of cell 
structure and polarity (Kohl et al., 2003). This finding was particularly 
interesting in light of the observation that BZ3 treatment of slender cells 
caused a temporary loss of motility, apparent only within the first 5 min of 
drug treatment at 37°C (Szoor B., personal communication). Therefore 
dyneins might potentially play a role in the TbPTP1 pathway in slender form 
cells.  
Tb11.01.3010 expression, but not Tb927.7.920, appeared to increase in stumpy 
forms compared to slender forms, and then to be maintained constant 
throughout differentiation to procyclic forms (Kabani et al., 2009).   
However, no studies have been done on these two particular dyneins, and 





The fourth protein detected in both experiment 1 and 2 was a 197-kDa 
hypothetical protein (Tb11.02.2090), characterised by the presence of one 
HEAT repeat.  
The HEAT repeat is a tandemly repeated, 37-47 amino acid long module, 
occurring in a number of cytoplasmic proteins, including the four name-
giving proteins huntingtin, elongation factor 3 (EF3), the 65 kDa alpha 
regulatory subunit of protein phosphatase 2A (PP2A) and the yeast PI3-
kinase TOR1 (Andrade et al., 1995). Arrays of HEAT repeats consists of 3 to 
36 units, which form a rod-like helical structure, made of antiparallel α-
helices, and appear to function as protein-protein interaction surfaces, with 
each repeat corresponding to a structural unit of antiparallel helices (Kobe et 
al., 1999).  
It is difficult to predict whether the presence of a single HEAT repeat in 
Tb11.02.2090 (aa 765-801) is sufficient to form a protein-protein interaction 
domain, but the observation that 13/33 (39%) of T. brucei HEAT-containing 
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proteins possess a single repeat is intriguing. Twelve such proteins do not 
have a known function and do not possess any additional domain, whereas 
one is predicted to be a transportin-2 like protein (Tb10.6k15.3020); 
transportins mediate the nuclear transport of other proteins in higher 
eukaryotes (Harvey et al., 2000). Other T. brucei HEAT-containing proteins 
are a PP2A regulatory subunit, a putative importin-β 1 subunit and the 
flagellar protein PF16, which contain 8, 5 and 3 repeats, respectively 
(www.genedb.org). 
A Blast search for proteins similar to Tb11.02.2090 in other Trypanosoma 
species showed that the protein is conserved in T. cruzi and L. major, with a 
percentage of identity over T. brucei of 45 and 31, respectively; in addition, a 
particular tyrosine residue (Tyr409 of Tb11.02.2090) was shown to be 
conserved within these orthologues. No higher eukaryotic homologues could 
be found, only a human transcriptional regulator, homologous to the 
Drosophila Nipped-B (Krantz et al., 2004), had a limited degree of identity 
(21%) with a small portion towards the C-terminal part of the protein (aa 
1341-1581).  
The Tb11.02.2090 mRNA expression profile showed a small level of down-
regulation 18 hr after initiation of differentiation to procyclic forms, but no 
significant changes at earlier or later time points (Kabani et al., 2009). 
 
Tb10.6k15.2800, Tb927.7.5700 and Tb11.01.0400 
 
In experiment number 3, three possible interacting proteins were identified, 
two of which were small hypothetical proteins (Tb10.6k15.2800 and 
Tb927.7.5700), with no particular structural domain (except the 
transmembrane helix of Tb927.7.5700), or any significant sequence similarity 
within the kinetoplastids or higher eukaryotes proteomes. They also did not 
show any change in mRNA levels during differentiation to procyclic forms 
(Kabani et al., 2009).  
The third protein (Tb11.01.0400) was a 138-kDa Ser/Thr kinase conserved 
among kinetoplastids and annotated as similar to the human Ser/Thr kinase 
36 (STK36) (www.genedb.org). A Blast search revealed that the N-terminal 
253 residues share 36 and 34 % of identity with mouse and human ULK4, 
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respectively, and 31% with human STK36, also known as “Fused homolog”. 
ULK kinases have been involved in autophagy in yeast (Hosokawa et al., 
2009) and in cell-cell signalling in Drosophila development (Therond et al., 
1996). Similarly, STK36 has been shown to be important for postnatal 
development in mice (Murone et al., 2000). Tb11.01.0400 has been identified 
in the kinome of T. brucei as a member of the ULK family, and reported to be 
catalytically inactive, due to mutations in essential residues, together with 12 
other inactive protein kinases in T. brucei, which are supposed to play a 
regulatory role via protein-protein interactions (Parsons, 2005).  
Tb11.01.0400 mRNA levels did not significantly change during 
differentiation to procyclic forms, except for a small decrease at 18 hr after 




Experiment 4 identified more proteins than experiment 3 but only one 
(Tb10.389.0310) was specifically selected by TbPTP1 and not found 
previously, corresponding to the 120 kDa band isolated from the gel of 
selection 4 (arrowhead of Figure 3.7). 
Tb10.389.0310 is a hypothetical protein with predicted molecular weight of 
96.3 kDa; it is conserved within kinetoplastids, with 36% and 28% identity 
with T. cruzi and L. major, respectively, and showing a conserved tyrosine 
residue (Tyr104 of Tb10.389.0310). In addition, the protein contains an IQ-
calmodulin binding domain (IQXXXRGXXXR at aa 115-140), which is found 
in proteins that bind calmodulin, such as myosins, and in many other 
proteins that have not been demonstrated to interact with calmodulin, such 
as PKC, connexin45 and sodium channel proteins (Rhoads et al., 1997).  
Tb10.389.0310 mRNA levels were found to be up-regulated in slender 
compared to stumpy forms, and to be maintained at constant levels during 
differentiation to procyclic forms (Kabani et al., 2009). 
 
Although it was difficult to estimate the importance of the identified hits as 
potential TbPTP1 substrate, the most promising candidates appeared to be 
the 197-kDa hypothetical protein with the HEAT repeat (Tb11.02.2090) and 
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the 96.3-kDa hypothetical protein with an IQ-calmodulin binding domain 
(Tb10.389.0310).  
The first one was chosen for further analysis because it was the only protein 
found in two different experiments, that seemed more specifically selected 
compared to the dynein heavy chains. 
The second was selected for additional studies because it was identified from 
the mass spectrometry analysis of the high molecular weight band visible 
from the protein gel of experiment 4 (arrowhead of Figure 3.6). Therefore its 
identification was probably the most reliable. Moreover, since the sensitivity 
of protein detection from the analysis of a single band is higher compared to 
the analysis of the whole sample (R. Burchmore, personal communication), it 
is possible that this hit was missed in the previous selections. 
 
3.8.  Tb10.389.0310 and Tb11.02.2090 RNAi cell lines 
 
Tb10.389.0310 and Tb11.02.2090 were considered the most interesting hits of 
the mass spectrometry analysis, and, in order to test whether the proteins 
were involved in T. brucei differentiation, cell lines were created, which 
downregulated their expression.  
In order to do so, both proteins were cloned into the p2T7 RNAi plasmid, 
which allows the tetracycline-inducible degradation of the targeted mRNA, 
and transfected into bloodstream form SMC 16 (“S16”) cell lines. 
Transfectants selected with phleomycin were then tested for the down-
regulation of the transcripts and for growth effects upon tetracycline 
treatment.  
 
For Tb10.389.0310 the RNAi was not effective in downregulating the 
expression level of the gene, on the contrary induced cell possessed higher 
amounts of Tb10.389.0310 transcript, compared to uninduced (Figure 3.8 A). 
Growth capacity of induced Tb10.389.0310 RNAi cells was similar to the 
parental S16 cells  (Figure 3.8 B). To avoid the possibility of a labeling 
mistake in the Northern blot, the analysis of the same samples was repeated 
twice. However, there could have been an error in the labeling of the 
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samples. Nonetheless, the lack of effect on cell growth (Figure 3.8 B) and 
differentiation (data not shown) ruled out the possibility for Tb10.389.0310 to 
play a role in parasite development to procyclic forms.   
 
For Tb11.02.2090 RNAi cell lines, several clones were analysed, of which 
clone C gave the best knock down. Indeed, Tb10.389.0310 clone C RNAi 
resulted in a 47% downregulation of the transcript, compared to untreated 
cells, on the first day of induction, which then decreased to 9 % and 32% on 
the second and third day, respectively (Figure 3.9). However, induced 
Tb11.02.2090 RNAi cells showed a level of Tb11.02.2090 transcript equal to 
the parental S16 lines.   
Next, the phenotype of induced Tb11.02.2090 RNAi cell lines was analysed, 
which resulted in a marked growth defect, visible from the first day of 
induction (black dashed line of Figure 3.10 A). The tetracycline-treated cells 
then slowly recovered until reaching untreated level of growth at day four. 
Analysed under the microscope, Tb11.02.2090 RNAi cells, after 24 hr of 
tetracycline treatment, showed a small increase in 2K2N cells, from about 
13% and 14% of uninduced and parental cells, respectively, to 22.7% of 
induced RNAi cells (Figure 3.10 B). In addition, the same cell line showed a 
small increase in aberrant cell types (“other” in Figure 3.10 B).  
These data suggested that Tb11.02.2090 might be implicated in T. brucei cell 
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Figure 3.8 Analysis of Tb10.389.0310 RNAi cell line: expression and growth.  (A) 
Northern blot analysis of the Tb10.389.0310 RNAi cell line C is shown, as one representative 
of three different cell lines. The levels of Tb10.389.0310 transcript, upon tetracycline addition 
(-/+ tet), to induce the RNAi, is shown for three consecutive days (d1-d3) (upper panel); the 
corresponding ethidium bromide stain (EtBr) is shown as loading control (lower panel). (B) 
The growth curves of parental S16 and Tb10.389.0310 RNAi lines in absence and presence 
of tetracycline (-/+ tet) are shown. 
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Figure 3.9 Expression of Tb11.02.2090 gene in the RNAi cell line C. (A) Northern blot 
analysis of the Tb11.02.1090 RNAi cell line C (Tb11 C) treated or not with tetracycline to 
induce the RNAi (-/+ tet) for three consecutive days (d1-d3) is shown (upper panel); the 
corresponding ethidium bromide stain (EtBr), as loading control, is also shown (lower panel). 
(B) The signal of the Tb11.02.2090 probe, normalized to the loading, has been quantified in 
order to calculate the percentage of Tb11.02.2090 transcript downregulation (number 
indicate percentage of downregulation of induced over uninduced Tb11.02.2090 RNAi). 
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Figure 3.10 Tb11.02.2090 RNAi cell growth and cell cycle profile. (A) Growth of clone C 
of Tb11.02.2090 RNAi in absence or presence of tetracycline (-/+ tet) is shown (black lines), 
together with the parental lines (S16 -/+tet, grey lines). (B) The cell cycle profile (karyotype, 
determined by microscopy) of the Tb11.02.2090 RNAi cell line is shown, 24 hr after addition 
of tetracycline (Tb11.02.2090 C -/+ tet), and is compared to the karyotype of the parental line 
(S16 -/+ tet). The cell cycle stages are abbreviated as described in paragraph 1.7 (K: 
kinetoplast; N: nucleus). A total of 150 cells per cell line were counted. 
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3.9. Effect of Tb11.02.2090 RNAi on differentiation of 
bloodstream form to procyclic form cells 
 
The role of Tb11.02.2090 on differentiation of bloodstream form to procyclic 
form T. brucei was investigated by inducing the RNAi in presence of the cis-
aconitate. Specifically, cells were treated with tetracycline for 24 hr and then 
6 mM cis-aconitate was added. After 72 hr the expression of the procyclic-
specific surface protein EP was measured by flow cytometry to assess the 
degree of differentiation of the different cell lines (Figure 3.11). 
Importantly, the cells were also analyzed by immunofluorescence in order to 
morphologically assess their degree of differentiation. This analysis revealed 
that 30% of the EP-positive Tb11.02.2090 RNAi lines treated with tetracycline 
and cis-aconitate did not possess procyclic form morphology, but were 
rounded. It is likely that the rounded cell phenotype was the consequence of 
the growth defect of the Tb11.02.2090 RNAi lines (Figure 3.9), exacerbated by 
the addition of cis-aconitate. 
The flow cytometry data, which showed that 18% of the induced cells were 
EP-positive (versus 4.7% of uninduced cells), was then corrected for the false 
positives identified by immunofluorescence, thus resulting in 12.6 % of the 
induced cells showing real differentiation (Figure 3.11).  
It is not known why the same cell line, in the absence of tetracycline, 
differentiated less well in response to cis-aconitate (Tb11C + CA, white 
rectangle of Figure 3.11). One possible reason could be the presence of a 
higher level of Tb11.02.20290 transcript in the uninduced RNAi cell lines 
versus the parental S16 line (Figure 3.9). This is more evident, if the change 
in EP and Tb11.02.2090 expression of the RNAi cell lines is compared to the 
parental lines (Figure 3.12). Indeed, the lower level of differentiation 
observed in the uninduced RNAi cell line could be explained by the higher 
level of Tb11.02.2090 mRNA (compared to parental line), if the protein was a 
negative regulator of differentiation.  
Similarly, when the level of Tb11.02.2090 and EP expression is compared 
within the RNAi line, then Tb11.02.2090 also appeared to be a negative 
regulator of differentiation, as lower expression levels caused increase in EP 
expression (Figure 3.12). 
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Figure 3.11. Effect of Tb11.02.2090 RNAi on differentiation to procyclic form cells. The 
degree of cellular differentiation to procyclic form in response to 6 mM cis-aconitate (CA) of 
clone C of Tb11.02.2090 RNAi (Tb11C) treated or not with tetracycline (white and grey 
rectangular), together with the parental cell line (S16) is shown. Differentiation is quantitated 
by EP protein expression after 72 hr of addition of cis-aconitate, and shown as percentage. 
Numbers above the histograms indicate the corresponding percentage of EP positive cells. 










































Figure 3.12 Expression of Tb11.02.2090 and EP protein in the parental S16 and in the 
Tb11.02.2090 RNAi cell line. The fold change in EP protein expression (EP protein) and 
Tb11.02.2090 mRNA expression  (Tb11 mRNA) in the induced and uninduced (-/+ tet), 
parental (S16) and Tb11.02.2090 RNAi lines (Tb11), in presence of 6 mM cis-aconitate (+ 
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3.10. Discussion 
 
3.10.1 Comparative analysis of PTP1B and TbPTP1 3-D structure 
 
The analysis of the predicted TbPTP1 3-D structure presented in the first part 
of this chapter was performed before the crystal structure of the phosphatase 
was published (Chou et al., 2010). Interestingly, the preliminary observations 
derived from homology modeling (Figure 3.1 B) agree with the conclusions 
recently reported by Chou et al. This is likely due to the fact that the PTP1B 
template used in the in silico modeling is very similar to TbPTP1. Indeed it 
has been shown that the more similar two sequences are, the closer the 
corresponding structures are expected and the more reliable the model is 
going to be (Chothia et al., 1986). However, it has been reported that with a 
percentage of identity of less than 30%, model quality estimation becomes 
unreliable, particularly in the presence of large insertions (Bordoli et al., 
2009). TbPTP1 shares 24% identity with PTP1B, but all the invariant residues 
of the PTP motifs (Andersen et al., 2001) are perfectly conserved (Table 3.1), 
thus suggesting that the low degree of identity is mainly due to variations in 
the sequence connecting the domains. Consequently, the homology model 
obtained for TbPTP1 is probably more reliable than expected for a 24% 
identity alignment and confirms the validity of such an in silico approach.  
The analysis of TbPTP1 3-D prediction showed that the backbone structure is 
very similar to the one of PTP1B and the trypanosome-specific sequences are 
found mainly on the surface of the enzyme (Figure 3.1). The crystallographic 
data of Chou et al., confirmed these observations by noting that the major 
differences of the superimposed structures of the parasite enzyme with 
human PTP1B or PTPRO were loops found on the surface of TbPTP1.  These 
parasite-specific regions were suggested to be involved in substrate 
recognition and regulation, being mapped at the periphery of the 
phosphatase, although not giving rise to new structural elements (Chou et al., 
2010).  
The above observations indicate that a conserved PTP fold extends to distant 
eukaryotes such as Trypanosoma brucei, and that the specificity of function 
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possessed by these enzymes, in different organisms, is conveyed structurally 
in ways that do not affect the core conformation, for example by the use of 
parasite-specific motifs. 
 
3.10.2   TbPTP1 substrate consensus sequence 
 
In addition to the 3-D structure of TbPTP1, the crystallographic analysis 
highlighted the presence of a continuous electropositive region on the 
surface of the enzyme (Chou et al., 2010). Since it has been reported that 
surface properties might account for PTPs substrate specificity (Barr et al., 
2009), such an electropositive region of TbPTP1 has been suggested to 
indicate a preference for electronegative regions of its substrates. This 
hypothesis seemed to be validated by the fact that both its recently identified 
substrates, Nopp44/46 (Chou et al., 2010) and TbPIP39 (Szoor et al., 2010), 
possess some negatively charged residues in the vicinity of the 
phosphorylated tyrosine (DDEApYDEDD and RTDEpYTKC). Chou et al., 
supported this hypothesis by analogy with the negatively charged surface of 
PTP1B and the positively charged region of its substrate, the insulin receptor.  
However, the authors did not mention the fact that not all the PTP1B 
substrates possess acidic sequences around the pTyr, such as caveolin (Lee et 
al., 2006), and the contradictory results reported by other studies were also 
not analysed (Sarmiento et al., 2000; Vetter et al., 2000; Walchli et al., 2004).  
In contrast to the hypothesis proposed by Chou et al., the TbPTP1 substrate 
consensus analysis reported in this chapter suggested a preference for 
aliphatic/aromatic residues. This hypothesis was based on the observation 
that TbPTP1 possesses Leu52 in place of Arg47 of PTP1B (Figure 3.2). The 
presence of an aliphatic amino acid (Leu52) in the parasite phosphatase 
suggested a possible preference for less charged residues N-terminal to the 
pTyr, since Arg47 has been shown to represent the major determinant of 
PTP1B substrate selectivity (Sarmiento et al., 1998).  
Of course this second hypothesis is pure speculation, and it is likely that the 
overall surface charges of the enzyme will influence the interaction of the 
enzyme with its substrates, but conclusions need to be drawn with caution, 
as only two TbPTP1 substrates have been identified so far.  
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The identification of additional substrates will probably reveal whether 
TbPTP1 selectively targets certain types of residues in the vicinity of the pTyr 
and might lead to the delineation of a substrate consensus sequence. The 
data currently available for PTP1B and TbPTP1 does not allow us to use any 
bioinformatics criteria to identify proteins that would more likely interact 
with the parasite enzyme. 
 
3.10.3 TbPTP1 substrate trapping mutants 
 
The most widely used method for the characterization of physiological 
substrates of mammalian PTPs has been the use of substrate-trapping mutant 
forms of the enzymes (Garton et al., 1996).  
Several substrate-trapping mutants exist, which possess a very low 
enzymatic activity and bind efficiently to their substrates, thereby trapping 
them in their catalytic pocket (see paragraph 1.15). Among them, the most 
successful mutant PTP used has been the one possessing an alanine residue 
in place of the catalytic aspartic acid (D→A mutant) (Blanchetot et al., 2005). 
However, the addition of a second mutation targeting the Q loop (Q→A), in 
the D→A mutant, has been shown to improve the substrate-binding 
capability of PTP1B (Laiping et al., 2001) and SHP2 (Kontaridis et al., 2004). 
Therefore the same approach was employed for TbPTP1, and the Q→A 
mutation was introduced in the single D199A mutant, already in use in the 
lab (Figure 3.4, A). In parallel, the C229S/D275Q was also created, as 
negative control (Figure 3.4, A). 
According to results published for PTP1B (Laiping et al., 2001) the 
C→S/D→Q  TbPTP1 mutant was not a good substrate trapping enzyme 
(Figure 3.4 B). In contrast, the D199A/Q275A TbPTP1 was found to trap 
several pTyr-containing proteins but not significantly better than the D199A 
enzyme (Figure 3.4 B), which was unexpected compared to what was 
reported for PTP1B (Laiping et al., 2001). It is possible that other enzyme-
specific factors contribute to such a difference, as it has been postulated for 
other PTPs. For example, the C→S mutant was shown to be a better substrate 
trapping mutant than the D→A for RPTPα (Blanchetot et al., 2002) and SHP2 
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(Persson et al., 2004), conversely to what was reported for most other 
enzymes. The exact reason for these differences is not known, but it has been 
suggested that the variable sensitivity to oxidation of the catalytic Cys, 
during the experimental procedure, might sometimes be the cause 
(Blanchetot et al., 2005). 
 
3.10.4 TbPIP39 selection by the TbPTP1 mutants 
 
The different TbPTP1 mutants were then used in a in vitro substrate trapping 
experiments, which possess the advantages of being easily up-scalable and 
usable in conjunction to mass spectrometry analysis. This approach was 
successfully used for the initial identification of TbPIP39 (performed before 
the start of this project), which was then visualized by using the anti-TbPIP39 
antibody (Figure 3.6). Differences were noted in the substrate trapping 
abilities of the C229S/D199A TbPTP1 between the amounts of tyrosine 
phosphorylated proteins detected (Figure 3.5 B) and the quantity of TbPIP39 
bound (Figure 3.6 A). This difference could be due to a more limited 
sensitivity of the anti phosphorylated tyrosine antibody compared to the anti 
TbPIP39 antibody.  
Another interesting observation was the fact that the TbPTP1 wild type 
enzyme showed to bind TbPIP39, under certain experimental conditions, 
such as in larger scale selections (Figure 3.6 B) and in immune-precipitations 
(Szoor et al., 2010). The fact that the wild type TbPTP1 interacts with TbPIP39 
in a manner stable enough for the substrate to be visualized in vitro or in vivo, 
has been noticed for other PTPs, suggesting that some phosphatases need to 
interact with the substrates through protein-protein domain prior to their 
dephosphorylation (Blanchetot et al., 2005).  
 
 
3.10.5 Mass spectrometry analysis 
 
The mass spectrometry analysis carried out on the proteins selectively bound 
to the substrate trapping D199A TbPTP1, identified a total of eight hits for 
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the four different large scale selections performed on stumpy cell extracts 
(Table 3.3).  
In the first two selections (experiment 1 and 2 of Table 3.3) four hits were 
found in both experiments, which were carried out before the start of this 
project. Among these four hits, one was the already characterized CTD 
phosphatase (TbPIP39) (Szoor et al., 2010) and two were large dynein heavy 
chains, which were considered likely contaminants, although never detected 
in the negative controls (beads alone incubated with cell extract). The fourth 
hit, a hypothetical protein containing one HEAT repeat (Tb11.02.20290), was 
considered more interesting, as these repeats are involved in protein-protein 
interactions (Andrade et al., 1995) .  
In the other two selection experiments (experiments 3 and 4 of Table 3.3), 
four hits were identified, none of which were found in the previous 
selections. This variability was also detected in the negative controls, indeed 
no common hits among the four selections were found in the beads alone 
incubated with cell extract. 
By comparing pairs of selections, the percentage of shared hits in the 
negative controls varied from 0 % (exp.4 and 1), to 10 % (exp. 1 and 2) and 
raised to a maximum of 55%  (exp. 4 and 2).  This variability could have been 
caused by the experimental set-up, although the same protocol for cell lysis 
and selection was used. In addition, the BZ3 treament of stumpy form cells 
that preceded protein extraction might also have been the cause of part of 
this variability. Similarly, the purity of the different batches of recombinant 
proteins employed was also likely to have played a role. Moreover, the 
biological variability always needs to be taken into account, for example the 
conditions of the cells might have differed between experiments. 
Consequently, it is maybe not surprising that no protein was found in all 
four or three of the selections.   
In selection 3 and 4, the only hit that was considered of interest was a 
hypothetical protein (Tb10.389.0310) possessing an IQ-calmodulin binding 
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3.10.6 Tb10.389.0310 and Tb11.02.2090  
 
In order to characterize the potential roles played by Tb10.389.0310 and 
Tb11.02.2090 in the TbPTP1 differentiation pathway, cell lines knocking 
down the two hits were created.   
As quantified by Northern blot analysis, Tb10.389.0310 RNAi lines showed 
an increase in Tb10.389.0310 mRNA levels, which had no effect on their 
growth kinetics (Figure 3.8) or differentiation capability (data not shown). 
Therefore, a possible role for this protein and in T. brucei development can be 
excluded.   
In contrast to this, Tb11.02.2090 expression was decreased of 47% upon 
induction of the RNAi for 24 hr in the cell line C (Figure 3.8). This level of 
downregulation was then lost on the second and third day of induction, 
likely due to a very high selection pressure on the treated cells. Indeed, a 
severe growth defect was observed in the same cell line as early as 24 hr of 
tetracycline treatment (Figure 3.10 A). These cells did not appear to present 
any other major morphological abnormality.  
In addition, 24-hr induced Tb11.02.2090 RNAi cells showed a small increase 
in 2K2N (M phase cells) and aberrant cells (Figure 3.10 B), thus suggesting 
that Tb11.02.2090 might be involved in cell cycle control, directly or 
indirectly. Specifically Tb11.01.2090 could act by inhibiting S or G2 phase, 
which precede M phase, or by inducing cell division, that follows M phase. 
Furthermore, cells expressing lower levels of Tb11.02.2090 transcript showed 
an increase in differentiation capacity (from 2.7% to 12.6 %), as judged by cell 
morphology and EP expression (Figure 3.11), thus suggesting that it might 
negatively regulate this life cycle transition. 
From the above data, it could be hypothesized that Tb11.02.2090 might be 
important for cell division to occur, thus required for cell growth. Therefore, 
by inhibiting entry into G0/G1, Tb11.02.2090 could negatively regulate 
initiation of differentiation to procyclic forms. Consequently, the action of 
this hypothetical protein would need to be inhibited for differentiation to 
occur, potentially through its increased phosphorylation level caused by 
decreased TbPTP1 activity (Figure 3.13).  
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In order to validate the potential role of Tb11.02.2090 during differentiation 
and as TbPTP1 substrates, further work will be needed. First of all it would 
be important to confirm the reproducibility and to better characterize the cell 
cycle and differentiation phenotypes observed upon induction of 
Tb11.02.2090 RNAi. In addition, the interaction between Tb11.02.2090 and 
TbPTP1 would need to be validated, similarly to what done for TbPIP39, by 












Figure 3.13. Model of the potential role of Tb11.02.2090 during differentiation from 
stumpy to procyclic form cells. Upon citrate/cis-aconitate (CCA) treatment of stumpy form 
cells, the inhibition of TbPTP1 would cause the increased phosphorylation of the negative 
regulator of differentiation Tb11.02.2090. This would render Tb11.02.2090 inactive, thereby 
ceasing cell division and, together with the action of other downstream effectors (such as 
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4.1. Introduction 
 
As mentioned in paragraph 1.17, the downstream effector and substrate of 
TbPTP1 has recently been identified as a glycosomal phosphatase, TbPIP39 
(Szoor et al., 2010), and a model has been proposed whereby citrate/cis-
aconitate (CCA) would be transported into the cells via PAD expression 
(Dean et al., 2009) causing TbPTP1 inhibition and increasing the level of 
phosphorylated TbPIP39, thus promoting the differentiation to procyclic 
forms (Figure 4.1). TbPTP1 activity has been shown to significantly increase 
in the presence of TbPIP39 and the addition of CCA have been shown to 
prevent such activation in vitro, potentially disrupting their interaction 
through the binding to the TbPIP39 citrate-binding pocket (Szoor et al., 2010). 
This part of the project aimed at investigating other potential mechanisms of 
TbPTP1 regulation during parasite differentiation.  
           
Figure 4. 1 Model of the TbPTP1-TbPIP39 pathway during differentiation from stumpy 
to procyclic forms (from Szoor et al., 2010). Citrate/cis-aconitate (CCA) is imported into 
stumpy form cells via PAD proteins (PAD); intracellular CCA inhibits the activation of 
TbPTP1 by TbPIP39 directly, but other indirect ways of TbPTP1 inactivation cannot be 
excluded. Upon TbPTP1 inactivation, the level of phosphorylated TbPIP39 would increase, 
which would promote differentiation to procyclic forms by acting on the glycosomes, through 
a yet uncharacterized mechanism.    
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4.2. Comparative analysis of TbPTP1 mechanisms of regulation 
 
4.2.1 Post-transcriptional regulation 
 
In higher eukaryotes, the targeted and temporally modulated activity of 
PTPs is obtained through different levels of regulation, from post-
transcriptional to post-translational (Bourdeau et al., 2005).  
In the case of PTP1B, one level of regulation is represented by alternative 
splicing, which produces two variants with slightly different C-terminal 
domains and whose quantities are controlled by growth factors and insulin 
(Shifrin et al., 1993; Sell et al., 1999). In Trypanosoma brucei only two genes 
have been shown to contain introns (Mair et al., 2000; Berriman et al., 2005), 
but there is growing evidence for the existence of differentially trans-spliced 
transcripts (Siegel et al., 2010), therefore the potential regulation of TbPTP1 
by this mechanism cannot be excluded.  
 
4.2.2 Post-translational regulation: proteolysis and differential targeting 
 
In addition to post-transcriptional regulation, PTP1B is subjected to different 
post-translational modifications, such as proteolysis, phosphorylation, 
sumoylation and oxidation.   
Proteolytic cleavage of PTP1B by calpains has been shown to generate a 
truncated form of the enzyme, lacking the 65-75 C-terminal residues, which 
is associated with enhanced enzyme activity, due to the loss of the C-
terminal negative regulatory domain (Frangioni et al., 1993).  
The C-terminal domain of PTP1B is not present in TbPTP1 and the final M10 
domain is followed only by a short trypanosome-specific motif (T4) (see 
paragraph 1.17). The sequence of T4 is not predicted to be an Arg/Lys 
cleavage site, as assessed by using the ProP online programme (Duckert et 
al., 2004), however aa 135-152 of TbPTP1 have been identified as a PEST 
domain using the prediction programme Mobyle@Pasteur 
(http://mobyle.pasteur.fr) (Szoor et al., 2006). The PEST motif is a region rich 
in Pro, Glu/Asp, Ser/Thr and flanked by Arg/Lys, which has been shown to 
be a high affinity substrate for calpains (Siman et al., 1989). In addition, it is 
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interesting to note that some Trypanosoma brucei calpains  are stage regulated 
during the parasite life cycle (Liu et al., 2010). 
The accessibility of PTP1B to its substrates is regulated in a spatial and 
temporal manner also by means of its 35 C-terminal residues, that are 
responsible for targeting the enzyme to the cytoplasmic face of the ER 
(Frangioni et al., 1992). TbPTP1 does not possess any recognizable targeting 
domain and cellular fractionation experiments have shown that the 
phosphatase is present mainly in the cytoskeletal fraction in slender, stumpy 
and procyclic form cells (Szoor et al., 2006; McElhinney, 2007).  
 
4.2.3 Post-translational regulation: phosphorylation 
 
A more complex level of PTP1B regulation occurs via phosphorylation of five 
Ser and three Tyr residues, which have been shown to often affect enzyme 
activity in a cell and growth factor-specific manner. For example, Ser50 
phosphorylation by AKT/PKB has been reported to decrease enzyme 
activity upon insulin stimulation (Ravichandran et al., 2001); the same 
residue, together with Ser242 and 243, have been shown to be targeted by 
CLK1 and 2, with Ser50 being the main residue phosphorylated and causing 
a 2-fold increase in PTP1B activity (Moeslein et al., 1999). In murine fat and 
skeletal muscle cells, insulin stimulation was also required for PTP1B Ser352 
phosphorylation by PKA to occur, which resulted in an increased enzymatic 
activity (Ravichandran et al., 2001; Tao et al., 2001). In addition to insulin, the 
cell cycle position has been shown to affect PTP1B Ser phosphorylation, 
specifically transition from G2 to M phase has been linked to increased 
phosphorylation of Ser352 and Ser386 (Flint et al., 1993).  
Three Tyr residues have also been shown to be phosphorylated: Tyr66, 
Tyr152 and Tyr153 of PTP1B have been identified as in vivo substrates of the 
insulin receptor and shown to cause a 38-fold increase activity; moreover, 
these Tyr residues were dephosphorylated by PTP1B in vitro, and thus the 
possibility of the enzyme to auto-dephosphorylate itself has been suggested, 
as a way to modulate its activity upon insulin stimulation (Dadke et al., 
2001). 
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Among all the PTP1B phosphorylation sites mentioned above, TbPTP1 shares 
only Tyr66 and Tyr152 (Tyr78 and Tyr164 of TbPTP1) (Figure 4.2) and 
possesses Thr257 in place of Ser242 of the human phosphatase. Tyr78 and 
Tyr164 are conserved among trypanosomes (T. congolense, T. vivax and T. 
cruzi) but not in Leishmania major, whereas Thr257 is conserved only between 
T. brucei and T. cruzi (Figure 4.2 A). A bioinformatics analysis using three 
different prediction programmes (GPS (Xue et al., 2005), NetPhos 2.0 (Blom et 
al., 1999) and ScanSite (Obenauer et al., 2003)) identified four potential 
phosphorylated residues of TbPTP1 conserved among trypanosomes (Ser42, 
Thr238, Tyr280 and Tyr284) but it did not identify residues Tyr78, Tyr164 
and Thr257 as possible phosphorylation sites. Of the four predicted TbPTP1 
phosphorylation sites two (Thr238 and Tyr284) are conserved in PTP1B, but 
there is no report of their phosphorylation in the literature; the other two 
predicted phosphorylation sites (Tyr280 and Ser42) are not conserved in the 
human homolog, and Ser42 is found in the trypanosome-specific motif PcT2. 
Since it is difficult to predict which sites of TbPTP1 might be phosphorylated 
from the analysis of the primary sequence, the residues were also mapped on 
the 3-D model of the enzyme (Figure 4.3). Most of the phosphorylated PTP1B 
residues are found on the surface of the enzyme, with the exception of Ser242 
and 243, which have been shown to be less preferred than Ser50 by CLK1 
and 2 (Moeslein et al., 1999); among the seven potential TbPTP1 
phosphorylation sites, three (Ser42, Tyr78 and Tyr164) are found on the 
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4.2.4 Experimental analysis of TbPTP1 phosphorylation 
 
Preliminary experiments in bloodstream form 427 cells over-expressing wild 
type TbPTP1, suggested that the protein did not seem to be Tyr-
phosphorylated after cis-aconitate treatment (Figure 4.4). Cells were induced 
to overexpress TY-tagged TbPTP1 by addition of tetracycline for 24 hr, then 
they were treated with 6 mM cis-aconitate for a further 48 hr. 
Immunoprecipitated TbPTP1 in presence or absence of cis-aconitate 
treatment was then subjected to Western blot analysis and the samples were 
probed with antibody anti TY-tag to determined the level of TbPTP1 
immune-precipitation and with antibody anti phosphorylated Tyr residues 
(pTyr) in order to detect potential enzyme phosphorylation (Figure 4.4 A).  
Although the efficiency of the immune-precipitation was low, as only very 
faint bands were visible in the anti TY-tag Western blot (Figure 4.4 A, 
arrowheads at around 34 kDa), such bands were specifically blocked in 
presence of the TY peptide (Figure 4.4 B, arrowheads). The anti pTyr 
Western blot showed a weak band co-migrating with immune-precipitated 
TbPTP1 (Figure 4.4 A, arrows) but this was not obviously blocked in the 
presence of the TY peptide (Figure 4.4 B, arrows), although the signal was 
somewhat obscured by the highly abundant 20-kDa protein G sepharose 
used to immunoprecipitate the antibody. Consequently, the pTyr positive 
band immunoprecipitated with TbPTP1 must represent some other protein 
that non-specifically bound the beads and not TbPTP1.  


























Figure 4.4 Detection of potential tyrosine-phosphorylated TbPTP1 in presence or 
absence of cis-aconitate treatment (CA). (A) Western blot (WB) analysis of 
immunoprecipitated TbPTP1 (IP) and flow-through after immuneorecipitation (FT) probed 
with anti TY-tag antibody (α TY-tag) and anti phosphorylated Tyr antibody (α pTyr). (B) 
Western blot analysis of the same experiment as in A, showing samples of the 
immunoprecipitation performed in presence of the blocking peptide (IP+b), specific for the 
TY-tag. Bands corresponding to immunoprecipitated TY-tagged TbPTP1 are highlighted 
(arrowheads, about 34 kDa), together with a co-migrating pTyr-positive band (arrows). The 
molecular weight markers are shown on the right-hand side in kDa; eluted protein G is visible 
on the blot following immunoprecipitation (dark thick band at around 20 kDa), together with 
light and heavy Ig chains (about 20 and 55 kDa, respectively). Western blots were all 
exposed for 5-20 min, except the A left panel, which was exposed overnight. 
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4.2.5 Post-translational modification: sumoylation 
 
In addition to protein phosphorylation, sumoylation has also been 
implicated in PTP1B regulation, specifically addition of small ubiquitin-like 
modifier (SUMO) on Lys335 and Lys347 has been shown to transiently 
inhibit the enzyme activity in vivo (Dadke et al., 2007). The precise 
mechanism of PTP1B regulation by sumoylation has not been characterized, 
but it has been suggested that such modification might block or alter the 
catalytic domain of the enzyme (Dadke et al., 2007).  
In T. brucei only one recent study has been conducted to elucidate the role of 
sumoylation (Liao et al., 2010), which revealed the existence of a SUMO 
homolog in T. brucei (TbSUMO) and showed  that TbSUMO is essential for 
the completion of mitosis in procyclic forms. The observation that 
sumoylation is important in the cell cycle regulation is potentially 
interesting, as T. brucei cell cycle is intrinsically linked to its differentiation 
(see paragraph 1.7).  
The comparative analysis of the residues sumoylated in PTP1B (Lys335 and 
Lys347) showed that none of them is conserved in TbPTP1, indeed they are 
found in the C-terminal domain that is not present in TbPTP1 (Figure 4.5 A). 
A bioinformatic prediction of sumoylation sites, using SUMOsp 2.0 (Ren et 
al., 2009), identified Lys131 (L-K-A-E) of the parasite enzyme, as potentially 
sumoylated, according to the consensus sequence: Ψ-K-X-E 
(Ψ=A/I/L/M/P/F/V; X is any aa). Lys131 is conserved in PTP1B (Lys121) 
but is not found within a consensus sequence, as the Gln residue, at position 
+2 to the Lys residue, is substituted by Ala (L-K-C-A). Such observation 
could suggest that Lys131 might be sumoylated in TbPTP1 and not in PTP1B. 
However, Lys 131 is located within the core of TbPTP1 (K131 in Figure 4.5 B), 
in contrast, Lys335 and Lys347 of PTP1B are found in the C-terminal domain 
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4.3. The role of reactive oxygen species (ROS) during 
differentiation to procyclic form 
 
In addition to proteolysis, phosphorylation and sumoylation, oxidation has 
been characterized as a physiological mechanism to regulate the activity of 
several mammalian PTPs in vivo (Monteiro et al., 1996; Denu et al., 1998). 
According to the work carried out for PTP1B, an intracellular oxidase would 
be activated in a ligand-dependent manner, causing a localized increase in 
intracellular reactive oxygen species (ROS), which would oxidize the 
catalytic Cys of the phosphatase, thus resulting in its reversible inactivation 
(Tonks, 2003). 
The possibility of TbPTP1 to be regulated via oxidation was particularly 
interesting since the enzyme had already shown to be sensitive to oxidation 
in vitro (Szoor et al., 2006). Moreover tyrosine phosphorylation has been 
shown to be, at least in part, hydrogen peroxide-sensitive in procyclic form 
cells (Nett et al., 2009a).  In addition, differentiation of stumpy form cells to 
procyclic forms can be triggered by extracellular stress conditions, and it is 
generally known that aerobic organisms respond to environmental stress and 
to some physiological stimuli through production of ROS (Fedoroff, 2006).  
In Trypanosoma brucei the real role of environmental stress on differentiation 
to procyclic forms is not known, but it has been noticed that several stress 
conditions induce such transformation, although with different kinetics and 
thus likely through several mechanisms (Rolin et al., 1998). For example, 
citrate, one of the differentiation triggers, was found to be associated with 
high rates of cell death in monomorphic lines, at concentration between 0.1 
and 3 mM (Hunt et al., 1994). Similarly, mild acid treatment of pleomorphic 
cells has been shown to cause death of slender form cells with concomitant 
transformation of stumpy form into procyclic form cells (Rolin et al., 1998). 
Moreover, treatment of bloodstream form with trypsin (Yabu et al., 1988) or 
pronase, a mixture of proteinases, have also been identified as inducers of 
trypanosome differentiation (Hunt et al., 1994; Sbicego et al., 1999) and the 
same compounds have been linked to increased oxidative stress in other cell 
types (Aoshiba et al., 2001). 
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 In addition, in the tsetse fly midgut, the site where trypanosome 
differentiation to procyclic form takes place, the pro-oxidant action of large 
amounts of heme generated during hydrolysis of hemoglobin produces a 
pro-oxidant environment which is counteracted by production of 
antioxidants by the fly (Souza et al., 1997). In such an environment, 
trypanosomes have been shown to be sensitive to oxidant-induced stress, 
which affected parasite survival and life cycle progression (MacLeod et al., 
2007).  
The work carried out for PTP1B has shown that a ligand-dependent localized 
increase in ROS, can reversibly inactivate the PTP found in its vicinity, thus 
promoting downstream tyrosine phosphorylation-dependent signalling 
(Tonks, 2003). According to this model, physiological differentiation of 
stumpy form cells to procyclic forms would require the production of 
intracellular ROS, which would cause oxidation of TbPTP1 and induce 
cellular transformation.  
To test this hypothesis, bloodstream form cells were treated with different 
concentrations of cis-aconitate or citrate (0.1, 4, 6 and 18 mM cis-aconitate 
and 10 or 18 mM citrate) and the formation of intracellular ROS was 
monitored using H2-DCFDA, a cell permeable indicator of ROS (Myhre et al., 
2003). Specifically Trypanosoma brucei bloodstream S16 cells or stumpy forms 
from an infected mouse, were incubated with 50 µM H2-DCFDA in PSG 
buffer at 37°C for 20 min, washed once, in order to remove the extracellular 
dye, transferred in HMI-9 and treated with different concentrations of cis-
aconitate or citrate and then monitored by FACS to detect ROS production 
(Figure 4.6 A). As visible in Figure 4.6 A, initial experiments showed a small 
but significant (P<0.01) increase in H2-DCFDA fluorescence after 40-50 
minutes, upon all treatments. However, further experiments indicated that 
cis-aconitate, citrate and isocitrate (another tricarboxylic acid, which does not 
trigger differentiation (Hunt et al., 1994))  reacted with the ROS indicator in a 
cell-free environment (Figure 4.6 B). This observation was surprising since 
H2-DCFDA is supposed to be sensitive to oxidation only intracellularly, as it 
first needs to be acetylated by cellular esterases; therefore the detection of 
fluorescence in the cells must have been caused by the de-esterification and 
oxidation of the ROS indicator by cis-aconitate/citrate outside the cell, 
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followed by its intracellular diffusion. In order to eliminate the artifact 
potentially caused by overloading, a lower concentration of H2-DCFDA was 
also tried; as visible in Figure 4.6 C, cis-aconitate and isocitrate reacted with 
the dye, in the absence of cells, even at 5 µM H2-DCFDA.  
To overcome the incompatibility of H2-DCFDA, another ROS indicator, 
Ampliflu™ red, was employed, which detects ROS expelled from the cell, 
and which has also been used as indicator of PTPs oxidation (Lou et al., 
2008). Ampliflu™ red did not react with cis-aconitate, citrate or isocitrate in 
the absence of cells and did not show increased fluorescence upon induction 
of cellular differentiation (Figure 4.7). This suggested that oxidation is 
















Figure 4.6 Detection of intracellular ROS upon induction of differentiation with cis-
aconitate or citrate using H2-DCFDA. (A) Stumpy form cells (+ St) were treated with 0.1, 4, 
6 and 18 mM cis-aconitate (CA), 10 and 18 mM citrate (CI), or 6 and 18 mM isocitrate (as 
negative control) and ROS production was monitored using 50 µM H2-DCFDA by FACS for 
60 min and FITC channel geometric mean intensity at 50 min is shown (B). Monomorphic 
bloodstream form cells (+ Bsf cells) were treated with 6 or 18 mM cis-aconitate (CA), 10 or 
30 mM citrate (CI), 6 or 18 mM isocitrate (isoc) in PSG buffer supplemented with 50 µM H2-
DCFDA, and ROS production was measured using a fluorimeter (exc. 490 nm, em. 520 nm); 
the same compounds in the absence of cells were also included, as negative control (-Bsf 
cells). (C) Stumpy form cells (+ Stumpy cells) and controls (- Stumpy cells) were treated as 
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Figure 4.7 Detection of intracellular ROS upon induction of differentiation with cis-
aconitate/citrate using Ampliflu™  red. Stumpy form cells (+ Stumpy cells) were treated 
with 0.1, 4, 6 and 18 mM cis-aconitate (CA), 10 and 18 mM citrate (CI) or 6 and 18 mM 
isocitrate (isoc., as negative control) and ROS production was monitored using Ampliflu™ red 
and quantified using a fluorimeter (ex. 544 nm, em. 590 nm). PSG buffer with cis-aconitate, 
citrate or isocitrate and no cells was included (- Stumpy cells) and H2O2 treatment was used 
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4.4. Effects of H2O2 and N-acetyl cysteine (NAC) on 
differentiation 
 
Exogenously supplied H2O2 has been shown to mimic the effect of insulin in 
mammalian cells through the inhibition of PTPs and activation of protein 
tyrosine kinases (Heffetz et al., 1992). Therefore it was interesting to 
investigate the effect of exogenous ROS on the differentiation of stumpy 
forms to procyclic forms. For this purpose, cells were treated with different 
concentrations of H2O2 and monitored for EP protein expression using FACS 
analysis. Stumpy form cells treated with 5 µM H2O2 for up to 48 hr did not 
show any sign of transformation (Figure 4.8 A) and concentrations of 50 and 
100 µM H2O2 on monomorphic bloodstream form were also ineffective (data 
not shown).  
Since, in this context, exogenous ROS might not possess the selectivity 
shown by stimuli-induced ROS, the effect on differentiation of endogenous 
ROS neutralization was also tested. For this purpose, the cell permeable anti-
oxidant N-acetyl cysteine (NAC) was employed, which has been used in 
trypanosomes to attenuate the effect of intracellular ROS (Figarella et al., 
2006). Initially the anti-oxidant properties of NAC against H2O2 were 
assessed (Figure 4.8 B).  As visible in Figure 4.8 B, cells treated with 
increasing concentrations of NAC showed decreased H2-DCFDA 
fluorescence over time upon H2O2 treatment, compared to untreated cells. 
The observed decrease in fluorescence indicated that 1-hr treatment with 
NAC concentrations between 0.25 and 2 mM neutralized most of the 
exogenous H2O2 supplied within 80 min of H2O2 addition; as expected, the 
level of NAC neutralization was directly proportional to its concentrations, 
with 0.25 and 0.4 mM NAC effectively neutralizing all of the exogenus H2O2 
supplied up to 40 min after H2O2 addition, and 0.8 and 2 mM NAC lasting 
twice as long.  
The same pre-treatment on stumpy cells subsequently induced to 
differentiate with 6 mM cis-aconitate did not result in a significant alteration 
of the number of EP positive cells (Figure 4.8 C). High concentrations of 
NAC, however, were found to be cytotoxic, as suggested by a marked 
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decrease in cell growth upon treatment with 0.8 and 2 mM NAC (Figure 4.8 
D).  
Nonetheless it was clear that ROS generation by H2O2, or its inhibition by 
NAC, did not affect the differentiation efficiencies of the cells. Apparently, 
therefore, ROS generation does not represent a major regulatory component 
of the differentiation signal, despite the effects of ROS on TbPTP1 activity 
observed in vitro. 
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Figure 4.8. Effect of H2O2 and N-acetyl Cysteine (NAC) on differentiation. (A) Stumpy 
form cells were treated with 5 mM H2O2 and stained for EP expression after 26 and 48 hr. (B) 
Bloodstream form S16 cells were treated 1 hr with 0.25, 0.40, 0.80 and 2 mM NAC prior 
stimulation with 0.2 mM H2O2 and the intracellular ROS level was quantified by monitoring 
the increase in H2-DCFDA fluorescence over time; (C) S16 cells were treated 1 hr with 0.25, 
0.40, 0.80 and 2 mM NAC and then induced to differentiate with 6 mM cis-aconitate. (D) 
Effect of NAC on cell growth. Growth of bloodstream form S16 cells in presence of 0.25, 0.4, 
0.8 and 2 mM NAC was monitored up to 48 hr after treatment; NAC was added after 24 hr 
(arrow). 
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4.5. Monitoring TbPIP39 phosphorylation  
 
In parallel to investigating the possible physiological mechanisms of TbPTP1 
regulation during differentiation, it was also interesting to test whether 
different compounds reported to induce stumpy to procyclic form transition 
acted through the same TbPTP1-TbPIP39 pathway as CCA signalling.  
In order to do so, changes in TbPIP39 phosphorylation were monitored 
under different conditions, using an antibody developed specifically to 
detect the phosphorylated tyrosine 278 (p-PIP39) of TbPIP39 (Szoor et al., 
2010). Initially, validation of the anti p-PIP39 antibody was carried out, as 
Figure 4.9 shows, the signal of the antibody completely disappeared when 
procyclic form cell extract, which contains phosphorylated TbPIP39, was 
incubated with recombinant TbPTP1.  
Interestingly, the anti p-PIP39 antibody reacted with two proteins of 
approximately 40 and 50 kDa, but only the lower band (arrow in Figure 4.9) 
reacted also with the anti-PIP39 antibody; therefore the 50-kDa band is not 
TbPIP39 but another protein, potentially possessing a phosphorylated 
tyrosine residue, which is also substrate of TbPTP1 in vitro. A Blast search 
against the T. brucei genome database, using the peptide sequence against 
which the p-PIP39 antibody was raised (ELDHWRTDEpYTKC) (Szoor et al., 
2010), found only TbPIP39 (Tb09.160.4450) and the almost identical protein 
(Tb09.160.4480); the same analysis carried out using a shorter sequence 
(DEYT), identified two other hits with similar molecular weight to TbPIP39 
(Tb10.70.1520: 41.2 kDa and Tb09.211.0590: 49.2 kDa). However, none of these 
two proteins were present in the list of proteins selected by the WT or D199A 
mutant TbPTP1 (see Chapter 3), or in the published T. brucei 
phosphoproteome (Nett et al., 2009b), hence the identity of the cross reacting 
band migrating at approximately 50 kDa remains uncertain.  
The tyrosine-phosphorylation status of TbPIP39 in the different life cycle 
forms was then assessed using the p-PIP39 antibody and the ratio of 
phosphorylated TbPIP39 over a loading control, such as tubulin, was 
quantified (Figure 4.10 A). As expected the ratio was greater in procyclic 
forms compared to stumpy and bloodstream forms, specifically showing a 
2.6 fold increase from stumpy to established procyclics. Similarly, the ratio of 
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phosphorylated TbPIP39 was quantified 1.5 hr after induction of 
differentiation with cis-aconitate or with the TbPTP1 inhibitor, BZ3 (Figure 
4.10 B). Also in this case a significant increase in the p-PIP39 signal was 
detected upon both treatments, this being 3-4 times the untreated level. 
Interestingly such increase was slightly greater than the 2.6 fold increase seen 















Figure 4.9 TbPTP1 dephosphorylation of TbPIP39 in procyclic forms cell extracts. 
Western blot of procyclic forms cell extracts incubated in presence or absence (+/-) of 
recombinant active TbPTP1 for 1 hr, at 37°C. The membrane was then probed with anti-
TbPIP39 antibody (α PIP39), anti- phosphorylated Y278 antibody (α p-PIP39) and anti-
tubulin antibody, as loading control (α tub). The molecular weight marker is shown on the 
left-hand side, numbers indicate kDa. The TbPIP39 signal (arrow) disappears upon TbPTP1 
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Figure 4.10 TbPIP39 phosphorylation analysis in the different life cycle forms and 
soon after induction of differentiation. (A) Western blot of slender (Sl), stumpy (St) and 
procyclic (Pc) form cell extracts probed for total TbPIP39, p-TbPIP39 and tubulin (α PIP39, α 
p-PIP39 and α tub) (left panel); the corresponding quantification of p-PIP39/tub signal is 
shown in A, right panel. (B) Western blot of untreated stumpy form cell extract (untr), cells 
treated for 1.5 hr with 6 mM cis-aconitate (CA) or with 150 µM BZ3 (BZ3), probed for total 
TbPIP39 and p-TbPIP39 (α PIP39 and α p-PIP39) (left panel); the corresponding 
quantification of p-PIP39/PIP39 signal is shown in the right panel. Quantifications are 
performed using Syngene G:Box for p-PIP39 and PIP39, and LICOR Odissey® imager 
system for tubulin (note that the p-PIP39/PIP39>1 is likely due to the processing of the 
Western blot, as the same membrane was first probed with α p-PIP39, stripped and 
reprobed with α PIP39, see Materials and Methods) .  
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4.6. Monitoring TbPIP39 phosphorylation upon treatment with 




In order to compare the effect of different triggers of differentiation on the 
TbPTP1-TbPIP39 signalling cascade, it was first important to characterize in 
more detail the size and timing of the increase in TbPIP39 phosphorylation 
upon citrate/cis-aconitate (CCA) treatment. Therefore the p-PIP39 signal 
normalized to tubulin, was compared at different time points after addition 
of 6 mM cis-aconitate (Figure 4.11). One representative Western blot is 
shown in Figure 4.11 A and the mean of the p-PIP39/tubulin signals of 
several experiments is shown in Figure 4.11 B; as evident from the Western 
blot and corresponding quantification, increasing p-PIP39 levels were 
detectable from 2 hr after addition of 6 mM cis-aconitate (CA) and appeared 
to peak at 6 hr (Figure 4.11 A and B). However, the level and timing of p-
PIP39 increase among experiments was variable, such that the changes in 
level of p-PIP39/tubulin signal over time did not result to be statistically 
significant (General linear model, P= 0.42). In parallel, cellular differentiation 
was analysed, by FACS analysis of EP protein expression, which did not 
show the same variability seen with the levels of p-PIP39 (Figure 4.11 C).  
In addition to cis-aconitate, the effect of citrate, the other citric acid cycle 
intermediate known to induce differentiation (Czichos et al., 1986), on 
TbPIP39 phosphorylation was assessed in the same way. As expected, 10 mM 
citrate induced a similar p-PIP39 increase in parallel to cellular 
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Figure 4.11 Monitoring the phosphorylation levels of TbPIP39 upon cis-aconitate (CA) 
treatment of stumpy form cells. (A) An example of Western blot analysis of stumpy form 
cells induced to differentiate by addition of 6 mM cis-aconitate (CA). Samples were probed 
with anti-PIP39, anti p-PIP39 or tubulin antibodies (α PIP39, α p-PIP39 and α tub, 
respectively). (B) The mean quantification of the p-PIP39/tubulin signal of different 
experiments (n=6 for untreated, 2 hr and 4 hr; n=4 for 6 hr; n=5 for 24 hr and n=2 for 48 hr) 
is shown, together with the corresponding percentage of cellular differentiation to procyclic 
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Figure 4.12 Analysis of the phosphorylation levels of TbPIP39 upon cis-aconitate (CA) 
and citrate (Ci) treatment of stumpy form cells. (A) Western blot analysis of stumpy form 
cells induced to differentiate by addition of 6 mM cis-aconitate (CA) or 10 mM citrate (CI). 
Samples were probed with anti-PIP39, anti p-PIP39 or tubulin antibodies (α PIP39, α p-
PIP39 and α tub, respectively). (B) Corresponding percentage of cellular differentiation to 
procyclic forms, as judged by EP protein   expression quantified by FACS. 
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Since the physiological differentiation of stumpy form to procyclic form cells 
is believed to be mediated through the cooperative effect of cis-aconitate and 
temperature reduction (Engstler et al., 2004), the consequences of cold shock 
on the PIP39 phosphorylation were investigated. Initially it was interesting 
to test the effect of cold shock alone, which has been reported to cause EP 
protein   expression on the stumpy cell surface, but not to induce cell 
proliferation and differentiation to procyclic forms (Engstler et al., 2004). 
Accordingly, Figure 4.13 shows that cold shock treatment did not induce an 
increase in the p-PIP39 signal (Figure 4.13 A) but it did cause EP protein   
expression in 15-20 % of the cell population at 2-4 hr (Figure 4.13 B).  
Next, the effect of cis-aconitate in the absence or presence of cold shock on 
the levels of phosphorylated PIP39 was tested. The shift from the 
bloodstream temperature of 37°C to 20°C, likely corresponding to the vector 
feeding environment, renders trypanosomes more sensitive to cis-aconitate. 
Therefore cis-aconitate concentrations such as 1 mM or lower, which at 27°C 
do not induce differentiation, are as effective as 6 mM, in presence of cold 
shock (Engstler et al., 2004). Hence, stumpy form cells were treated with 6 
mM or 1 mM cis-aconitate in presence or absence of an overnight incubation 
at 20°C (cold shock). Under these conditions, however, similar levels of p-
PIP39 were detected and no significant difference was visible between cells 
exposed to 1 mM cis-aconitate without or with cold shock (1 mM CA -/+ CS) 










Figure 4.13 Effect of cold shock on the phosphorylation levels of TbPIP39. Three 
independent Western blots of stumpy form cells cold shocked overnight at 20°C are shown 
in A; the 0 hr time point represents samples taken after an overnight incubation at 20°C. The 
experiment was conducted in triplicate, with cells from the same mouse kept at 20°C in three 
different flasks. As for the previous figures, samples were probed with anti-PIP39, anti p-
PIP39 or tubulin antibodies (α PIP39, α p-PIP39 and α tub, respectively). (B) Corresponding 
percentage of cellular differentiation to procyclic forms, as judged by EP protein   expression. 
 
 






Figure 4.14 Effect of cis-aconitate (CA) without or with cold shock (CS) on the 
phosphorylation levels of TbPIP39. (A) Western blot analysis of stumpy form cells induced 
to differentiate by addition of 6 mM or 1 mM cis-aconitate (CA) in presence of absence of 
cold shock (CS) (the 0 hr time point represents samples taken after an overnight incubation 
at 20°C). Samples were probed with anti-PIP39, anti p-PIP39 or tubulin antibodies (α PIP39, 
α p-PIP39 and α tub, respectively). (B) Corresponding percentage of cellular differentiation 
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In addition to citrate/cis-aconitate, another trigger of differentiation to 
procyclic forms is mild acid treatment, which has been shown to induce 
transition to procyclic forms in absence of CCA, albeit with different kinetics 
(Rolin et al., 1998) (see paragraph 1.9.2.2). Indeed, a pre-incubation in HMI-9 
media at pH 5.5 for 2-hr before transferring the cells in HMI-9 at normal pH 
(pH 7.8) at 27°C, resulted in limited differentiation, reaching less than 50 % 
after 48 hr (Figure 4.15 B). Moreover, the level of TbPIP39 phosphorylation 
during this time did not seem to visibly increase compared to CCA-treatment 
(Figure 4.15 A, compare with Figure 4.11 A).  
In addition to mild acid, proteolytic stress, such as trypsin or pronase 
treatments, have been shown to induce transformation of stumpy form cells 
into procyclics through an unknown mechanism (Hunt et al., 1994; Sbicego et 
al., 1999). In order to test whether the TbPTP1-TbPIP39 pathway is involved 
in proteolytic stress-induced differentiation, the level of TbPIP39 
phosphorylation was assessed under pronase treatment. Such treatment 
resulted in a much weaker p-PIP39 signal compared to that seen for CCA-
treated cells (Figure 4.16 A and B), despite a similar degree of EP expression 
(Figure 4.16 C). The difference was particularly striking at 2 and 4 hr, as no 
increase in p-PIP39 levels was detected for pronase-treated cells compared to 
a 1 and 1.5 fold increase for cis-aconitate treated cells, although the degree of 
cellular differentiation was higher for the first treatment.  
In conclusion, both cis-aconitate and citrate-induced differentiation 
stimulated TbPIP39 phosphorylation, whereas cold shock, mild acid and, 
particularly, pronase did not. This indicates the presence of alternative 













































Figure 4.15   Effect of mild acid treatment on the phosphorylation levels of TbPIP39. 
(A) Western blot analysis of stumpy form cells placed in HMI-9 media at pH 5.5 for 2 hr and 
then in normal HIM-9 at 27°C, according to Rolin et al., 1998; as for the previous figures, 
samples were probed with anti-PIP39, anti p-PIP39 or anti tubulin antibodies (α PIP39, α p-
PIP39 and α tub, respectively). (B) Corresponding percentage of cellular differentiation to 
procyclic forms, as judged by EP protein expression. The 0 hr time point corresponds to the 
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Figure 4.16 Effect of pronase treatment on the phosphorylation levels of TbPIP39. (A) 
Western blot analysis of stumpy form cells treated with pronase according to Sbicego et al., 
1999; as for the previous figures, samples were probed with anti-PIP39, anti p-PIP39 or anti 
tubulin antibodies (α PIP39, α p-PIP39 and α tub, respectively). (B) Quantification of the fold 
increase compared to untreated cells of the p-PIP39 signal normalized to tubulin. (C) 
Corresponding percentage of cellular differentiation to procyclic forms, as judged by EP 



















4.7.1 Comparative analysis of TbPTP1 mechanism of regulation during 
differentiation to procyclic forms 
 
The spatial and temporal regulation of Protein Tyrosine Phosphatases (PTPs) 
is essential to ensure the proper propagation of cellular signalling in 
response to different stimuli (den Hertog et al., 2008).  In mammalian cells, 81 
active PTPs are present (Alonso et al., 2004) that  are involved in a plethora of 
cellular functions, from cell cycle, shape and motility, to gene transcription 
and mRNA processing, and which display a variety of regulatory 
mechanisms. 
In the trypanosomatid genomes, the large number of protein kinases clearly 
indicates that protein phosphorylation is an important mechanism of signal 
transduction. However, the lack of recognizable tyrosine kinases (Parsons, 
2005), together with a very limited number of classical tyrosine phosphatases 
(Brenchley et al., 2007) could suggest the presence of a more discrete 
repertoire of proteins regulated by tyrosine phosphorylation compared to 
serine/threonine phosphorylation. If this is the case, it is then possible that a 
less tight PTP regulation may be needed in these protozoan organisms. 
However, experimental evidence has also shown that a certain degree of 
tyrosine phosphorylation is present in Trypanosoma brucei, with two 
developmentally regulated phosphotyrosine-containing proteins being 
characterized (Parsons et al., 1994; Chou et al., 2010; Szoor et al., 2010) and 13 
phosphorylated tyrosine sites being identified on protein kinases (Nett et al., 
2009b). Moreover, the lack in kinetoplastid PTPs of additional structural 
domains, such as targeting motifs or protein-protein interaction domains, 
(Brenchley et al., 2007) might indicate a greater requirement for regulatory 
mechanisms.  
In the context of TbPTP1, the inhibition of phosphatase activity responsible 
for the transition from stumpy to procyclic forms, suggests the need for an 
enzymatic regulation sensitive to the environmental changes that the parasite 
encounters (Szoor et al., 2006). 
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Higher eukaryote PTPs, particularly PTP1B, have been shown to be 
regulated at different levels: transcriptionally, post-transcriptionally, 
translationally and post-translationally (Bourdeau et al., 2005).  
Within the transcriptional regulation level several mechanisms are present in 
mammalian cells to obtain tissue or stimuli-dependent control of PTPs, for 
example downregulation through promoter methylation, upregulation via 
enhancer elements or differential expression by the alternate use of 
promoters (den Hertog et al., 2008). In Trypanosoma brucei, gene regulation is 
mainly post-transcriptional due to lack of recognizable promoters in the 
protein-coding genes (Clayton, 2002), therefore TbPTP1 transcriptional 
regulation can probably be excluded.  
 
4.7.1.1. Post-transcriptional regulation of TbPTP1 
 
Only a few studies have addressed the issue of post-transcriptional, 
translational or protein stability control of mammalian PTPs, showing that 
increase in mRNA stability (Rajendrakumar et al., 1993) or reduced rate of 
protein degradation (Gebbink et al., 1995) can be responsible for changes in 
PTPs quantity, although the extent of this level of regulation compared to 
others is not clear. In Trypanosoma brucei, altered mRNA processing, mRNA 
degradation or stabilization and translational control, are all mechanisms 
that account for the developmental regulation of more than 30 transcripts 
(Clayton, 2002), and thus could potentially play an important role in TbPTP1 
regulation. However, whilst TbPTP1 gene expression through the different 
life cycle stages has been reported to increase 1.5-3 fold in stumpy form 
compared to slender and procyclic forms (Szoor et al., 2006), this change is 
not reflected by increased protein levels, which are maintained equal 
throughout differentiation. Likewise, since the size of the TbPTP1 transcript 
was found to be the same in the different T. brucei life cycle stages (Szoor et 
al., 2006), it is unlikely that trans-splicing plays a role in the phosphatase 
regulation. Hence, post-transcriptional mechanism cannot account for 
TbPTP1 inactivation upon differentiation to procyclic forms.  
A constant TbPTP1 level could still result in differential enzyme activity if 
coupled to changes in protein subcellular localization, as it is achieved 
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through the presence of protein-protein interaction or targeting domains in 
various mammalian PTPs (den Hertog et al., 2008). For example, cytoplasmic 
PTPs can be recruited to sites of cell-cell adhesion or cell-surface tyrosine 
phosphorylation through FERM, PDZ or SH2 motifs (Alonso et al., 2004); 
similarly, some PTPs, such as PTP1B, possess ER-anchoring sequences that 
target them to the ER, where they are able to interact with ER-transported 
proteins, such as EGFR and PGFR (Haj et al., 2002). However TbPTP1, 
together with the other kinetoplastids PTPs, lack any additional recognizable 
regulatory or targeting domains (Brenchley et al., 2007); in addition, TbPTP1 
cytoskeletal localization has not been shown to change during the parasite 
life cycle (Szoor et al., 2006; McElhinney, 2007), likely excluding differential 
targeting as a regulatory mechanism.   
 
In addition to protein localization, another mechanism identified for PTP1B 
recruitment to specific cellular targets has been through adaptor molecules, for 
example it has been shown that phospholipase Cγ1 mediates the interaction 
between PTP1B and its target Jak2 by directly binding to both proteins (Choi et 
al., 2006). TbPTP1 possesses several trypanosome-specific motifs located on the 
surface of the protein, which have been proposed to play a role in protein-
protein interaction (Chou et al., 2010), and thus could potentially mediate the 
phosphatase recruitment to a target protein through adaptor molecules. 
Experimental evidence would be needed to validate this hypothesis, however. 
  
Another example of PTP regulation at the protein level is represented by 
limited proteolysis. Several mammalian PTPs, including PTP1B, have been 
shown to undergo limited cleavage by calpain upon platelet activation, 
resulting in increased activity due to the removal of a negative regulatory 
domain (Frangioni et al., 1993; Falet et al., 1998). It is not known whether 
TbPTP1 possesses negative regulatory motifs or if it can be proteolytically 
cleaved under certain stimuli, but residues 135-152 have been identified as 
predicted PEST motif (Szoor et al., 2006), a region rich in Pro, Glu/Asp, 
Ser/Thr and flanked by Arg/Lys, a high affinity substrate for calpains (Siman 
et al., 1989). Moreover, some T. brucei calpain-like proteins, have been shown 
to be developmentally regulated, although their catalytic domain is not 
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perfectly conserved and their proteolytic activity has not been demonstrated 
(Hertz-Fowler et al., 2001; Liu et al., 2010). Due to the limited characterization 
of T. brucei proteases, there is a lack of tools, such as calpain inhibitors or 
stimulators, with which to assess the potential involvement of these molecules 
in TbPTP1 regulation. Indeed proteolytic cleavage of PTP1B was only 
visualized by the change in electrophoretic motility of the phosphatase, after 
treatment with calcium ionophores, which activate calpains by raising 
intracellular calcium concentration, or with calpain inhibitors (Frangioni et al., 
1993).    
 
4.7.1.2. TbPTP1 phosphorylation 
 
Probably the best characterized mechanism of PTP regulation, particularly 
for PTP1B, is phosphorylation. As previously mentioned, PTP1B activity has 
been shown to be modulated in a growth factor-dependent manner through 
phosphorylation of three serine and three tyrosine residues (Bourdeau et al., 
2005) and in a cell cycle-specific manner via phosphorylation  of Ser352 and 
Ser386 (Flint et al., 1993). Although these phosphorylation events have been 
shown to affect enzyme activity, little is known about their mechanism of 
action. Generally it is believed that this post-translational modification either 
directly interferes with catalysis or indirectly recruits phosphate-binding 
proteins, which are responsible for the change in enzymatic activity (den 
Hertog et al., 2008). For example, PTP1B phospho-Tyr66 was found to be 
located within the consensus sequence for the SH2 domain of Grb2, an 
adaptor protein which binds to the EGFR, and thus it has been suggested to 
mediate PTP1B inhibition by competing with other substrates 
(Bandyopadhyay et al., 1997).  
A comparative analysis of PTP1B and TbPTP1 phosphorylation sites showed 
that, among the eight phosphorylated residues of the human phosphatases, 
only two (PTP1B Tyr66 and Tyr152) are conserved in the parasite enzyme 
(TbPTP1 Tyr78 and Tyr164), and also in the T. congolense, T. vivax and T. cruzi 
but not in Leishmania major homologues (Figure 4.2). Both these sites are 
predicted to map onto the surface of TbPTP1 (Figure 4.3) and thus could 
possibly be phosphorylated. PTP1B Ser242 is substituted by Thr255 in 
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TbPTP1, but is found within a sequence showing very low similarity to the 
human counterpart, and not found on the surface of the phosphatase (Figure 
4.3), and thus may be less likely to be phosphorylated. Among the four 
TbPTP1 residues predicted to be phosphorylated by bioinformatics analysis 
(Ser42, Thr238, Tyr280 and Tyr284) (Figure 4.2), only Ser42 is found in a 
more accessible position on the enzyme, compared to the others (Figure 4.3); 
in addition, Ser42 is conserved among trypanosomes and is found in the 
trypanosome-specific motif PcT2, and thus might represent a different 
phosphorylation site acquired by this family of kinetoplastid protozoa.    
Although the presence and position of the conserved Tyr66 and Tyr152 could 
support the hypothesis of TbPTP1 being tyrosine-phosphorylated, 
preliminary experimental evidence does not show any presence of pTyr 
residues in the enzyme, either before or after induction of differentiation to 
procyclic form (Figure 4.4). One reason for the lack of detectable pTyr 
residues in TbPTP1 enzyme might be the limited amount of immuno-
precipitated enzyme; moreover the phosphorylation could be transient and 
thus not visible after 48 hr of cis-aconitate treatment. Similarly, it could be 
argued that monomorphic cell lines, like the ones used for the immuno-
precipitation, do not mimic physiological differentiation, as they do not pass 
through stumpy form stage. Consequently monomorphic lines might display 
a different mechanism of TbPTP1 regulation, or the potential level of enzyme 
phosphorylation might be too low to be detectable, given the limited amount 
of cellular differentiation.  
In order to address this issue, the creation of a pleomorphic cell line 
overexpressing TbPTP1 would be needed, or alternatively, the endogenous 
phosphatase could be immunoprecipitated from wild type stumpy form 
cells. This however, would require a better TbPTP1-specific antibody than the 
one available. In addition, the potential phosphorylation of the enzyme 
should be monitored from minutes to a few hours after induction of 
differentiation, in order to detect the transient or very early phosphorylation 
in the developmental pathway. Indeed, in the case of PTP1B, the 
phosphorylation of Tyr66 has been detected 5 minutes after insulin 
stimulation (Bandyopadhyay et al., 1997). The stumpy-specific and likely 
transient nature of the potential TbPTP1 phosphorylation, could also account 
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for the absence of the phosphatase in the list of T. brucei phosphorylated 
protein (Nett et al., 2009b).  
Taken together, the above observations indicate that more experiments will 
be needed to definitely rule out the possibility of TbPTP1 being regulated by 
Tyr or Thr/Ser phosphorylation.  
 
4.7.1.3. TbPTP1 sumoylation 
 
A relatively recently described post-translational modification regulating 
PTPs activity is sumoylation. Generally, sumoylation can affect protein 
function by masking or creating binding sites on the sumoylated molecule, or 
by changing its conformation (Wilkinson et al., 2010). In the case of PTP1B, 
the only PTP identified to date as being regulated by this modification 
(Dadke et al., 2007), sumoylation of Lys335 and Lys347 has been suggested to 
block the catalytic domain of the phosphatase thus inhibiting its activity 
upon insulin stimulation.  
Interestingly, TbPTP1 also possesses the sumoylation consensus motif on 
Lys131 (ΨKxD/E, where Ψ is A/I/L/M/P/F/V and X is any aa), which is 
conserved among T. congolense, T. vivax, T. cruzi and L. major but not with 
human PTP1B (which lacks the D/E residue) (Figure 4.5 A).  However, 
TbPTP1 Lys131 is not found on the surface on the enzyme, whereas the 
residues shown to be sumoylated in PTP1B are found in the C-terminal 
domain of the protein, which is probably much more accessible to SUMO-
conjugating enzymes (Dadke et al., 2007). Moreover, although about 75% of 
sumoylation occurs within the consensus motif, it can also occur at lysine 
residues outside the motif and not all ΨKxD/E sequences are sumoylated 
(Wilkinson et al., 2010).  
The role of protein sumoylation in T. brucei is not known, but one SUMO 
homologue has been recently characterized and showed to be essential for 
the cell-cycle regulation of procyclic forms (Liao et al., 2010). As visualization 
of protein sumoylation is often missed in absence of strong SUMO 
isopeptidase inhibitors (Dadke et al., 2007), the conserved functionality of 
such inhibitors in T. brucei would have to be tested before being used to 
experimentally validate the presence of sumoylated TbPTP1. Consequently, 
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conclusions on the potential role of this modification on TbPTP1 regulation 
can not be drawn at this time. 
 
4.7.1.4. TbPTP1 oxidation 
 
A well-established post-translational mechanism of PTPs regulation is 
oxidation (Monteiro et al., 1996; Denu et al., 1998). Most PTPs are sensitive to 
oxidation due to the unique environment of the active site, which renders the 
catalytic cysteine particularly vulnerable to oxidative agents (Meng et al., 
2002). Crystallographic studies performed on PTP1B have characterized the 
mechanism in detail, whereby the oxidation of the cysteine to sulphenic acid 
(S-OH) causes the formation of a covalent bond between the cysteine sulphur 
atom and the main chain nitrogen of the adjacent serine residue (Salmeen et 
al., 2003). Such modifications result in changes in the architecture of the 
active site, which have been suggested to protect the enzyme from further 
irreversible oxidation and to facilitate reduction back to the active form of the 
phosphatase (Tonks, 2005). PTP inactivation through reversible oxidation has 
been shown to happen in response to several physiological stimuli, such as 
insulin (Mahadev et al., 2001) and growth factors (Chen et al., 2006), and is 
often mediated by the action of ligand-activated NADPH oxidases (Chen et 
al., 2008). The interaction between ROS-generating enzymes and PTPs is 
believed to convey signal specificity, since phosphatases are not the only 
ROS target present in the cell. For example, PTP1B has been shown to be 
inhibited by oxidation upon interleukin-4 stimulation in T cells, through the 
activation of the NADPH oxidase NOX1 (Sharma et al., 2008a). However, 
exogenous H2O2 has also been shown to mimic insulin activity on PTPs 
(Heffetz et al., 1992). 
Trypanosoma brucei possesses a peculiar redox metabolism compared to 
higher eukaryotes. Indeed trypanosomes lack the proteins responsible for 
mammalian detoxification from ROS, such as glutathione reductase, 
thioredoxin reductase, and catalase. Neutralization of hydrogen peroxide is 
obtained through the action of Prx (2-Cys-peroxiredoxin) and Px 
(glutathione-peroxidase-type enzymes), which derive their reducing 
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equivalents from the cascade composed of T(SH)2 (trypanothione) and TXN 
(tryparedoxin) (Krauth-Siegel et al., 2008).  
ROS have been shown to play a role in T. brucei programmed cell death 
(Figarella et al., 2006), drug resistance (Tsuda et al., 2006) and parasite 
clearance in the tseste fly (Hao et al., 2003), but their potential involvement in 
parasite differentiation has not been studied. However, some stress 
conditions, which are generally known to produce increase in intracellular 
ROS in higher eukaryotes (Fedoroff, 2006), have been linked to parasite 
differentiation from stumpy to procyclic forms. Notably treatment of 
bloodstream form cells with trypsin (Yabu et al., 1988) or pronase, a mixture 
of proteinases, have been shown to induce expression of the procyclic form-
specific EP protein   (Hunt et al., 1994; Sbicego et al., 1999). Moreover, mild 
acid treatment of pleomorphic cells has been shown to cause transformation 
of stumpy form into procyclic form cells (Rolin et al., 1998). However, it is 
also worth noting that it is not known whether these triggers possess a real 
physiological role in trypanosome differentiation or if they act in a similar 
way. Interestingly, trypsin and pronase have also been involved in the 
induction of intracellular ROS in lung fibroblasts, and although their 
mechanism of action have not been characterized, potential ways in which 
these compounds could act have been suggested, such as through proteinase-
activated receptors or ion channels, or via increase membrane permeability 
and loss of intracellular antioxidants (Aoshiba et al., 2001).  
Although the links between ROS and mammalian PTPs inactivation and ROS 
and cellular stress are well established, there is no example in the literature 
showing phosphatase oxidation under stress conditions, as the only stimuli 
identified so far to produce ROS-mediated enzyme inhibition have been 
insulin (Mahadev et al., 2001) and growth factors (Chen et al., 2006; Sharma et 
al., 2008a). It is possible that PTP regulation via oxidation requires a more 
localized increase in ROS, achievable through activation of cellular oxidases 
in a ligand-dependent manner, as reported for PTP1B under certain stimuli 
(Tonks, 2003; Sharma et al., 2008a), rather than a generalized ROS production 
usually originated from the mitochondria (Aoshiba et al., 2001). However, as 
mentioned earlier, exogenous H2O2 has been shown to mimic the insulin 
effect on protein phosphorylation in intact cells (Heffetz et al., 1992). For 
4- Dissection of TbPTP1 signalling pathway during differentiation to procyclic forms 173 
these reasons the potential role of both stimulus-dependent and exogenous 
H2O2-induced increase in intracellular ROS during trypanosome 
differentiation were investigated. 
Since the physiological trigger of parasite differentiation to procyclic forms is 
considered to be citrate/cis-aconitate (CCA) (Overath et al., 1986; Engstler et 
al., 2004) it was particularly interesting to test whether CCA could cause 
TbPTP1 inhibition through production of intracellular ROS, similarly to what 
is observed for insulin and PTP1B (Mahadev et al., 2001). In order to do so, it 
was first necessary to monitor intracellular ROS upon CCA treatment of 
bloodstream form cells. Unexpectedly, the most widely used redox-sensitive 
probe H2-DCFDA, reacted with CCA in a cell-free environment (Figure 4.6), 
thus excluding this dye as a useful tool to assess ROS formation. To 
overcome this problem a different compound (Ampliflu™ red) had to be 
used, as most of the redox-sensitive compounds share the fluorescein moiety 
found in H2-DCFDA. Cells were monitored continuously from 5 minutes 
after CCA addition, since ROS signalling events have been shown to start as 
early as 5 minutes after EGF stimulation (Bae et al., 1997) or peak at 45 
minutes after integrin-mediated cell adhesion (Chiarugi et al., 2003). In fact, 3 
hr was chosen as upper limit for detection of potential signalling events 
leading to differentiation, since the first detectable cytological event is the 
appearance of EP protein   at 2-4 hr after CCA addition (Ziegelbauer et al., 
1990).  During this time, Ampliflu™ red did not show increased fluorescence 
upon CCA treatment of bloodstream or stumpy form cells (Figure 4.7).  
These results suggest that CCA do not induce formation of intracellular ROS 
under these conditions, however it is also possible that Ampliflu™ red might 
not be sensitive enough to detect potentially small ROS increase, since it 
reacts with H2O2 outside the cell and thus might require a greater ROS 
gradient. Indeed Ampliflu™ red has been used mainly to compare baseline 
levels of ROS among different cell types, rather than to detect transient 
increase of ROS upon stimulation (Lou et al., 2008). It is also possible that a 
different stimulus or stimuli might be needed, as PTP inactivation by 
oxidation has been shown to be growth factor-specific (Meng et al., 2002). 
Since CCA-induced differentiation did not result in increased intracellular 
ROS, the possibility of exogenous H2O2 regulating TbPTP1 activity was then 
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investigated. To test this hypothesis, bloodstream or stumpy form cells were 
treated with different concentrations of H2O2 ranging between 5 and 100 µM. 
The lack of EP protein expression, even after 48 hr of treatment, indicated 
that exogenous H2O2 was not able to induce trypanosome differentiation to 
procyclic forms (Figure 4.8 A), unlike what seen in mammalian cells (Heffetz 
et al., 1992). 
Having shown that CCA and exogenous H2O2 are unlikely to be responsible 
for TbPTP1 oxidation, it was then interesting to test the role of endogenous 
ROS, potentially produced by stimuli other than CCA, in cellular 
differentiation. For this purpose, cells were treated with the ROS scavenger 
N-acetyl cysteine (NAC), at 0.25 and 0.4 mM, concentrations found to be 
effective in preventing intracellular ROS increase upon H2O2-exposure but 
not to be cytotoxic (Figure 4.8 B and D, respectively). The results showed 
that NAC treatment did not affect the number of EP positive cells (Figure 4.8 
C), thus suggesting that H2O2 is unlikely to play a role in the parasite 
differentiation pathway.  
The above observations indicate that TbPTP1 might not be regulated through 
oxidation in vivo. Indeed, although TbPTP1 has been shown to be sensitive to 
this modification in vitro, reaching 0% of activity after 15 min of 0.25 mM 
H2O2 treatment (Szoor et al., 2006), another PTP, PTEN, has shown similar 
inhibition after only 5 min of 0.1 mM H2O2 (Ross et al., 2007). Therefore it is 
possible that TbPTP1 might be relatively resistant to oxidation, as reported 
for other PTPs (Ross et al., 2007), but to validate this hypothesis a more 
uniform and detailed comparative analysis would be needed.  
Differences in PTPs oxidation levels have also been noted to be cell type-
specific, probably due to the different oxidative environment of the cell lines 
(Weibrecht et al., 2007). This phenomenon, although not directly relevant to 
the signalling events leading to differentiation, could maybe account for the 
maintenance of TbPTP1 inactivation in procyclic forms, since insect-stage 
cells display higher mitochondrial activity than bloodstream forms and thus 
have potentially higher ROS production (Vickerman et al., 1988). 
In addition, recent experimental evidence has shown that TbPTP1 is 
regulated by its own substrate, TbPIP39, in a CCA-dependent manner, with 
CCA inhibiting the increase in activity seen when TbPTP1 is incubated with 
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TbPIP39 in vitro (Szoor et al., 2010). If this observation reflects the in vivo 
situation, then TbPTP1 would be positively regulated by its own substrate in 
stumpy form cells and addition of CCA would neutralize such regulation. It 
is not known how TbPIP39 affects TbPTP1 activity, but one possibility might 
be through enzyme-substrate interaction leading to conformational changes 
in the enzyme and resulting in its increased activity. In this case, CCA would 
interfere with this interaction by binding to the TbPIP39 citrate binding 
pocket, thus loosening the enzyme-substrate cooperative interaction and 
decreasing its activity. Such a mechanism might not require additional levels 
of TbPTP1 control and would represent a novel way of PTP regulation, 
different from the ones described in literature to date (den Hertog et al., 
2008).  
 
In order to dissect the physiological importance of the possible different 
TbPTP1 regulatory mechanisms it would be necessary to assess the in vivo 
activity of this phosphatase during differentiation. Monitoring enzyme 
oxidation through techniques such as the in-cell oxidation assay (Ross et al., 
2007), in-gel phosphatase assay (Meng et al., 2004) and through the use of 
oxidation-specific antibodies (Persson et al., 2004)  or by mass spectrometry 
(Caselli et al., 1998) would be an obvious choice to address this question. In 
addition, it would be important to test phosphatase activity under a certain 
stimulus by performing activity assays “ex-vivo” on the immuno-
precipitated enzyme (Chiarugi et al., 2003). All these techniques require very 
specific conditions of cell lysis and protein manipulation to avoid 
spontaneous enzyme oxidation, for example lysing cells under anearobic 
conditions, and thus are relatively laborious. In addition, they require the 
phosphatase to be immunoprecipitated, which is technically difficult in the 
absence of a good antibody against endogenous TbPTP1 or of a pleomorphic 
line expressing the tagged enzyme, as already mentioned.  In the future, it 
would also be useful to express mutant versions of TbPTP1, lacking the 
potential phosphorylation/sumoylation sites or PEST sequence, to dissect 
the role of these different modifications on the phosphatase activity. 
Similarly, monitoring TbPTP1 activity in vivo, in cells expressing different 
versions of TbPIP39, for example possessing a mutated citrate-binding site, 
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would be needed to address the importance of TbPIP39 and the CCA-
mediated regulation of TbPTP1.  
 
4.7.2 Monitoring TbPIP39 phosphorylation upon treatment of stumpy 
form cells with different differentiation triggers 
 
Parallel to the dissection of TbPTP1 regulation during differentiation, it was 
interesting to investigate whether other triggers of the transition to procyclic 
forms also act through the TbPTP1-TbPIP39 signalling cascade, as seen for 
CCA (Szoor et al., 2010).  
The antibody developed for the phosphorylated Y278 residue of TbPIP39 (p-
PIP39) was a useful tool for this purpose. As expected, the signal of the anti 
p-PIP39 antibody disappeared in the presence of recombinant active TbPTP1 
(Figure 4.9 middle panel, arrow) and detected the same 40-kDa band 
recognized by the anti-PIP39 antibody (Figure 4.9 upper panel), thus 
demonstrating its specificity. Moreover, analysis of cell extracts from 
different life cycle stages showed an increasing level of phosphorylated 
TbPIP39 progressing from slender, to stumpy and procyclic form (Figure 4.10 
A), with established procyclics showing approximately a 2.6 fold increase 
compared to stumpy forms. Similarly greater levels of phosphorylated 
TbPIP39 were detected after 1.5 hr treatment with cis-aconitate or with the 
TbPTP1 inhibitor BZ3 (Figure 4.10 B). Interestingly, a slightly greater increase 
in p-PIP39 signal was obtained at 1.5 hr after induction of differentiation 
compared to established procyclics (3-4 fold versus 2.6 fold, compared p-
PIP39 quantification in Figure 4.10 B and A). This observation suggests that 
TbPIP39 phosphorylation might peak soon after induction of differentiation 
after which it is maintained at somewhat lower levels in established procyclic 
forms. However, because of the small difference in p-PIP39 signal, repeats of 
this analysis will be needed to statistically validate these preliminary results.   
In order to better characterize the degree and timing of p-PIP39 increase 
during CCA-induced differentiation, the p-PIP39 signal, normalized to 
tubulin, was compared at different time points and among several 
experiments; the level of p-PIP39 showed a reproducible increase from 2 to 
24 hr of treatment (Figure 4.11 B). However, because of the variability 
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between different blots of the same experiment and among different 
experiments, this increase was not statistically validated. Variations in p-
PIP39 quantification were not matched by variations in cellular 
differentiation, as most experiments showed very similar levels of EP protein 
expression at the different time points (Figure 4.11 C). Therefore, it is likely 
that Western blot processing and quantitation account for most of the 
variability observed and consequently, it was not possible to identify the 
time point after cis-aconitate treatment at which the p-PIP39 level peaked. As 
expected, citrate, the other citric acid cycle intermediate known inducer of 
differentiation (Czichos et al., 1986), also generated an increase in TbPIP39 
phosphorylation levels similar to those obtained with cis-aconitate (Figure 
4.12 A).  
 
4.7.2.1. Effects of cold shock on the phosphorylation levels of TbPIP39 
 
Since the physiological differentiation of stumpy form to procyclic form cells, 
is believed to be achieved through the cooperative effect of cis-aconitate and 
temperature reduction (Engstler et al., 2004), the consequences of cold shock 
on p-PIP39 were investigated. It was first interesting to test the effect of cold 
shock alone, which has been shown to cause EP protein expression but not 
cell proliferation and differentiation (Engstler et al., 2004). Upon overnight 
incubation at 20°C (cold shock), no increase in p-PIP39 level was detected 
(Figure 4.13 A), in accordance with the lack of differentiation previously 
reported. In contrast, increased p-PIP39 levels were observed when cells 
were cold shocked in presence of 1 mM cis-aconitate (Figure 4.14 A), which 
was able to induce differentiation, as the temperature shift renders the cells 
sensitive to concentrations of cis-aconitate lower than 6 mM (Engstler et al., 
2004). However, the increase in p-PIP39 detected under these conditions was 
comparable to what seen if cells were treated with 6 mM cis-aconitate with or 
without cold shock (Figure 4.14 A).  
Taken together, the above results suggest that cold shock does not directly 
affect the levels of TbPIP39 phosphorylation, and that cold shock-induced 
sensitization of stumpy form cells to cis-aconitate does not seem to be 
achieved through increased p-PIP39 levels. The latter observation, which 
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apparently contradicts the hypothesis that cold shock-induced expression of 
TbPIP39 would increase the level of phosphorylated TbPIP39 promoting 
differentiation (Szoor et al., 2010), in reality indicates that TbPIP39 
upregulation might not always be required to induce transition to procyclic 
forms, as long as increased levels of p-PIP39 are present. Therefore cold 
shock would sensitize trypanosomes to cis-aconitate by promoting its 
transport into the cell, through expression of the PAD transporter (Dean et 
al., 2009). Thereafter, the presence of higher intracellular CCA would inhibit 
the feedback activation of TbPTP1 by TbPIP39, thus increasing the levels of 
phosphorylated TbPIP39, responsible for transmitting the differentiation 
signal to the glycosomes (Szoor et al., 2010).  
 
4.7.2.2. Effects of mild acid treatment on the phosphorylation levels of 
TbPIP39 
 
In addition to CCA and cold shock, mild acid treatment has been reported to 
induce differentiation to procyclic form cells, although with different kinetics 
(Rolin et al., 1998). A 2-hr incubation of pleomorphic cells in media at pH 5.5 
resulted in loss of slender forms and a concomitant increase in stumpy forms, 
probably due to the death of the less resistant slender forms to acidic stress 
and likely mediated by the glycophosphatidilinositol-specific phospholipase 
C (GPI-PLC) (Rolin et al., 1998; Nolan et al., 2000). According to the published 
data, mild acid treatment induced a more limited degree of cellular 
differentiation compared to CCA, with less than 50 % of the cells showing EP 
positivity after 48 hr (Figure 4.15 B). No visible change in the level of 
phosphorylated TbPIP39 was detected during the treatment (Figure 4.15 A) 
suggesting that acid stress might not act through the TbPTP1-TbPIP39 
pathway. However, due to the more limited degree of differentiation after 
mild acid treatment and to the potentially transient nature of TbPIP39 
phosphorylation, comparison with CCA-induced differentiation is difficult 
and thus more experiments would be needed to draw convincing 
conclusions.  
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4.7.2.3. Effects of pronase treatment on the phosphorylation levels of 
TbPIP39 
 
Proteolytic stress has also been shown to induce trypanosome differentiation 
to procyclic forms (Hunt et al., 1994; Sbicego et al., 1999). The importance of 
the potential role of proteolytic stress in the physiological transition from 
bloodstream to the vector stage parasite has been supported by the 
observations that bloodstream form cells have been shown to release 
proteinases (Nwagwu et al., 1988) and that trypsin-like enzymes have been 
found in the tsetse fly midguts (Imbuga et al., 1992).  
Studies looking at the effect of pronase or trypsin treatment on pleomorphic 
bloodstream form trypanosomes have reported a different kinetic of EP 
protein  expression and timing of morphological changes compared to CCA-
treatment; specifically a faster EP protein  expression has been shown, with 
100% of positive cells at 6 hr after pronase treatment compared to 90% after 
CCA-induced differentiation (Sbicego et al., 1999). Similarly, a faster 
acquisition of the typical procyclic-form morphology has been reported, with 
95% of procyclic-like cells visible at 72 hr after pronase treatment, compared 
to 55% of CCA-treated cells at the same time point (Hunt et al., 1994). 
Moreover both studies have highlighted the fact that the protease-treated 
cells showed some degree of cell death, reaching 5-6 times lower cell density 
than for CCA treated (Sbicego et al., 1999), with slender form cells being more 
sensitive than stumpy forms (Hunt et al., 1994). The latter observation 
prompted the investigators to test whether the effect of pronase treatment on 
pleomorphic cells differentiation was merely due to selection of stumpy 
forms. For this reason they subjected to pronase treatment a population of 
pure stumpy cells, which resulted in transition to procyclic form cells, thus 
demonstrating that proteinase treatment acted directly, triggering 
differentiation (Sbicego et al., 1999).  
Interestingly, both papers made two other potentially important 
observations. Firstly that proteinase and CCA seemed to act through a 
different mechanism, as judged by different kinetics of differentiation (Hunt 
et al., 1994) and demonstrated by the fact that addition of the soybean trypsin 
inhibitor did not inhibit CCA-induced differentiation (Sbicego et al., 1999). 
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Secondly, they both observed an additive effect of pronase/tryspin and CCA 
treatment compared to CCA treatment alone.  
According to the published results, treatment of stumpy form cells with 4 
U/ml of pronase, for 10 min at 25°C, resulted in higher EP protein   
expression than what is usually seen with 6 mM cis-aconitate, with almost 
50% of EP-positive cells detected at 2 hr compared to 0% of CCA-treated 
(Figure 4.16 C). However, the pronase-treated cells never reached 90-100% of 
EP positivity, probably caused by the high rate of cell death, possibly due to 
the use of a stronger proteinase treatment than published (Hunt et al., 1994).  
In addition, the procyclic morphology that was seen at 72 hr of pronase 
treatment by Hunt et al., and Sbicego et al., was not present after 24 hr of 
treatment in the experiments presented here. The only report monitoring in 
detail the morphological changes during pronase treatment (Frevert et al., 
1986) highlighted the presence of major structural changes, such as removal 
of the surface coat, flagellar internalization and dissolvement of the flagellar 
pocket, between 10 seconds and 20 minutes of treatment. However, these 
morphological changes do not mirror the ones induced by cellular 
differentiation, with the exception of surface coat removal. Furthermore, the 
concentration of pronase used by Frevert et al., is difficult to compare with 
other studies, due to the different origin of the enzymes, and thus the 
massive morphological changes reported could be explained by a higher and 
unphysiological pronase concentration. Interestingly, pronase treatment had 
a much weaker effect on the phosphorylation levels of TbPIP39 compared to 
cis-aconitate, with only faint bands visible at most of the timepoints (Figure 
4.16 A α p-PIP39) and in at least three different experiments. This 
observation supports the hypothesis suggested by both Hunt et al., and 
Sbicego et al., regarding a potential different mechanism of pronase and 
CCA-induced differentiation. For example, it is possible that proteinase 
treatment induces a fast EP expression by bypassing the initial signalling 
events required for CCA-induced differentiation (Figure 4.17). 
 
In order to draw conclusions about these two potentially different pathways, 
I believe, that it would first be necessary to monitor the effect of pronase 
treatment on EP expression and the morphology of stumpy cells in more 
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detail. In parallel, it would also be useful to investigate the kinetics of the 
events in vivo, as differences have been observed between the timing of 
transformation in culture and in the fly (Turner et al., 1988). If the 
physiological roles and the different kinetics of the two triggers are 
confirmed, then the hypothesis of the existence of two pathways should 
seriously be considered. Although the presence of more than one mechanism 
of trypanosome differentiation may be unexpected, pronase and CCA might 
actually act complementarily and might both be required for differentiation 
in the vector. Indeed, the cooperative action of pronase and CCA has been 
suggested from the observation that the simultaneous treatment of cells with 
both triggers resulted in a twice as fast kinetics of EP expression (Sbicego et 















Figure 4.17 Signalling pathways involved in T. brucei differentiation from stumpy to 
procyclic forms. Diagram depicting the potentially different pathways involved in parasite 
differentiation triggered by citrate/cis-aconitate (CCA), cold shock (CS) (which acts together 
with CCA, although here is represented as different for clarity), and pronase. CCA acts by 
inhibiting TbPTP1, thereby promoting TbPIP39 phosphorylation, which leads to EP protein   
expression and the subsequent functional and morphological changes. Pronase treatment of 
stumpy forms does not seem to act through TbPIP39, but via another pathway resulting in a 
faster EP protein expression and probably in morphological changes characteristic of 
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5.1. Background 
 
The rationale behind targeting TbPTP1 as a means to control sleeping 
sickness transmission lies in the fact that inhibition of the phosphatase causes 
bloodstream stumpy form parasites to differentiate into procyclic form cells 
(Szoor et al., 2006).  Stumpy forms are the only bloodstream form cells that 
are pre-adapted to survive in the vector (Vickerman et al., 1988), therefore 
treating an infected individual or animal with a drug inhibiting TbPTP1 
would decrease the chance of disease transmission.  
TbPTP1 is 24% identical at protein level with the human protein tyrosine 
phosphatase 1B (PTP1B) (see paragraph 1.17), which is one of the most 
attractive PTPs in the field of drug discovery; indeed PTP1B is a negative 
regulator of the insulin and leptin pathways, and mice deficient for such 
protein have shown increased sensitivity to insulin and resistance to obesity, 
thus establishing PTP1B as a therapeutic target for the treatment of type 2 
diabetes and obesity (Elchebly et al., 1999). Several pharmaceutical 
companies have been working to develop potent and selective PTP1B 
inhibitors (Zasloff et al., 2001; van Montfort et al., 2003), as obesity represents 
a hugely lucrative market: according to the WHO projections, approximately 
2.3 billion adults will be overweight and more than 700 million will be obese 
by 2015. 
The possibility of using a PTP1B inhibitor to target the parasite enzyme 
would provide a “piggy-back” strategy to control sleeping sickness 
transmission. “Piggy-back” denotes a drug discovery approach for neglected 
tropical diseases, which relies on the existence of a molecular target in the 
parasite, that has been pursued for other commercial indications (Nwaka et 
al., 2006). This strategy facilitates the identification of chemical entities active 
towards the parasite target, and has been used for the screening of 
antimalarial drugs from mammalian inhibitors of histone deacetylase 
(Andrews et al., 2000) and of cysteine proteases (Semenov et al., 1998), 
originally developed for treatment of cancer and osteoporosis, respectively.  
The additional advantage of the “piggy-back” approach is the potential use 
of existing drugs to target the parasite protein (“label extension” or drug 
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repositoning) (Nwaka et al., 2006). The use of an existing drug for the 
treatment of a disease, different to the one the drug was originally developed 
for, has the advantage that the candidate has known safety and 
pharmacokinetics properties, since it has been through some clinical 
development, and thus represents a less risky, cheaper and faster pathway to 
the market (Ashburn et al., 2004). The possibility of delivering a drug more 
quickly and at lower costs is particularly attractive for sleeping sickness and 
for other neglected tropical diseases, because they affect mainly poor people, 
and therefore do not represent lucrative markets for pharmaceutical 
companies (Trouiller et al., 2001). For this reason, label extension is 
considered the most successful drug discovery strategy for the treatment of 
neglected tropical diseases, and it has resulted in the identification of several 
anti-parasitic drugs in use today, such as eflornithine for sleeping sickness 
(see paragraph 1.5.5), ivermectin for filariasis and praziquantel for 
schistosomiasis (Nwaka et al., 2006). 
For the above reasons, seventeen PTP1B inhibitors, derived from the Drug 
Discovery Portal (DDP) at the University of Strathclyde in Glasgow, were 
tested against TbPTP1 in vitro and their IC50 and Ki values were calculated in 
order to identify the most potent compounds. In addition, in vitro 
competition assays were performed to find out whether the compounds bind 
the catalytic site of the enzyme, thus further characterizing their mechanism 
of action.  The inhibitors with lower IC50 were also tested on stumpy form T. 
brucei to evaluate their specificity against TbPTP1 in vivo.  
In addition to the seventeen compounds received from the Drug Discovery 
Portal, two other known PTP1B inhibitors were tested: oleanolic acid (Zhang 
et al., 2008) and suramin (McCain et al., 2004). Oleanolic acid was chosen 
because it is a natural compound discovered from traditional Chinese 
medicinal herbs, like several well-established anti-protozoal drugs, such as 
quinine and artemisinin (Klayman, 1985); moreover its cheapness, 
commercial availability and safety (Zhang et al., 2008) represented valuable 
properties for a potential drug, particularly for the control of a neglected 
tropical disease. Oleanolic acid is a triterpenoid compound present in a wide 
variety of foods, and in more than 120 plant species and demonstrating a 
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plethora of effects, including anti-inflammatory, antimicrobial, 
hepatoprotective and antitumoral activity (Liu, 1995). In addition, oleanolic 
acid has been found to have antimalarial properties (Steele et al., 1999) and to 
be trypanocidal for bloodstream form T. b. brucei (Salem et al., 2006).  
Suramin is a drug already in use for the treatment of early stage HAT, whose 
mode of trypanocidal action has not been definitely proven. Although it has 
been shown to inhibit glycerolphosphate oxidase and other glycolytic 
enzymes (Fairlamb et al., 1977), it is believed to have additional targets due to 
its six negative charges, which can easily form strong electrostatic 
interactions with a variety of enzymes (Fairlamb et al., 1977; Wierenga et al., 
1987; Barrett et al., 2007). Moreover it has been found to be an effective 
inhibitor of human PTP1B (McCain et al., 2004). In order to elucidate suramin 
activity and to potentially further characterize its mode of action, it was 
interesting to test the drug against TbPTP1 in vitro and in vivo. 
 
5.2. In vitro Screening of PTP1B inhibitors against TbPTP1  
 
Among the variety of assays available to monitor protein tyrosine 
phosphatase activity (Montalibet et al., 2005) the method chosen was the use 
of p-nitrophenyl phosphate (pNPP), a colorless substrate that upon 
hydrolysis to p-nitrophenol (pNP) becomes yellow, and the formation of 
which can be monitored by absorbance at 405 nm. Since the phenolate ion 
has a pKa of 7.2, the pNP absorbs mostly at alkaline pH, which is not the 
ideal pH of many tyrosine phosphatases (including TbPTP1 (Szoor et al., 
2006)). Hence the reaction needs to be stopped and the pH raised in order to 
detect the product formed (Montalibet et al., 2005). 
In order to determine the optimal reaction rate before performing enzymatic 
assays, it was important to perform a rate assay: an assay with serial 
dilutions of enzyme and at saturating concentrations of substrate (pNPP). 
Enzyme concentration was then plotted against the initial rate of the 
reaction, which was calculated by dividing the absorbance measured by the 
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reaction time (Figure 5.1 A). From the rate assay graph it could be 
determined the minimum enzyme concentration found within the linear 
range of the reaction (between approximately 100 and 300 nM, since higher 
concentrations gave a O.D measure that was outside the software test range 
of 0-2.5). Converting moles into grams (for a 34-kDa protein 100 pmoles= 3 
µg), the concentration range, in order to have detectable level of product 
within the linearity of the reaction, was between approximately 0.24 and 0.8 
µg per reaction.                
The next step important for enzyme characterization and necessary for 
further assays was the determination of the Michaelis and Menten kinetics. 
The Michaelis and Menten model describes the rate of catalysis of most 
enzymes, which rises with increasing concentration of substrate, until it 
reaches a maximum and begins to level off (hyperbolic plot) and is 
formalized in the following equation: Y= (Vmaxx X)/(KM+X), where Y is the 
enzyme velocity, X is the substrate concentration, KM is the Michaelis and 
Menten constant and Vmax the maximal rate or enzyme turnover. Both KM and 
Vmax depend on the substrate and on the environment of the enzyme (buffer 
pH and composition); the KM is equal to the substrate concentration when V 
is equal to (½)Vmax and thus provides a measure of the substrate 
concentration required for significant catalysis to occur. In addition, the KM is 
a measure of the strength of the enzyme-substrate complex: low KM values 
indicate strong binding, high KM values indicate weak binding. The maximal 
rate of enzyme reaction (Vmax) is defined as the number of substrate 
molecules that are converted into product in a unit time when the enzyme is 
fully saturated with substrate (Berg et al., 2002). In order to obtain KM and 
Vmax, a constant concentration of enzyme was assayed against increasing 
concentrations of substrate (pNPP) and the velocity (V0) of pNPP hydrolysis 
was plotted against the pNPP concentration (Figure 5.1 B). The velocity of 
pNPP hydrolysis was calculated using the following formula: V=A/(ε x 1 cm 
x 15 min), where A is the absorbance measured and ε is the pNPP extinction 
coefficient (see Materials and Methods). The data were then analysed with 
GraphPad Prism software, which calculated a Vmax of 3.03 mmol/min and KM 
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of 2.72 mM, when the quantity of enzyme used was 0.4 µg/reaction (Figure 
5.1 B). 
 














Figure 5.1.TbPTP1 rate assay and Michaelis and Menten kinetics. A shows the plot of 
the initial rate of reaction; on the y-axis is plotted the absorbance at 405 nm of the enzyme 
and substrate minus the absorbance of buffer and substrate alone (blank), and on the x-axis 
is plotted the concentration of enzyme ([TbPTP1]). B shows the Michaelis and Menten plot of 
enzyme velocity, measured in millimoles per minute (mmol/min), versus substrate 
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In order to compare the activity of different inhibitors for a certain enzyme it 
was important to determine the concentration of the inhibitor that reduced 
the maximum enzyme velocity by half (IC50). The IC50 value can be calculated 
from the sigmoidal dose-response curve, formalized in the following 
equation: Y= Bottom+ (Top-Bottom)/(1+10 LogIC50-X), where Y is the enzyme 
velocity, X is the logarithmic concentration of the inhibitor, the variable 
Bottom is the Y value at the bottom of the plateau, the Top is the Y value at 
the top of the plateau and LogIC50 is the X value when the response is 
halfway between Bottom and Top (Motlusky et al., 2003). In order to calculate 
the IC50 a series of reactions were carried out, each containing a different 
concentration of inhibitor; the enzyme and substrate concentrations were 
maintained constant and the latter was kept lower than the saturating 
concentration (usually at KM) in order to allow the competition of the 
inhibitor for the enzyme.  
Since the IC50 value depends on the reaction conditions, it cannot be used to 
compare the affinity of a certain inhibitor under different experimental 
conditions, for this purpose the dissociation constant (Ki) can be used. Ki is 
the concentration of inhibitor that will bind to half the enzyme sites in the 
absence of substrate. The dissociation constant is inversely proportional to 
the binding affinity of the inhibitor: if Ki is low, the affinity is high (Motlusky 
et al., 2003). In order to compare the activity of the inhibitors for PTP1B and 
for TbPTP1, Ki values were calculated using GraphPad Prism software, by 
choosing the one-site binding equation: Y=(Vmaxx X)/(KM+X), where X= 
log[In] and Y= V, then selecting the option of calculating Ki from IC50 using 
the KM value of the enzyme in absence of inhibitor, and the concentration of 
substrate used for the competition assays (0.175 mM). 
Seventeen DDP PTP1B inhibitors were tested against TbPTP1 and the relative 
IC50 were calculated (Table 5.1 and see Appendix A for their dose-response 
curves). Among them four (DDP inhibitor 2, 5, 7 and 12) possessed IC50 
between 50 and 100 µM, with 95% confidence interval between 10 and 300 
µM) (Figure 5.2 and highlighted in blue in Table 5.1); three compounds 
(DDP inhibitor 11, 15 and 17) showed an IC50 between 100 and 200 µM 
(highlighted in pink in Table 5.1), and three (DDP inhibitor 1, 12 and 13) 
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showed IC50 between 200 and 350 µM (Table 5.1). For the remaining seven 
DDP inhibitors it was not possible to calculate accurate values, probably due 
to very low inhibitory activities or sometimes to precipitation of the 
compounds.  
In addition to the DDP inhibitor 2, 5 and 7, BZ3, suramin and vanadate 
showed Ki and IC50 values of less than 100 µM, whereas oleanolic acid was 
found to have a Ki and IC50 between 100 and 200 µM. BZ3 and vanadate 
represented positive controls, as their inhibitory activity on TbPTP1 had 
already been tested (Szoor et al., 2006). 
The comparative analysis of the inhibitory activities of the same compounds 
against TbPTP1 and PTP1B (Appendix A and B and Table 5.1), revealed no 
significant differences in Ki and IC50 values for most of them; only DDP 
inhibitor 6 showed a significantly greater inhibition of the human enzyme 























Figure 5.2 Dose-response curves for DDP inhibitors 2, 5, 7 and 12 against TbPTP1. A 
constant concentration of enzyme (0.3-0.4 µg/reaction) and substrate (0.175 mM) was 
incubated with serial dilutions of inhibitors (from 200 to 0 µM). The percentage of substrate 
hydrolysis in presence of inhibitor compared to control without inhibitor (Hydrolysis % of 
control) is plotted against the logarithmic concentration of inhibitor (Log[In]); The calculated 
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Table 5.1 Summary of the IC50 and Ki calculated for the different inhibitors against 
TbPTP1 and PTP1B. The number of the DDP inhibitors tested (In. 1-17), together with the 
other four  PTP1B inhibitors are listed with the corresponding Ki and IC50 values for TbPTP1 
and PTP1B. Values are expressed in µM and the 95% confidence interval are shown in 
parethesis. The DDP inhibitors that showed calculated IC50 or Ki  between 50 and 100 µM 
(within a 95% CI between 100 and 200 µM) are highlighted in blue, whereas compounds 
showing calculated IC50 or Ki values between 100 and 200 µM are highlighed in pink. The 
values listed for BZ3, oleanolic acid (Oleanolic ac.), suramin and vanadate against PTP1B 
are the published ones (Huyer et al., 1997; McCain et al., 2004; Wiesmann et al., 2004; 
Zhang et al., 2008); n.d is not determined. See Appendix A and B for TbPTP1 and PTP1B 
dose-response curves. 
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5.3. TbPTP1 competition assays 
 
In order to further characterize the mechanism of action of the inhibitors 
tested, competition assays were performed between the compounds and the 
synthetic substrate pNPP. A constant enzyme and inhibitor concentration 
was tested against increasing concentrations of substrate and the Michaelis 
and Menten equation was used to calculate Vmax and KM. The comparison of 
the Michaelis and Menten constants, between enzyme alone and enzyme in 
presence of inhibitor, defines the type of inhibition; if an inhibitor binds to 
the same site as the substrate (competitive inhibitor) (Figure 5.3), it reduces 
enzyme velocity at low concentrations of substrate, thus increasing KM, but it 
does not alter the maximum velocity (Vmax) at saturating concentrations of 
substrate. An example of a competitive PTP inhibitor is vanadate, which has 
been shown to inhibit PTPs (Swarup et al., 1982) by binding to the active-site  
cysteine (Denu et al., 1996), with a calculated Ki for PTP1B of 0.38 µM (Huyer 
et al., 1997). 
Contrasting with this, if the inhibitor does not bind to the same substrate-
binding site (non-competitive inhibitor), the reaction will be partly inhibited, 
even at saturating concentrations of substrate, thus resulting in a decreased 
Vmax and constant KM.  Non-competitive inhibitors bind with equal affinities 
to both the enzyme alone and to the enzyme-substrate complex, whereas 
competitive inhibitors, by targeting only to the active site, are unable to bind 
to the enzyme-substrate complex (Figure 5.3).  
In addition it is possible that a certain inhibitor can both hinder the binding 
of the substrate and decrease the turnover number of the enzyme (mixed 
inhibitor), thus lowering Vmax and increasing KM (Berg et al., 2002). From the 
molecular point of view, mixed type inhibitors bind with different affinities 
to both the enzyme and the enzyme-substrate complex and therefore 
interfere with enzyme-substrate binding as well as with the activity of the 
enzyme-substrate complex formed (Figure 5.3).  
Non-competitive and mixed-type inhibitors are allosteric inhibitors, which 
bind to a different site on the enzyme (Berg et al., 2002). An example of a non-
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competitive allosteric inhibitor of PTP1B is a derivative of benzbromarone 
(BZ3), which was shown to bind a novel site of the enzyme and to trap the 
phosphatase into the inactive conformation by preventing the closure of the 






Figure 5.3 Diagram showing the mode of action of competitive, non-competitive and 
mixed type inhibitors. Schematic representation of the mode of action of competitive 
(Comp.), non-competitive (Non-comp.) and mixed type inhibitors (Mixed); competitive 
inhibitors can bind only the enzyme alone (E), whereas non-competitive and mixed inhibitors 
bind to both the enzyme and the enzyme-substrate complex (ES); non-competitive inhibitors 
bind with equal affinities to E and ES, whereas mixed type bind preferentially to E (thick 
arrow).  
As shown in Table 5.2 A and in the Michaelis and Menten plots of Appendix 
C, the two positive controls included for competitive and mixed type 
inhibition, vanadate and BZ3, respectively, showed the expected changes in 
Vmax and KM. Of the nine DDP inhibitors tested six (In.5, 11, 12, 13, 15 and 17) 
showed a non-competitive type of inhibition, indicated by a decreased Vmax 
but constant KM, compared to control assays without inhibitors (highlighted 
in blue in Table 5.2 A). Only DDP inhibitor 7 was found to be competitive, 
causing a 4-fold increase in KM (highlighted in green in Table 5.2 A). The KM 
and Vmax values for DDP inhibitor 2 were not confidently determined due to 
poor fitting of the data to the Michealis and Menten equation for unknown 
reasons. DDP inhibitor 1 did not significantly affect Vmax and KM at half IC50 
concentration and inhibitor 6 was excluded from the competition assays, 
being a very weak TbPTP1 inhibitor (IC50 >1 mM).  Among the other PTP1B 
inhibitors, oleanolic acid was found to be a non-competitive inhibitor, 
   Comp.    Non-comp.               Mixed 
E + S ES 
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similarly to most of the DDP inhibitors, whereas suramin showed to be a 
competitive inhibitor of TbPTP1 (Table 5.2 A).  
The comparative analysis between the data obtained with TbPTP1 and with 
the human PTP1B (Rachel Clark, personal communication) is shown in Table 
5.2 B. Most of the DDP inhibitors showed the same type of behavior for the 
two enzymes, with the exception of inhibitor 7, which was found to be 
competitive for TbPTP1. Oleanolic acid, which has been shown to be a 
competitive PTP1B inhibitor (Zhang et al., 2008), resulted instead not to bind 
the TbPTP1 catalytic site. Contrasting with this, suramin was found to be a 
competitive inhibitor for both enzymes (McCain et al., 2004) (Table 5.2 B). 
     
 
  


















Table 5.2. Competition experiments performed with TbPTP1. (A) In Table A the name of 
the inhibitor tested is listed in the first column from the left-hand side, together with the 
concentration of the inhibitor used in the assay in the second column ([In.] in µM); the third 
and fourth columns show the calculated Vmax and KM for the compounds (including the 
corresponding 95% confidence interval) and the last column summarizes the type of 
inhibition, according to the changed in Vmax and KM (as shown by the legend in the lower 
right-hand side panel); all the concentrations are in µM units. Note that BZ3 has been 
classified as “mixed” because of its clear increase in KM, despite the wide 95% confidence 
interval. (B) In Table B the comparative summary of the type of inhibitors tested for TbPTP1 
and human PTP1B is shown. The type of inhibition (competitive in pink, non competitive in 
blue and mixed in purple) is shown for the DDP inhibitors tested (In.5-17), oleanolic acid, 
suramin and the controls used for mixed type and competitive inhibitor (BZ3 and vanadate, 
respectively). Data for TbPTP1 was obtained from competition assays performed during the 
course of this project, whereas PTP1B data is reported from personal communication with 
Rachel Clark (DDP inhibitors) or from published work for oleanolic acid (Zhang et al., 2008), 
suramin (McCain et al., 2004), and vanadate (Huyer et al., 1997). See Appendix C for the 
corresponding TbPTP1 graphs. 
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5.4. Activity on stumpy form cells of the PTP1B inhibitors 
 
 After the in vitro characterisation of the different PTP1B inhibitors, it was 
important to test the compounds in vivo, on stumpy form cells. The 
specificity of the compounds for TbPTP1 was assessed by determining 
whether they induced differentiation of stumpy to procyclic forms, the 
phenotype that has been observed in TbPTP1 RNAi lines and in cells treated 
with BZ3 (Szoor et al., 2006). The eight most potent DDP inhibitors, together 
with inhibitor 4 as negative control, were tested at 150 µM and 300 µM, 
concentrations that have been shown to be effective for BZ3 (Szoor et al., 
2006). Stumpy form cells were treated with the various inhibitors or with 
DMSO alone, in HMI-9 at 27° C for 4 hr; this time point was chosen because 
it had been reported to be the earliest time point at which EP protein 
expression, a marker of procyclic form cells, is detectable in about 90% of the 
cells after cis-aconitate or BZ3 treatment (Szoor et al., 2006). It was important 
to minimize the incubation length, since some of the inhibitors altered the 
pH of the media, which could have affected their overall viability. Together 
with the DDP inhibitors, oleanolic acid and suramin were also tested, but at 
lower concentrations, as they had shown to be trypanocidal (Fairlamb et al., 
1977; Salem et al., 2006).  
The results are shown in Figure 5.4, where it is visible that none of the 
compounds caused EP protein expression, as detected by FACS stain of the 
cells. Inhibitor 2 showed some positivity to EP staining, but that was only an 
artifact probably due the intrinsic fluorescence of the compound, as judged 
by immune-fluorescence analysis of the same samples. The positive control, 
cis-aconitate and the inhibitor BZ3, did however, induce efficient procyclin 
expression (Figure 5.4).   
Unexpectedly, the DDP inhibitor 12 was found to have trypanocidal activity 
when tested on stumpy form cells at 150 µM and 300 µM, and thus its LD50, 
the dose resulting to be lethal for 50% of the population (Albrecht et al., 
1996), was calculated in order to quantify its potency. For this aim, the 
Alamar Blue assay was employed, which is based on the reduction of the 
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redox indicator in the media upon cell growth. Due to its simplicity and 
reproducibility, this method has been extensively used for anti-protozoan 
drug discovery (Raz et al., 1997; de Oliveira-Silva et al., 2008). As shown in 
Figure 5.5 A, DDP inhibitor 12 generated a LD50 of approximately 40 µM 
(with 95% CI between 11 and 74 µM) or 9.4 x106 ng/ml; this value was 
determined on bloodstream  S16 T. brucei brucei, by plotting the decrease in 
the reduction of Alamar Blue, due to inhibition of cell growth, over 
different concentrations of inhibitor (Figure 5.5 A). Suramin was also 
included, as positive control, which showed a LD50 of 20 nM (3380 ng/ml) 
(Figure 5.5 B), in agreement with data obtained using the same cell type and 
assay (Ishiyama et al., 2008).  
Unlike to DDP inhibitor 12, the other DDP inhibitors did not cause cell death 
when tested for differentiation at 150 and 300 µM on stumpy forms and thus 
were not subjected to cell viability assays. Indeed it was considered unlikely 
that compounds ineffective against stumpy forms at milimolar 
concentrations would display significant trypanocidal activity on slender 
form cells.    




















Figure 5.5 Trypanocidal activity of DDP inhibitor 12 and suramin. DDP inhibitor 12 and 
suramin were tested on bloodstream form S16 cells and their effect on cell viability was 
quantified as LD50 using the Alamar Blue assay and found to be 40 and 0.02 µM, 
respectively (A and B); the percentage of Alamar Blue reduction of treated versus 
untreated cells is shown on the y-axis and the logarithmic of concentration in µM is shown on 
the x-axis.  
A 
B 





TbPTP1 is an unusual drug target candidate, since it does not meet the 
classical requirements of being essential for parasite survival and of lacking 
closely related mammalian homologues (Aguero et al., 2008). Nevertheless, 
the peculiar and unique function of TbPTP1 in regulating the transition from 
bloodstream form to insect form parasite represents an opportunity to 
control African trypanosomiasis transmission. So far, research targeting 
sleeping sickness transmission has not been considered a priority, since other 
strategies, such as vector control or animal reservoir treatment, are already in 
use (Welburn et al., 2001), and safer drugs to cure the disease are still under- 
developed (Barrett et al., 2007). Nevertheless, in a scenario where African 
trypanosomiasis incidence has been reduced and the focus is on its 
elimination, the use of a drug targeting disease transmission would be 
beneficial. HAT elimination has already been considered a reasonable aim in 
countries reporting less than 100 cases per year (Welburn et al., 2009); in these 
countries, the removal of the vector altogether has been chosen as the main 
solution for disease elimination. However, tsetse re-invasion remains 
possible making this strategy questionable (Hargrove, 2003). In addition, 
tsetse control has been successful only where transmission sites are localized, 
such as in the savanna and along forest galleries, whereas vector control has 
proven to be more difficult in forest habitats where Glossina spp. are more 
dispersed (Fevre et al., 2006b).  
For the above reasons it is clear that, in order to avoid African 
trypanosomiasis re-occurence, additional strategies to vector controls are 
going to be needed. Treatment of the animal reservoir is a possible strategy, 
but useful only for Rhodesian sleeping sickness and not for the Gambiense 
form (Welburn et al., 2001), which represents the majority of the cases (WHO, 
2006a). For this form of the disease, active case finding and treatment is 
nowadays the only control measure, but the remoteness of the rural areas 
and the weakness of the local health system make this approach 
unsustainable. Moreover, Gambiense HAT is characterized by a chronic 
infection, often with the first signs and symptoms appearing after years 
(WHO, 1998), thus rendering its control even more challenging.  Therefore, 
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in areas with low sleeping sickness incidence, the possibility of treating the 
human host with a safe oral drug reducing the number of transmissible 
forms of the parasite would provide a novel and valuable approach to 
minimize the risk of diseases re-occurence, particularly for the Gambiense 
form. In the context of Rhodesian HAT, such a drug could also be employed 
for the treatment of the animal reservoir, in combination with curative 
trypanocides. 
 
The apparently undesired similarity of TbPTP1 with the human PTP1B 
could, on the other hand, be exploited to use inhibitors developed for the 
human enzyme. The interest of pharmaceutical companies for PTP1B and the 
possible future release to the market of an oral drug treating diabetes and 
obesity, could provide a way to overcome the financial limitations of drug 
discovery for sleeping sickness. HAT has already witnessed a similar 
situation with eflornithine, a drug initially developed as an anti-cancer agent, 
then commercialized mainly as a hair growth inhibitor cream and discovered 
to be effective against trypanosomes (TDRnews, 2001). Currently eflornithine 
is in use, in combination with Nifurtimox, for the treatment of phase II 
Gambiense HAT (Priotto et al., 2006; Priotto et al., 2009) and represents the 
only new drug registered in the last 50 years.  The potential impact of a drug 
controlling African trypanosomiasis transmission, together with the 
possibility of exploiting pharmaceutical pre-clinical and clinical studies 
carried out for PTP1B inhibitors, prompted us to test some of such inhibitors 
against TbPTP1.  
 
5.5.1. Inhibitory activities of the compounds on TbPTP1 and PTP1B 
The PTP1B inhibitors were obtained from the Drug Discovery Portal (DDP) 
of the University of Strathclyde in Glasgow, and were identified as inhibitors 
of human PTP1B. In addition to these seventeen compounds, two published 
PTP1B inhibitors were also included: oleanolic acid (Zhang et al., 2008) and 
suramin (McCain et al., 2004). As mentioned at the beginning of this chapter, 
it was interesting to test oleanolic acid because it is a natural compound, 
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commercially available and safe; similarly suramin represented an attractive 
candidate, being a drug used for treatment of first stage HAT. The initial 
screening was conducted in vitro, on recombinant TbPTP1, in order to assess 
the degree of activity of the compounds. For ten out of the seventeen DDP 
inhibitors an accurate IC50 value was calculated (Table 5.1 and Appendix A), 
whereas for the remaining seven a dose-response curve was not confidently 
extrapolated from the data, likely due to low inhibitory activity and 
sometimes precipitation of the compound in the buffer used. Four of the 
DDP inhibitors (inhibitors 2, 5, 7 and 12) were found to have a calculated IC50 
or Ki between 50 and 100 µM (or between approximately 20 and 300 µM, if 
the 95% confidence intervals are considered) (Figure 5.2); three DDP 
inhibitors (inhibitors 11, 15 and 17) showed IC50 values between 100 and 200 
µM and three (inhibitors 1, 6 and 13) between 200 and 350 µM. Oleanolic acid 
displayed a moderate inhibitory activity (IC50 of 111 µM) and suramin was 
found to be the most powerful of the compounds screened (IC50 of 7 µM) 
(Table 5.1 and Appendidx A).  
 
A comparative analysis of the same inhibitors tested against TbPTP1 and 
PTP1B showed that most of them had a similar activity towards the two 
enzymes (Table 5.1 and Appendix B). Indeed, despite the fact that calculated 
IC50 and Ki values seemed to indicate differences in inhibitory activities, the 
confidence intervals of the constants need to be taken into account, which 
vary from compound to compound. Therefore, even if a cut-off of 0.9 was 
used for the coefficient of determination (R2), which quantifies the goodness 
of fit of the data, in order to confidently extrapolate the IC50 and Ki values, 
these values need to be compared with caution. Larger confidence intervals 
were usually found for the assays performed against TbPTP1 compared to 
assays against PTP1B, maybe indicating a less ideal combination of 
buffer/substrate/enzyme.  
Among the compounds tested, the DDP inhibitor 6 was the only one to show 
a significantly different IC50, being more powerful against PTP1B than 
against the parasite phosphatase, with calculated IC50 values of 39 µM and 
1786 µM, respectively (Table 5.1). However, the wide 95% confidence 
interval of the IC50 value for TbPTP1 and the fact that its corresponding Ki 
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value was not confidently extrapolated from the data, suggested that the fit 
of DDP inhibitor 6 was probably not very sensible, although the reason for 
this was not clear.    
 
 
5.5.2. Type of inhibition of the compounds against TbPTP1 and PTP1B 
 
A large variety of compounds have been identified as PTP inhibitors, most of 
which are nonhydrolyzable phospho-tyrosine mimics. By targeting the PTP 
active site, this type of compounds are usually potent inhibitors but often 
show limited selectivity and poor cell permeability (Vintonyak et al., 2009). 
Examples of competitive PTP1B compounds are oleanolic acid (Zhang et al., 
2008), suramin (McCain et al., 2004) and vanadate (Huyer et al., 1997). 
Suramin and vanadate were found to retain the same type of inhibition for 
TbPTP1, whereas oleanolic acid showed to bind the catalytic site of the 
human enzyme, but not of the parasite one (Table 5.2).  Moreover, one of the 
DDP inhibitors tested, inhibitor 7, showed to be competitive for TbPTP1 but 
not for PTP1B. These observations suggest the presence of potential 
structural differences between the two proteins. This difference must be 
found in the regions located in the vicinity of the catalytic site, since the 
catalytic residues are perfectly conserved (see paragraph 1.17). 
 
In addition to phospho-tyrosine mimics, allosteric PTP1B inhibitors have also 
been developed. The best characterised example of this type of PTP1B 
inhibitors is BZ3, which was shown to bind to a second site on the enzyme, 
far from the catalytic pocket (Wiesmann et al., 2004). Since this second site is 
much less conserved than the catalytic one, compounds targeting this region 
are likely to show increased selectivity for PTP1B over other PTPs. Therefore 
the development of allosteric PTP1B inhibitors has been considered one of 
the most promising strategies for the identification of lead compounds 
(Vintonyak et al., 2009). In agreement with the published data, BZ3 was 
found to be an allosteric (“mixed type” of inhibition) inhibitor of TbPTP1. 
Similarly all the DDP inhibitors tested, except inhibitor 7, (inhibitor 5, 11, 12, 
13, 15 and 17) were found to be non-competitive, i.e. to bind to a site different 
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from the catalytic site of the enzyme, which was true also for PTP1B (Rachel 
Clark, personal communication) (Figure 5.2 and Appendix C).  
 
 
5.5.3. In vivo activity of the compounds  
 
The eight most potent TbPTP1 DDP inhibitors were then tested in vivo on 
stumpy form cells but did not specifically inhibit the phosphatase, as judged 
by lack of expression of the procyclic surface protein EP (Figure 5.4). The 
possibility that the compounds did not permeate the trypanosome’s 
membrane is unlikely, since DDP inhibitor 12, which belongs to a similar 
chemical family (Figure 5.6), was found to have a lethal effect on the cell 
(Figure 5.5 A). In addition, it is improbable that the concentrations used (150 
and 300 µM) were insufficient to inhibit TbPTP1 in vivo, as BZ3, which 
displayed an in vitro inhibitory activity comparable to DDP inhibitors 2, 5 
and 7, showed a specific effect at concentrations between 50 and 150 µM 
(Szoor et al., 2006). Similarly, oleanolic acid and suramin did not induce 
stumpy to procyclic form transition (Figure 5.4).  
The most likely explanation for the lack of activity of the inhibitors tested is a 
limited in vivo specificity for TbPTP1, which was less surprising for oleanolic 
acid and suramin. Indeed, oleanolic acid has been reported to affect a wide 
variety of physiological functions (Liu, 1995), and suramin  has shown to 
bind different enzymes probably because of its six negative charges 
(Fairlamb et al., 1977; Wierenga et al., 1987; Barrett et al., 2007).  
 
During the course of the screening for TbPTP1 inhibitors, one of the DDP 
compounds tested showed an unexpected lethal activity against S16 
bloodstream form Trypanosoma brucei brucei. The calculated LD50 for DDP 
inhibitor 12 was found to be 9.4 ng/ml or 40 µM (11-74 µM, 95% confidence 
interval) (Figure 5.5 A), which is higher than the 0.2 µg/ml or 10 µM 
threshold set by the current drug discovery programme for HAT 
(www.dndi.org; Nwaka et al., 2006). However, the activity of the compound 
should also be tested on T. brucei rhodesiense and gambiense, as some drugs 
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can show a certain degree of species-specific variability (Raz et al., 1997). In 
addition, its cytotoxicity on mammalian cells has should also be assessed. 
 
5.5.4. Analysis of the structure/activity relationship of the compounds  
 
The screening of compounds for drug discovery is a complex process that 
includes several phases. Initially, a hit or a set of hits, which are molecules 
with adequate activity towards the chosen target, need to be identified and 
then refined, in order to find a smaller subset of compounds with improved 
activity and selectivity. This phase involves the analysis of structure/activity 
relationship, which is the correlation of structural features or groups with the 
biological activity of the compounds. These lead compounds will then be 
subjected to further optimization, aiming at the generation of a clinical 
candidate, possessing the required pharmacological properties (Bleicher et 
al., 2003).  
The screening of the PTP1B inhibitors reported here represents only the very 
initial phase of drug discovery, which would aim at the identification of a set 
of hits acting against TbPTP1. However, the generation and refinement of the 
hits usually requires the screening of thousands of compounds, whereas a 
much more limited number of molecules were tested during the course of 
this study. Consequently, the analysis of structure/activity relationship of 
these inhibitors is very difficult with the current set of data. In addition, a 
better understanding of the chemical structures and their reactivity would be 
required to properly interpret the results. Furthermore, the wide 95% 
confidence intervals obtained for the IC50 and Ki values of some of the 
compounds renders their comparison not particularly useful.   
At the moment, only a few general observations on the data can be made. For 
example, it is interesting to note that DDP inhibitors with similar structure 
(as indicated by their DDP identification number), such as inhibitor 12 and 13 
(DDP_1113_03578 and DDP_1113_04818) (Figure 5.6 A and C) were found to 
display different inhibitory activities (IC50 of 66 µM and 330 µM, 
respectively). In addition, compounds showing IC50 or Ki values between 50 
and 100 µM seemed to have a more “compact” structure, possessing two 
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aromatic rings, compared to three in the second group of inhibitors (with IC50 
or Ki values between 100 and 200 µM) (Figure 5.6 A and B). However, some 
compounds of the third group (IC50 or Ki values between 200 and 300 µM) 
also showed two aromatic rings (Figure 5.6 C). Moreover, it is interesting the 
fact that the three DDP inhibitors (DDP inhibitor 8, 9 and 10) that lacked 
activity against TbPTP1, possessed a similar formula, thus suggesting that 
their structure might not be particularly active against TbPTP1, and that 
similar compounds could be excluded from future drug screenings (Figure 






























Figure 5.6 Chemical formulae of the different inhibitors tested on TbPTP1. (A) 
Chemical formulae of the inhibitors that showed an IC50 or Ki values between 50 and 100 
µM, together with the corresponding DDP ID and calculated IC50; suramin and vanadate are 
grouped together since they are both competitive inhibitors, whereas all the other 
compounds were non-competitive inhibitors, with the exception of DDP inhibitor 7, which was 
found to be competitive as well. (B) Chemical formulae of the inhibitors that showed an IC50 
or Ki values between 100 and 200 µM. (C) Chemical formulae of the inhibitors that showed 
an IC50 or Ki values between 200 and 350 µM. (D) Chemical formulae of the inhibitors that 
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5.5.5. Future directions 
 
In future drug screenings, more compounds will need to be tested in order to 
better analyze their structure/activity relationship. In addition, future 
studies should focus more on the identification of candidates with in vivo 
specificity, for example through larger scale analysis that could provide an 
insight into the chemical requirements for achieving such specificity. The 
comparison of the structure of BZ3 with the ones of the DDP inhibitors 
would be the first step to understand their different activity and to select 
new compounds with potentially better specificity. For example, it would be 
interesting to “virtually” screen compound libraries using the ligand-based 
design (Jacob et al., 2008), which would exploit the knowledge available from 
the numerous studies done on PTP1B inhibitors (Zhang et al., 2007). 
Moreover, since the TbPTP1 structure has been recently characterized (Chou 
et al., 2010), it is now possible to find more specific inhibitors in silico, 
through the method of Structure Based Design (Cavalli et al., 2009).  
It would also be important to test PTP1B inhibitors further down the drug 
development line, in order to maximize the benefits of the “piggy-back” 
approach. Unfortunately pharmaceutical companies are often unwilling to 
share their lead compounds for financial reasons or, when they are, 
bureaucratic procedure can be long and exhaustive. Indeed during this 
project a small American pharmaceutical company was contacted, which 
possessed the PTP1B inhibitor trodusquemine (MSI-1436) (Takahashi et al., 
2004) in phase I clinical trial, and a material transfer agreement was initiated 
but with no outcome for almost two years. The compound in question was 
particularly attractive as it was found to be effective in vitro against PTP1B 
and in an in vivo animal model of obesity (Zasloff et al., 2001; Ahima et al., 
2002).  
 
The identification of a hit or set of hits with a good inhibitory activity is not 
the only requirement to further develop the compounds. Indeed successful 
inhibitors require the detailed characterization of their mode of action, 
particularly the identification of their binding site on the enzyme. 
Competitive inhibitors target the active site of the enzyme, but allosteric 
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inhibitors (non-competitive or mixed inhibitors), like most of the DDP 
compounds tested, can bind anywhere on the protein. Therefore, it would be 
essential to find out where the best DDP inhibitors, or other good inhibitors 
that will potentially be identified, bind on TbPTP1. In order to do so, one 
possible approach would consist in the use of competition assays with other 
inhibitors, for which the binding site is known. For example the compound 
OBA5, whose interaction with PTP1B is stabilized by the closure of the WPD 
loop, only has been used to identify whether a certain PTP1B inhibitor 
prevents the closure of this loop (Wiesmann et al., 2004). A complementary 
approach has been the use of mass spectrometry to monitor the 
dephosphorylation reaction, so that the stage at which the inhibitor binds to 
the enzyme can be identified (Wiesmann et al., 2004). Probably the most 
accurate method to determine the binding site of a non-competitive 
compound would be the resolution of the crystallographic structure of the 
compound bound to the enzyme.  
 
Drug discovery is a notoriously difficult process that requires long-term 
commitment and huge resources, and thus, is mainly carried out by big 
pharmaceutical companies. Nonetheless, the initial proof-of-principle often 
comes from research carried out in Universities. Consequently small projects 
investigating new therapeutic or preventive strategies, such as the one 
described in this chapter, represent essential first steps and important 
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6.1. General overview 
 
Protein Tyrosine Phosphatase 1 (TbPTP1) is the one of the few factors 
identified to be responsible for differentiation from stumpy to procyclic form 
parasite (Szoor et al., 2006), acting through the novel substrate TbPIP39 
(Szoor et al., 2010). However, the stimulus and the mechanism responsible for 
the physiological inhibition of TbPTP1 upon initiation of differentiation are 
not known and only two TbPTP1 substrates have been identified (Chou et al., 
2010; Szoor et al., 2010). Moreover, the unique function of TbPTP1 in 
regulating transition from the stumpy form to the insect form parasite, could 
be targeted as a means to decrease disease transmission. 
 
6.2. TbPTP1 substrate identification 
 
In order to identify novel TbPTP1 substrates, the potential use of a substrate 
consensus sequence was investigated, as this approach has been successfully 
used for human PTP1B (Myers et al., 2001). For this aim, it was first 
important to compare the 3-D structure of the two phosphatases. Since the 
TbPTP1 crystal structure was not known during the course of this project, the 
phosphatase 3-D structure had to be predicted in silico. The homology 
modeling of the 3-D structure of TbPTP1 revealed the presence of a 
conserved catalytic structure with human PTP1B, in agreement with its 
published crystallographic structure (Chou et al., 2010). In addition, the 
bioinformatics model correctly predicted the position of the four 
trypanosome-specific motifs, which are mainly found on the surface of the 
enzyme and thus might be involved in substrate recognition and regulation. 
 
A review of the literature analysing the potential presence of a substrate 
consensus sequence for PTP1B highlighted the existence of a clear consensus 
mainly for the tandem phosphorylated substrates, which have not been 
detected in T. brucei (Nett et al., 2009b). Moreover the residue responsible for 
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the formation of the second phosphate binding site in PTP1B (Arg254) (Puius 
YA et al., 1997) is not conserved in TbPTP1 (Lys267), suggesting that the 
parasite phosphatase might not prefer substrates containing tandem pTyr 
over mono pTyr. The data currently available for the mono pTyr consensus 
sequence of PTP1B does not allow the use any bioinformatics criteria to 
identify proteins that would be more likely substrates of TbPTP1.  However, 
the presence of a leucine residue in TbPTP1 (Leu52) instead of an arginine 
residue in the corresponding position of PTP1B (Arg47), might suggest a 
possible preference for aliphatic/aromatic residues N-terminal to the 
phosphorylated tyrosine of the substrates of the parasite enzyme. This 
hypothesis is in contrast with the one supported by Chou et al., which 
proposed the preference for negatively charged residues in the vicinity of the 
phosphorylated tyrosine, as suggested by the presence of a nearly 
uninterrupted acidic sequence in the TbPTP1 procyclic stage substrate 
Nopp44-46. Similarly, acidic residues are also found in the stumpy stage 
TbPTP1 substrate TbPIP39. Nonetheless, only the identification of additional 
substrates will reveal which hypothesis was right and might lead to the 
delineation of a substrate consensus sequence for TbPTP1. 
 
In order to identify novel TbPTP1 substrates the substrate trapping approach 
was used in selections of stumpy form cell extracts. In agreement with the 
data for human PTP1B, the D→A mutant was a better substrate trapping 
enzyme than the wild type TbPTP1. Similarly, the D→A/Q→A double 
mutant was also able to bind to more substrates then wild type enzyme, 
although less than the D→A mutant. Moreover the C→S/D→A mutant 
TbPTP1 was shown  not to trap tyrosine phosphorylated proteins, as seen for 
PTP1B. However, this double mutant enzyme did bind to TbPIP39, with 
similar efficiency as the D→A and D→A/Q→A mutants TbPTP1. Overall the 
mutants TbPTP1 showed similar substrate trapping ability as the PTP1B 
mutants, particularly when tyrosine phosphorylated proteins were 
visualized by Western blot. The main exception was the D→A/Q→A mutant 
TbPTP1 that did not seem to display the 6-fold increase binding efficiency 
reported for the human enzyme (Laiping X et al., 2001). 
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Consequently, the D→A TbPTP1 mutant (D199A) was used in larger scale 
stumpy cell extract selections, both to validate the phosphatase interaction 
with its first identified substrate, TbPIP39, and to identify novel substrates. 
Confirming the mass spectrometry analysis performed before the start of this 
project, TbPIP39 was found to bind the substrate trapping mutants TbPTP1, 
as well as to the wild type protein, under certain experimental conditions.  
Two new mass spectrometry analyses of stumpy cell extract selections were 
performed, and the data obtained was examined, together with the results of 
previous experiments. Two hits were considered the most interesting, 
Tb10.389.0310 and Tb11.02.2090, and thus were chosen for further studies. 
Although Tb10.389.0310 downregulation by RNAi did not succeed, changes 
in its transcript level did not affect cell growth or differentiation capacity, 
thus excluding the protein from playing a role in parasite differentiation. 
On the contrary Tb11.02.2090 mRNA downregulation, to almost half the wild 
type level, caused a marked growth defect in bloodstream form cells, and the 
accumulation of cells in the 2K2N cell cycle stage. Moreover, the same cells 
treated with cis-aconitate showed increased differentiation levels compared 
to uninduced cells (from 4.7 % to 12.6 %). These preliminary results 
suggested that Tb11.02.2090 might act as a negative regulator of 
differentiation, likely by affecting the parasite cell cycle.  Further experiments 
will be needed to validate Tb11.02.2090 RNAi phenotype and its interaction 
of with TbPTP1. 
 
6.3. Dissection of TbPTP1 signalling pathway during differentiation from 
stumpy to procyclic forms 
 
Higher eukaryotic PTPs, particularly human PTP1B, have been shown to be 
regulated in a variety of ways, from post-transcriptionally to post-
translationally (den Hertog et al., 2008). In contrast, it is not known how the 
activity T. brucei PTPs, and particularly TbPTP1, is controlled.  
In order to understand the mechanism by which TbPTP1 is physiologically 
inactivated during differentiation from stumpy to procyclic forms, the 
mechanisms of regulation of the human homolog, PTP1B, were examined. 
This comparative analysis highlighted a few potential interesting differences, 
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as the parasite enzyme appeared to lack several levels of regulation reported 
for human PTP1B. Indeed, in contrast to PTP1B, TbPTP1 activity during 
differentiation is unlikely to be controlled post-transcriptionally, since no 
changes in the size of the transcript and in the protein quantity have been 
detected in the different life cycle stages (Szoor et al., 2006). Similarly, 
differential targeting has also been excluded, as the phosphatase showed the 
same cellular fractionation profiles in stumpy and procyclic forms 
(McElhinney, 2007).  
In addition, TbPTP1 regulation through oxidation could be excluded, as no 
increase in intracellular ROS was detected upon treatment of stumpy form 
cells with the differentiation triggers citrate or cis-aconitate, as shown by the 
experiments included in chapter 3. Moreover, the differentiation capacity of 
the parasites did not appear to be influenced by addition of exogenous H2O2 
or by neutralization of endogenous H2O2.  
Likewise, no evidence for TbPTP1 tyrosine phosphorylation during 
differentiation was found, despite the presence of two conserved tyrosine 
residues (Tyr78 and Tyr164 of TbPTP1). However, the existence of a 
potentially transient tyrosine phosphorylation could still be a possibility. 
Furthermore, Ser/Thr phosphorylation of the in silico predicted 
phosphorylation sites of TbPTP1 (Ser42 and Thr238) has not been tested, 
although none of them is conserved in PTP1B, and Thr238 is substituted by a 
serine residue that was not shown to be phosphorylated in the human 
phosphatase.  
Other potential mechanisms of TbPTP1 regulation, like proteolysis and 
sumoylation, have not been tested, since the tools required for these 
analyses, such as protease and SUMO inhibitors, have not been fully 
characterized in T. brucei.  
TbPTP1 regulation might also, and maybe solely, be achieved via its 
interaction with substrates, adaptor proteins, or other molecules, like the 
changes in the in vitro activity of the TbPTP1-TbPIP39 complex in the 
presence of CCA have suggested (Szoor et al., 2010).  
Overall TbPTP1 was shown to lack most of the regulatory mechanisms found 
in higher eukaryotic PTPs, suggesting that, despite a conserved catalytic 
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structure, the parasite enzyme possesses different ways to control its activity 
compared to its human homolog.  
 
In order to characterize the stimuli responsible for TbPTP1 inhibition during 
differentiation, TbPIP39 phosphorylation was monitored in stumpy form 
cells treated with different differentiation triggers. Citrate and cis-aconitate 
resulted in an increase in TbPIP39 phosphorylation, whereas mild acid 
treatment and, particularly, pronase did not.  This difference suggested the 
presence of two separate, but potentially complementary, pathways 
responsible for T. brucei differentiation to procyclic forms, in agreement with 
other published data (Hunt et al., 1994; Sbicego et al., 1999).  
Therefore, despite the presence of a small repertoire of structurally simple 
protein tyrosine phosphatases, T. brucei appears to possess different 
signalling pathways involved in the parasite development from stumpy to 
procyclic forms.  
Future studies will need to confirm these observations, for example by 
monitoring TbPIP39 activity or function, once they have been characterized, 
rather than merely its phosphorylation. In addition, it would be important to 
analyse in more detail the role of CCA, pronase and the other differentiation 
triggers in vivo, in order to better understand the physiological relevance of 
the TbPTP1 signalling.   
 
6.4. Investigation of TbPTP1 as therapeutic target for the control of 
disease transmission 
 
The peculiar and unique function of TbPTP1 in regulating the transition from 
bloodstream to insect form parasites, represents an opportunity to limit 
disease transmission, as an alternative to vector control. Moreover, the 
interest that pharmaceutical companies are showing in developing human 
PTP1B inhibitors could be used to identify compounds active against 
TbPTP1. This strategy could result in a less risky, cheaper and faster 
development of a drug, which is particularly valuable for the control of a 
neglected tropical disease, like sleeping sickness, since these diseases do not 
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represent a lucrative market for pharmaceutical companies (Trouiller et al., 
2001).  
 
The preliminary screening of nineteen PTP1B inhibitors showed that most of 
them retained their inhibitory activity and type of inhibition for TbPTP1. 
However, none of the compounds tested displayed in vivo specificity for the 
phosphatase, when tested on stumpy form cells. Supporting the hypothesis 
of the lack of in vivo specificity towards TbPTP1, was also the observation 
that one of these compounds caused death of bloodstream form parasites, 
which is not the phenotype expected from TbPTP1 inhibition. Therefore, 
future studies will need to focus more on the identification of the chemical 
requirements to achieve this specificity. Moreover, larger scale screenings 
will be needed in order to better analyse the structure/activity relationships 
of different classes of compounds. Nonetheless, the results reported in 
chapter 4 validated the use of a “piggy back” strategy targeting TbPTP1, as 
most PTP1B inhibitors showed the same inhibitory activity and mode of 



























































    
 
 




            
                                            




                   
                    
 



























































































































































TbPTP1 dose-response curves for the different PTP1B inhibitors. The dose-response 
curve of ten DDP inhibitors (In. 1, 2, 5, 6, 7, 11, 12, 13, 15 and 17), together with BZ3, 
oleanolic acid, suramin and vanadate are shown; the relative IC50 and Ki are shown next to 










































































































PTP1B dose-response curves for the different DDP inhibitors. The dose-response 
curves of nine DDP inhibitors (In.1, 2, 5, 6, 7, 12, 13, 15 and 17) are shown, with the relative 
IC50 and Ki values listed next to each graph. Graphs and calculations were performed using 






















































































































































TbPTP1 competition assays with the different PTP1B inhibitors. The Michealis and 
Menten curves for the seven DDP inhibitors tested (In.5, 7, 11, 12, 13, 15 and 17), together 
with oleanolic acid, BZ3, vanadate and suramin are shown; the concentration of inhibitor 
used is shown in the right-hand side panel of each graph (control= TbPTP1 alone). The gra












































Cell culture solutions: 
 
PSG  
3 mM NaH2PO4-2H2O,  
43.6 mM NaCl, 
 57 mM Na2HPO4  
 83 mM D-glucose, pH 7.8 
 
Freezing mix 
SDM-79 or HMI-9 
14 % glycerol 
 
DNA manipulation solutions: 
 
TE 
10 mM Tris-HCl pH 8.0, 
 1 mM EDTA 
TAE  
0.4 mM Tris-HCl,  
0.1 mM EDTA, pH 7.7 
 
Mini-scale DNA preparation: 
 
Solution I   
50 mM glucose,  
25 mM Tris-HCl pH 8.0  
10 mM EDTA  
 
 
Solution II  




3 M KAc 
40% of Glacial Acetic acid 
 
 







Large-scale DNA preparation: 
 
Solution P1 
50 mM Tris-HCl, pH 8.0,  
10 mM EDTA 
100 µg/ml RNase A 
 
Solution P2  
200 mM NaOH  
 1% SDS 
 
Solution P3  
3 M KAc, pH 5.5 
 
Solution QC 
1 M NaCl, 




1.25 M NaCl, 




Northern blot solutions: 
 
10X MOPS  
40 mM 4-morpholinepropanesulfonic acid, 
10 mM sodium acetate, pH 7.0  
1 mM EDTA 
 
RNA loading buffer 
 
6 % formaldehyde, 
30 % formamide, 
1x MOPS, 
10% glycerol  




1.5 M NaCl,  









5x SSC,  
50% formamide,  
0.02% SDS  
2% blocking solution 
 
Wash buffer 
100 mM maleic acid, 
150 mM NaCl, pH 7.4  
0.3 % Tween 20 
 
Maleic acid buffer  
100 mM maleic acid, 
150 mM NaCl, pH 7.4 
 
Detection buffer 
100 mM Tris-HCl pH 9.5 
100 mM NaCl. 
 
 
Western blot solutions: 
 
TBS 
140 mM NaCl 
10 mM Tris-HCl, pH 7.4 
 
PBS 
137 mM NaCl, 
3 mM KCl,  
16 mM Na2HPO4,  




62.5 mM Tris-HCl, pH6.8, 
 2% SDS,  
10% glycerol 
traces of bromophenol blue 
 
 
Running gel buffer 
 




Stacking gel buffer 
0.5 M Tris-HCl pH 6.8,  
0.4% SDS 
 





25 mM Tris-HCl, pH 8.3,  





Wet blotting buffer 
 
2.5 mM Tris,  
192 mM Glycine  
20% methanol 
 
Semi-dry blotting buffer 
 
2.5 mM Tris, 
15 mM Glycine,  





0.4 % of Ponceau S  











10 mM Tirs-HCl, pH 8.0,  
0.05 mM EDTA   
150 mM NaCl 
 
 
Recombinant protein buffers: 
 
His lysis buffer  
20 mM Tris-HCl, pH 7.5-8.0, 
250 mM NaCl,  
1% Trition X-100,  
1 mM β mercapthoethanol   




Appendix  D 
 
237 
Wash 1  
20 mM Tris-HCl, pH 8.0,  
250 mM NaCl  
5 mM imidazole 
 
Wash 2 
20 mM Tris-HCl, pH 8.0,  
250 mM NaCl  
20 mM imidazole 
 
Elution 1 
20 mM Tris-HCl, pH 8.0, 
250 mM NaCl  
250 mM imidazole 
 
Elution 2  
20 mM Tris-HCl, pH 8.0,  
250 mM NaCl,  
500 mM imidazole 
1mM β mercapthoethanol 
 
 
TbPTP1 pNPP activity buffer 
 
50 mM Tris,  
50 mM Bis-Tris  
100 mM NaAc, pH 5.5 
 
 
PTP1B buffer  
 
25 mM Hepes pH 7.2,  
50 mM NaCl,  
2.5 mM EDTA 
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A novel phosphatase cascade regulates
differentiation in Trypanosoma brucei
via a glycosomal signaling pathway
Balázs Szö}or,1,4 Irene Ruberto,1 Richard Burchmore,2 and Keith R. Matthews1,3
1Centre for Immunity, Infection, and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences,
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In the mammalian bloodstream, the sleeping sickness parasite Trypanosoma brucei is held poised for trans-
mission by the activity of a tyrosine phosphatase, TbPTP1. This prevents differentiation of the transmissible
‘‘stumpy forms’’ until entry into the tsetse fly, whereupon TbPTP1 is inactivated and major changes in parasite
physiology are initiated to allow colonization of the arthropod vector. Using a substrate-trapping approach, we
identified the downstream step in this developmental signaling pathway as a DxDxT phosphatase, TbPIP39,
which is activated upon tyrosine phosphorylation, and hence is negatively regulated by TbPTP1. In vitro, TbPIP39
promotes the activity of TbPTP1, thereby reinforcing its own repression, this being alleviated by the trypanosome
differentiation triggers citrate and cis-aconitate, generating a potentially bistable regulatory switch. Supporting
a role in signal transduction, TbPIP39 becomes rapidly tyrosine-phosphorylated during differentiation, and RNAi-
mediated transcript ablation in stumpy forms inhibits parasite development. Interestingly, TbPIP39 localizes in
glycosomes, peroxisome-like organelles that compartmentalize the trypanosome glycolytic reactions among other
enzymatic activities. Our results invoke a phosphatase signaling cascade in which the developmental signal is
trafficked to a unique metabolic organelle in the parasite: the glycosome. This is the first characterized
environmental signaling pathway targeted directly to a peroxisome-like organelle in any eukaryotic cell.
[Keywords: Glycosome; peroxisome; signal transduction; phosphatase; Trypanosoma brucei; differentiation]
Supplemental material is available at http://www.genesdev.org.
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Developmental events in eukaryotic cells are often driven
by a transmembrane signaling event, this being trans-
duced via phosphorylation/dephosphorylation of signal-
ing proteins to generate a cellular response. Such signaling
events are particularly important in unicellular eukary-
otes, which are required to react to external stimuli, either
as part of an adaptive response to a changing environment,
or through triggered developmental responses intrinsic to
their normal life cycle progression. An excellent model for
such developmentally regulated responses is the African
trypanosome,Trypanosoma brucei (Fenn and Matthews
2007). These are important disease organisms of sub-
Saharan Africa, where they generate significant problems
for public health and economic welfare (Barrett et al.
2003). Furthermore, as highly diverged and evolutionarily
ancient organisms (Sogin et al. 1986), they have provided
an important paradigm for organelle evolution and func-
tion in the eukaryotic cell (Hannaert et al. 2003; He et al.
2004, 2005; Broadhead et al. 2006; He 2007), exemplified
by their use of extensive RNA editing for mitochon-
drial transcripts (Stuart et al. 2005), and by their posses-
sion of unusual peroxisome-like organelles, glycosomes
(Opperdoes 1987). These compartmentalize the trypano-
some glycolytic enzymes, which in other eukaryotes are
cytosolic, thereby avoiding the lethal consequences of the
‘‘turbo design’’ of glycolysis (Teusink et al. 1998; Bakker
et al. 2000). Glycosomes also contain enzymes required
for ether lipid biosynthesis, the b oxidation of fatty acids,
as well as several additional activities (Michels et al.
2006; Opperdoes and Szikora 2006), although their pre-
cise enzymatic composition and number is regulated dur-
ing the trypanosome life cycle (Michels et al. 2006).
The life cycle regulation of organellar function is a
central component of the developmental biology of the
trypanosome, which entails extensive cellular remodel-
ing during passage from the mammalian blood to the mid-
gut of the tsetse fly, the parasite’s vector (Matthews 2005).
These differentiation events are triggered by exposure
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of bloodstream parasites to citrate/cis-aconitate (CCA)
(Czichos et al. 1986; Engstler and Boshart 2004). This
signal is transduced via a family of surface transporters,
PAD proteins (Dean et al. 2009), with signal recognition
being promoted by temperature reduction to 20°C—
conditions encountered upon uptake by feeding tsetse
flies (Engstler and Boshart 2004). PAD proteins are
expressed on the cell surface of stumpy forms, the stage
of the bloodstream parasite population adapted for trans-
mission to tsetse flies. Importantly, stumpy forms are
held ready for this developmental change by the action of
a tyrosine phosphatase, TbPTP1 (Szö}or et al. 2006), until
differentiation is triggered. Thus, the activity of TbPTP1
prevents stumpy forms from initiating differentiation
and, when this enzyme is inactivated after exposure to
either CCA or chemical inhibitors of PTPs, the cells dif-
ferentiate from bloodstream to procyclic forms (Szö}or
et al. 2006). This places TbPTP1 at the head of an intra-
cellular signaling pathway whose components are com-
pletely unknown.
Here we exploited a tyrosine phosphatase substrate
selection strategy to identify the downstream step in the
differentiation signaling pathway. This has identified a
glycosomally targeted DxDxT family Ser/Thr phospha-
tase, invoking the presence of a phosphatase signaling
cascade directing developmental regulation in trypano-
somes. Our findings provide the first evidence of de-
velopmentally regulated signal transduction via the gly-
cosome, and link the external differentiation stimulus
through this signaling pathway to control of the trypano-
some life cycle.
Results
TbPTP1 substrate is a novel DxDxT
phosphatase, TbPIP39
To identify potential substrates of TbPTP1, we exploited
the ability to generate mutant PTP enzymes, which bind
but do not release substrates (Blanchetot et al. 2005).
Specifically, His-tagged TbPTP1 was generated in which
residue 199, the catalytic aspartic acid in the predicted
WPD loop (Szö}or et al. 2006), was mutated to alanine.
This ‘‘substrate-trapping’’ mutant (TbPTP1-D199A) was
bound to a His trap chelating column, and was used to
select interacting proteins and substrates of TbPTP1 from
stumpy cell lysates. Mass spectrometry reproducibly
identified a selected protein encoded by a gene on chro-
mosome 9, Tb09.160.4460, this being almost identical
(339 out of 343 amino acids) to that encoded by its im-
mediately downstream gene (Tb09.160.4480), invoking
a gene duplication event. Tb09.160.4460 encodes a protein
with a predicted molecular mass of 39 kDa, this being
named TbPIP39 (TbPTP1-interacting protein, 39 kDa).
The TbPIP39 gene is well conserved in those kinetoplas-
tids that have been subject to genome sequence analysis,
although in Trypanosoma cruzi, Trypanosoma vivax, and
Leishmania major, it has not undergone gene duplication
(Supplemental Fig. 1).
To confirm the interaction between TbPTP1 and
TbPIP39, an antibody was raised to TbPIP39 and used to
probe the eluate from stumpy cell lysates incubated with
either His-tagged TbPTP1D199A or wild-type TbPTP1.
Figure 1A demonstrates that the binding of TbPIP39 to
the substrate-trapping TbPTP-D199A was much more
effective than to the wild-type protein (Fig. 1A, lanes 2,3).
To validate this interaction in vivo, transgenic blood-
stream forms were generated ectopically expressing wild-
type TbPTP1 or TbPTP1-D199A proteins, each with a
C-terminal Ty1 epitope tag (Bastin et al. 1996). Since
TbPIP39 expression is induced during differentiation (see
later), cells were treated with cis-aconitate for 24 h,
and Ty1-specific antibody was used to immunoprecipi-
tate TbPTP1. This revealed coimmunoprecipitation of
TbPIP39 with the TbPTP-D199A substrate-trapping mu-
tant, selection being blocked in the presence of a synthetic
peptide comprising the Ty1 epitope (Fig. 1B, cf. lanes 3
and 5). Matching the in vitro pull-down assay, TbPIP39
was selected less efficiently with wild-type TbPTP1 (Fig.
1B, cf. lanes 5 and 10), supportive of the interaction being
stabilized by the substrate-trapping mutation. Confirming
Figure 1. TbPTP1 interacts with TbPIP39 in vitro and in vivo.
(A) Substrate-trapping selection of TbPIP39 by TbPTP1. Wild-
type (WT) or substrate-trapping recombinant TbPTP1 (D199A)
was expressed as a His-tagged fusion protein and then bound to
a His trap chelating column. Lysate from 5 3 108 stumpy cells
was then passed over the column in order to select interacting
proteins. Bound material was eluted from the beads and reacted
with either antibody specific for the His tag (detecting the
TbPTP1 ligand), or TbPIP39. TbPIP39 was preferentially se-
lected by the D199A TbPTP1 substrate-trapping mutant. (B)
Wild-type or D199A TbPTP1-Ty was expressed in cultured
bloodstream form T. brucei, which were then induced to differ-
entiate to procyclic forms for 24 h by the addition of 6 mM cis-
aconitate. Immunoprecipitation was then performed using the
TY-1 epitope-specific antibody, which had been incubated either
with (‘‘blocked beads’’) or without a peptide sequence recog-
nized by the antibody. Input cell lysate, flow-through (ft), or
precipitated material (beads) from each immunoprecipitation,
either with or without blocking, was then reacted with the Ty1-
specific antibody (to detect the ectopically expressed TbPTP1
or D199A TbPTP1) or antibodies detecting TbPIP39 or aldolase
(as a negative control). The D199A-trapping mutant of TbPTP1
preferentially selected TbPIP39, whereas aldolase was not
selected.
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specificity, an unrelated protein, aldolase, was not cose-
lected by immunoprecipitation of the substrate-trapping
or wild-type TbPTP1 (Fig. 1B).
Examination of the sequence of TbPIP39 and its ortho-
logous sequences in related kinetoplastids revealed the
presence of a conserved predicted tyrosine phosphoryla-
tion site (Y278) toward the C terminus (Supplemental
Fig. 1A). Although the trypanosome genome encodes no
tyrosine-specific kinases (Parsons et al. 2005), a group-
based phosphorylation scoring analysis (Xue et al. 2005)
predicted that the Y278 residue could be phosphorylated
effectively in vitro by the human Gardner-Rasheed feline
sarcoma viral (v-fgr) oncogene homolog FGR kinase.
Confirming this, incubating recombinant TbPIP39 with
FGR kinase rapidly generated tyrosine-phosphorylated
TbPIP39 (Fig. 2A, left panel), whereas mutation of Y278
to phenylalanine (Y278F) in TbPIP39 prevented tyrosine
phosphorylation under the same conditions (Fig. 2A, right
panel). Tyrosine-phosphorylated TbPIP39 was then in-
cubated with either wild-type TbPTP1, or a catalytically
dead mutant of TbPTP1 in which the active site cysteine
was mutated to serine (C229S). Figure 2B demonstrates
that TbPIP39 was effectively dephosphorylated by wild-
type TbPTP1, but not by the inactive C229S mutant,
establishing that TbPIP39 not only interacted with sub-
strate-trapping TbPTP1 in cell lysates, but that it could
form a TbPTP1 substrate.
Regulatory interactions between TbPTP1 and TbPIP39
The protein sequence of TbPIP39 suggested that it was
a member of an unusual class of serine/threonine phos-
phatases, with a characteristic DxDx (T/V) motif toward
the N terminus of the predicted catalytic domain (Sup-
plemental Fig. 1A). This family of proteins comprises
FCP1/SCP1, responsible for the dephosphorylation of the
eukaryotic C-terminal domain of RNA polymerase II
(Kamenski et al. 2004), as well as several stress response
phosphatases, typified by the yeast haloacid dehalogenase-
type phosphatases PSR1/PSR2 (Siniossoglou et al. 2000)
and a phosphatase required in nuclear membrane bio-
genesis, Dullard (Kim et al. 2007). The catalytic activity of
this group of phosphatases depends on magnesium ions,
requiring the integrity of the DxDxT motif as the inter-
mediate phosphoryl acceptor (Collet et al. 1998). Con-
sistent with this, the activity of recombinant TbPIP39
against the artificial phosphatase substrate pNPP was
enhanced dramatically (P < 0.001) in the presence of
15 mM Mg2+ (Fig. 2C, columns 1,2). Moreover, when res-
idues 55D and 57D were each mutated to glutamic acid
(TbPIP39dEdE), no catalytic activity could be detected
under the same conditions (Fig. 2C, column 3).
To investigate the possibility that the tyrosine phos-
phorylation status of TbPIP39 might modulate its activ-
ity, the activity of TbPIP39 against pNPP was assayed at
time points after incubation with FGR kinase to generate
the tyrosine-phosphorylated form (Fig. 2D). As a control,
the nonphosphorylable TbPIP39 mutant (Y278F) was
incubated under the same conditions. TbPIP39 activity
was progressively enhanced with increasing phosphory-
lation, while the nonphosphorylatable mutant showed no
enhanced activity above its baseline activity. This con-
firmed that the activity of TbPIP39 was enhanced upon
Figure 2. TbPIP39 is a phosphatase with regulatory interaction
with TbPTP1. (A). Recombinant TbPIP39 was incubated with
FGR kinase to generate a tyrosine-phosphorylated form over the
course of 120 min. Tyrosine phosphorylation of the recombinant
protein was detected using the phophotyrosine-specific anti-
body 4G10 (a-pTyr; Millipore). The right panel shows the same
analysis using a mutant form of TbPIP39 in which the predicted
tyrosine phosphorylation site Y278 is mutated to phenylalanine
(F278). In this case, a-pTyr reactivity is lost. (B) Tyrosine-
phosphorylated TbPIP39 is a substrate of TbPTP1. TbPIP39
was incubated with FGR kinase to generate tyrosine-phosphor-
ylated protein, this being detected with the 4G10 antibody
(a-pTyr). Upon incubation with wild-type TbPTP1, tyrosine
phosphorylation of TbPIP39 is lost. In contrast, when incubated
with either buffer alone or a catalytically dead (C229S) TbPTP1
mutant, TbPIP39 remains phosphorylated. (C) Activity against
pNPP of recombinant TbPIP39 in the absence (column 1) or
presence (column 2) of Mg2+. Column 3 shows the same assay as
in column 2, using a dEdE mutant of TbPIP39. Columns 4–7
show the activity against pNPP of TbPTP1 alone (column 4) or
in the presence of 1 mg (column 5), 0.1 mg (column 6), or 0.01 mg
of TbPIP39. No Mg2+ was included in the reactions in columns
4–7, preventing TbPIP39 activity. Statistical analyses used a
general linear model. (*) P < 0.05; (**) P < 0.001. (D) Activity
against pNPP of recombinant TbPIP39 as it becomes tyrosine-
phosphorylated by FGR kinase. With increasing phosphoryla-
tion, the activity increases. (Right graphs) In TbPIP39-Y278F,
no enhanced activity is observed, demonstrating that tyrosine
phosphorylation on Y278 is responsible for TbPIP39 regulation.
The input recombinant proteins are those depicted in A. Sta-
tistical analyses used a general linear model. (*) P < 0.05.
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the phosphorylation of Y278, this site being the target of
TbPTP1 activity (Fig. 2B).
As well as TbPTP1 regulating TbPIP39 activity, we also
found evidence that TbPIP39 could reciprocally influence
the activity of TbPTP1. Thus, although 1 mg of TbPIP39
showed negligible activity against pNPP in the absence of
magnesium (Fig. 2C, column 1), when it was incubated
together with 0.1 mg of TbPTP1, the overall activity of the
combined phosphatase enzymes was significantly greater
than the activity of 0.1 mg of TbPTP1 alone (Fig. 2C, cf.
columns 1,4,5). Confirming that this was due to the
activity of TbPTP1, the same analysis using the inactive
D199A mutant of TbPTP1 generated no increase in
phosphatase activity (Supplemental Fig. 2). This demon-
strated that a positive interaction existed between
TbPTP1 and TbPIP39, such that TbPIP39 promoted the
activity of TbPTP1 when in significant molar excess.
In a final assay of the interaction between TbPIP39 and
TbPTP1, we investigated the effect on their respective
phosphatase activities of incubation with citrate, which
acts as a trypanosome differentiation trigger. This was
prompted by the structural analysis of the DxDxT class
phosphatase SCP1, which exhibits a citrate-binding pocket
(Kamenski et al. 2004), the required residues for which are
conserved in TbPIP39 (Supplemental Fig. 1A). Therefore,
we investigated the ability of citrate and the structurally
related differentiation trigger cis-aconitate to moderate
the activity of either TbPIP39 or TbPTP1, or the two
phosphatases in combination (Supplemental Fig. 3A,B,
columns 5–8). This demonstrated that both metabolites
produced a concentration-dependent reduction of the
enhanced phosphatase activity of TbPTP1/TbPIP39 when
combined. Eliminating the possibility that divalent cat-
ion chelation was responsible for this, citrate or cis-
aconitate had no effect on either TbPIP39 or TbPTP1 alone
(Supplemental Fig. 3A,B, columns 1–4,9–12).
Combined, these experiments demonstrated that
TbPIP39 showed less activity when nonphosphorylated;
i.e., as the product of TbPTP1 activity, whereas TbPIP39
could activate TbPTP1. Moreover, we found that this
regulatory interaction between TbPTP1 and TbPIP39 was
abolished by citrate and cis-aconitate, both of which act
as trypanosome differentiation stimuli.
Life cycle regulation and glycosomal location
of TbPIP39
TbPTP1 acts in stumpy forms to prevent the parasites
undergoing spontaneous differentiation to procyclic forms
(Szö}or et al. 2006). To investigate whether its substrate,
TbPIP39, was present at the same life cycle stage, the
RNA and protein expression of TbPIP39 was investigated
in bloodstream slender, bloodstream stumpy, and cultured
procyclic forms of T. brucei. Although the mRNA for
TbPIP39 was abundant in all life cycle stages (albeit
enriched in bloodstream stumpy forms) (Fig. 3A), TbPIP39
protein was barely detectable in slender forms, but was
expressed in stumpy and elevated during differentiation
and in procyclic forms (Fig. 3B; Supplemental Fig. 4A),
demonstrating regulation at the level of protein synthesis
or turnover. Interestingly, the migration of the TbPIP39
protein was altered between stumpy and procyclic forms
(Fig. 3B), there being a slightly higher-molecular-weight
form in the latter. This was expected to represent the
phosphorylated form of TbPIP39. To establish the tyrosine
phosphorylation status of TbPIP39 during differentiation,
Figure 3. TbPIP39 is a procyclic-enriched
glycosomal phosphoprotein. (A) Northern
blot of TbPIP39 expression in bloodstream
slender (Sl), bloodstream stumpy (St), or
cultured procyclic (Pro) forms. The bot-
tom panel shows the ethidium bromide-
stained rRNA, indicating loading. (B)
Western blot of TbPIP39 in bloodstream
slender (Sl), bloodstream stumpy (St), or
cultured procyclic (Pro) forms. In stumpy
forms, a lower-molecular-weight form is
observed, whereas in procyclic forms, a
higher-molecular-weight form predomi-
nates (arrowheads). The constitutively
expressed protein TbZFP3 (Paterou et al.
2006) is included as a loading control.
An empty intervening lane between the
stumpy and procyclic form samples has
been removed for clarity. (C) Digitonin
fractionation of procyclic and stumpy
form cells reacted with an antibody specific for TbPIP39, TbPIP39 (phospho-Y278), a glycosomal protein (aldolase), or a cytosolic
protein (cytosolic PGK). Exposures have been adjusted to best reveal the distribution between fractions for each protein and are not
equivalent between the distinct profiles. In each case, the digitonin concentration is shown with the cell extract being separated into
either soluble or pelleted (organellar) fractions. TbPIP39 cofractionates with glycosomal aldolase. A quantitative analysis of the
fractionation of procyclic forms is shown in Supplemental Figure 6. (D) Localization of TbPIP39 (red) with an N-terminal GFP fusion of
the glycosomal protein TbPEX13 (green). The two proteins colocalize precisely. DNA of the cells was counterstained using DAPI (blue).
Bar, 5 mm.
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an anti-peptide tyrosine phospho-specific antibody di-
rected to Y278 of TbPIP39 (ELD HWR TDE Y*TK C)
was generated. This revealed enhanced phosphorylation
of TbPIP39 within 120 min of exposure to cis-aconitate or
the tyrosine phosphatase inhibitor BZ3 (Supplemental Fig.
4B). Moreover, reactivity of the phospho-specific antibody
was lost upon treatment of procyclic cell extracts with
TbPTP1 (Supplemental Fig. 5B C), establishing Y278 as
the tyrosine phosphorylation site of TbPIP39 in vivo and
the target of TbPTP1. The expression of TbPIP39 was also
elevated in stumpy forms exposed to 20°C (Supplemental
Fig. 4C)—conditions that sensitize trypanosomes to the
differentiation stimuli CCA (Engstler and Boshart 2004),
and elevate the expression and surface distribution of
PAD2, one member of the protein family responsible for
conveying the CCA differentiation signal (Dean et al.
2009). Hence, the developmental expression, thermal reg-
ulation, and predicted phosphorylation profile of TbPIP39
matched expectations for a TbPTP1 substrate involved in
the differentiation control pathway.
When the cellular location of TbPIP39 was investigated
by immunofluorescence, a punctate staining was de-
tected, similar to that of trypanosome glycosomal pro-
teins. This was supported by the analysis of the TbPIP39
protein sequence, which exhibited a predicted C-terminal
peroxisomal location signal (PTS1) (SRL) (Supplemental
Fig. 1A; Opperdoes and Szikora 2006), and the detection
of TbPIP39 in purified procyclic form glycosomes by
proteomic analysis (Colasante et al. 2006). Nonetheless,
to verify that TbPIP39 associated with the glycosomes, we
assessed the fractionation of the protein under a digitonin
detergent titration. This demonstrated that TbPIP39
cofractionated with a glycosomal marker protein (aldol-
ase) in both procyclic and stumpy forms, this profile being
shared with the phosphorylated form of TbPIP39 detected
using the Y278 phospho-specific antibody (Fig. 3C; Sup-
plemental Fig. 6B). Confirming its association with gly-
cosomes, TbPIP39 colocalized with GFP in a transgenic
procyclic line expressing an N-terminal GFP fusion of
TbPEX13, a glycosomal import protein (Fig. 3D; Verplaetse
et al. 2009; the plasmid was a kind gift of P. Michels,
Brussels). Hence, by sequence prediction, biochemical and
cellular fractionation, and colocalization studies, TbPIP39
was identified as a glycosome-associated protein.
TbPIP39 RNAi inhibits differentiation
of bloodstream forms
To investigate whether TbPIP39 was a component of the
differentiation signaling pathway, its mRNA was ablated
by tetracycline-regulated RNAi. To assay early differen-
tiation events in a biologically relevant context, it was
important to assay stumpy cells capable of synchronous
differentiation to procyclic forms. Thus, the T. brucei
AnTat1.1 90:13 pleomorphic line was transfected with
the stem–loop RNAi vector pALC14 containing opposing
fragments of the TbPIP39 gene. A transfectant line was
then grown for 6 d in mice provided either without
(DOX) or with (+DOX) 200 mg/mL doxycyline in their
drinking water to induce transcript ablation, and hence
prevent TbPIP39 protein expression in developing
stumpy forms. Although TbPIP39 was ;85% depleted
in the +DOX parasites (Fig. 4A), no reproducible differ-
ence between the progression of the parasitaemia for the
uninduced (DOX) or induced (+DOX) parasites was
observed; moreover, both samples generated highly
enriched stumpy form populations within 6 d (Supple-
mental Fig. 7). This demonstrated that TbPIP39 was not
required for stumpy formation or viability. The stumpy
forms were then harvested and incubated for 16 h at
either 37°C or 20°C, the latter sensitizing the parasites to
physiological levels of CCA (i.e., ;0.1 mM) (Engstler and
Boshart 2004; Dean et al. 2009). Both the +DOX and
DOX populations were then exposed to 0 mM, 0.1 mM,
or 6 mM cis-aconitate in vitro and assayed for their
expression of the differentiation marker EP procyclin
after 4 and 24 h to detect effects on the initiation of
Figure 4. TbPIP39 depletion in stumpy forms inhibits differ-
entiation. (A) Western blots of TbPIP39 from samples derived
from TbPIP39-RNAi cells either induced (+Dox) or uninduced
(Dox) with doxycycline. Samples were incubated overnight at
20°C, and then proteins were isolated 0 h, 4 h, or 24 h after
exposure to 0 mM, 0.1 mM, or 6 mM cis-aconitate. The bottom
panels represent analysis of the same samples using an antibody
against a-tubulin as a loading control. (B) Flow cytometry traces
of EP procyclin expression in four independent stumpy cell
populations either induced (+Dox, orange and green traces) or
not (Dox, blue and red traces) to ablate TbPIP39 by RNAi.
Individual stumpy cell samples were derived from day 6 in-
fections of mice either with or without doxycyline in their
drinking water. Samples were incubated at 20°C before the ad-
dition of cis-aconitate, and flow cytometry was carried out
either 4 h or 24 h later. The induced populations showed re-
duced differentiation at 0.1 mM (4 h and 24 h); at 6 mM,
differentiation was efficient in all populations (likely enabled by
the remaining ;15% TbPIP39 in the RNAi line), although it
was delayed in the induced samples. Flow cytometry traces
from this experiment with cells incubated at 37°C are available
in Supplemental Figure 8.
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differentiation. Although the extent of TbPIP39 depletion
and the overall kinetics of EP procyclin expression in
different experiments varied, perhaps reflecting the
amount of remaining enzyme following RNAi (;15%),
the TbPIP39-depleted parasites showed reduced differen-
tiation with 0.1 mM cis-aconitate (mean, 58% reduction;
range, 52%–67% reduction at 24 h) (Fig. 4B), this effect
being consistent in five out of five experiments, whereas
at 6 mM cis-aconitate, an effect of TbPIP39 depletion was
observed in only two out of five experiments. Hence, the
depletion of TbPIP39 reduced the differentiation of
stumpy forms, with a reduction of sensitivity to physio-
logical levels of CCA. Being detected in uniform popula-
tions of cells before the onset of outgrowth as procyclic
forms, we conclude that TbPIP39 acts as a positive signal-
ing component operating downstream from, and nega-
tively regulated by, TbPTP1.
To confirm that the differentiation signaling response
required the glycosomal location of TbPIP39, we inves-
tigated the ability of mutants with a deleted or an epi-
tope tag-blocked C-terminal PTS1 signal to rescue the
TbPIP39 RNAi-mediated differentiation phenotype. To
achieve this, monomorphic bloodstream forms capable of
TbPIP39 RNAi (Supplemental Fig. 9) were engineered to
express recoded synthetic genes that would be immune to
RNAi, but encode proteins of the same amino sequence
as endogenous TbPIP39 (Supplemental Fig. 10A,B). Ini-
tially, the monomorphic TbPIP39 RNAi line was stimu-
lated to differentiate with cis-aconitate, demonstrating
reduced procyclin expression over 48 h when RNAi was
induced with tetracycline (Fig. 5A). When a wild-type
recoded TbPIP39 copy was coexpressed in the same line,
however, differentiation was fully restored, supporting
rescue of the phenotype (Fig. 5B). In contrast, the expres-
sion of TbPIP39DSRL or TbPIP39-C terminal Ty, both
of which were cytosolic by digitonin fractionation (Sup-
plemental Fig. 10C), failed to rescue the differentiation
phenotype (Fig. 5C,D), as did a catalytically inactive
(TbPIP39dEdE) TbPIP39 mutant (Fig. 5E). These observa-
tions support the glycosomal location and activity of
TbPIP39 being important for differentiation signaling.
Discussion
We demonstrated previously that the tyrosine phospha-
tase TbPTP1 acts as a ‘‘molecular brake’’ that prevents
differentiation of bloodstreams stumpy forms in the
mammalian bloodstream (Szö}or et al. 2006). In this study,
we identify a downstream substrate of TbPTP1 as a sec-
ond phosphatase, TbPIP39. TbPIP39 is shown to be a
developmentally regulated magnesium-dependent phos-
phatase whose activity is modulated by tyrosine phos-
phorylation. Moreover, we show that TbPIP39 contrib-
utes to the efficient differentiation to procyclic forms,
thereby invoking the existence of a phosphatase signaling
cascade regulating trypanosome development. Support-
ing this, we show regulatory cross-talk between TbPIP39
and TbPTP1 in vitro, this being abolished by the differ-
entiation regulators citrate and cis-aconitate. Finally, we
demonstrate that TbPIP39 is glycosomal, identifying this
molecule as a new marker for distinguishing bloodstream
from procyclic form glycosomes, and the first example of
a signaling molecule targeted to this fundamental meta-
bolic organelle in trypanosomes. To our knowledge, this
is the first well-characterized signaling pathway targeted
directly to a peroxisomal-type organelle in any eukaryotic
cell.
TbPIP39 was identified as an unusual type of Ser/Thr
phosphatase, a DxDxT phosphatase. This is an emerging
family of phosphatases, and one of a group of such phos-
phatases encoded in kinetoplastid genomes (14, 13, and 13
members, in T.brucei, T.cruzi, and L. major, respectively)
Figure 5. An intact glycosomal targeting signal is required for
TbPIP39-dependent differentiation. (A) T. brucei single-marker
bloodstream forms were transfected with the TbPIP39 RNAi
construct used in Figure 4. The resulting transfectant cell line
was then induced (blue) or not induced (red) to ablate TbPIP39
by incubation with 1 mg/mL tetracycline for 2 d. The RNAi-
depleted cells and the uninduced controls were then stimulated
to differentiate to procyclic forms by the addition of 6 mM cis-
aconitate and the expression of the differentiation marker EP
procyclin monitored by flow cytometry. Depletion of TbPIP39
resulted in reduced differentiation efficiency at 48 h after ex-
posure to cis-aconitate. (B) The same cell line as in A was
transfected with pHD451 expressing an intact recoded synthetic
TbPIP39 gene, expressed under tetracycline regulation. Cells
were grown with tetracycline for 2 d, allowing silencing of the
endogenous TbPIP39 transcript and expression of the recoded
gene. Differentiation was then monitored for EP procyclin ex-
pression 48 h after exposure to 6 mM cis-aconitate using flow
cytometry. The differentiation phenotype was fully rescued. (C)
As in B, but the recoded synthetic gene product lacked the DSRL
glycosomal targeting signal and redistributed to the cytosolic
fraction (Supplemental Fig. 10C). In this case, the differentiation
defect was not rescued. (D) As in B, but the recoded synthetic
gene product contained a Ty1 epitope tag after the DSRL
glycosomal targeting signal. As with the truncated mutant,
the protein was redistributed to the cytosolic fraction (Supple-
mental Fig. 10C) and the differentiation defect was not rescued.
(E) As in B, but the recoded synthetic gene product was mutated
for the DxDxT motif (to ExExT) to prevent catalytic activity. No
rescue of the differentiation defect was observed.
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(Brenchley et al. 2007), but the only representative pos-
sessing a predicted PTS1. Consistent with expectations
for this class of molecules (Selengut and Levine 2000;
Ndubuisil et al. 2002), TbPIP39 showed magnesium-
dependent activity, with its activity being abolished by
mutation of the predicted magnesium-coordinating as-
partate residues in the DxDxT phosphoryl acceptor motif
(Collet et al. 1998). Interestingly, however, when TbPIP39
was coincubated with TbPTP1, the overall phosphatase
activity of the combined enzymes was elevated over their
predicted additive values. Since the effect was observed
with inactive TbPIP39 (i.e., in the absence of magnesium)
and was not recapitulated when TbPIP39 was incubated
with a catalytically dead C229S mutant of TbPTP1, we
assign the enhanced phosphatase activity of TbPTP1/
TbPIP39 to an activation of TbPTP1. While being poten-
tially muted by the relatively high levels of citrate in the
Escherichia coli expression system (;5 mM), we ob-
served that the activation of recombinant TbPTP1 re-
quired a 10-fold excess of its substrate, TbPIP39, in vitro.
In vivo, the physiological interactions between the pro-
teins could be enhanced significantly by their relative
context or the presence of associated proteins in the cell,
but nonetheless TbPIP39 is in considerable excess of
TbPTP1 in stumpy forms (Supplemental Fig. 4D). Hence,
TbPIP39 is predicted to promote its own dephosphoryla-
tion by activating TbPTP1. Given our finding that the
Y278-phosphorylated form of TbPIP39 shows greater
phosphatase activity than its unphosphorylated form,
these observations combine to generate a feedback loop
whereby TbPIP39 reinforces its own dephosphorylation,
and hence repression, by activating TbPTP1.
Although TbPTP1 was found to be a cytosolic/
cytoskeletally associated protein (Szö}or et al. 2006), its
substrate, TbPIP39, was found to be glycosomally asso-
ciated. This apparent paradox can be resolved by consid-
ering the maturation of proteins as they are trafficked to
peroxisome-related organelles, such as glycosomes. Such
proteins are initially translated in the cytosol and then
folded. The peroxisomal targeting signal is then recog-
nized, and the protein is translocated to the peroxisome
membrane where it is imported via peroxins to the
lumen. This passage through the cytosol, from synthesis
to import, has been measured to take from 5 to 60 min
(McNew and Goodman 1994; Terlecky et al. 2001), pro-
viding ample opportunity for TbPIP39 to be phosphory-
lated or dephosphorylated prior to glycosome targeting.
Based on our experiments, we propose a new model for
the early steps in trypanosome differentiation (Fig. 6). In
stumpy forms, TbPIP39 would be synthesized, but held
relatively inactive through its dephosphorylation by
TbPTP1, this being reinforced by the enhanced activity
of TbPTP1 generated by its substrate when in excess.
When trafficked to the glycosome, dephosphorylated,
inactive TbPIP39 would not stimulate differentiation.
When entering the tsetse, however, temperature reduc-
tion to 20°C would facilitate CCA transport into the cell
via PAD expression (Dean et al. 2009). If matching our
in vitro observations, this would prevent the feedback
activation of TbPTP1 by TbPIP39, although CCA may
also inhibit TbPTP1 indirectly through other unknown
mechanisms. Combined with the enhanced expression of
TbPIP39 at low temperature, this would increase the
level of phosphorylated TbPIP39, which, upon entry to
the glycosome, would promote differentiation.
The proposed pathway is reminiscent of cell fate de-
cision pathways in other eukaryotes, whereby phosphor-
ylation–dephosphorylation events coordinate a transition
from one stable state to another—a so-called bistable
switch (Pomerening et al. 2003; Ingolia and Murray 2007).
In this case, the activation of TbPTP1 by TbPIP39 would
repress differentiation by enhancing the dephosphoryla-
tion of TbPIP39, whereas exposure to CCA would allevi-
ate this repression, favor TbPIP39 phosphorylation, and
so stimulate differentiation. Importantly, the sequestra-
tion of phosphorylated TbPIP39 in the glycosomal com-
partment would protect it from further TbPTP1 activity,
rendering its activation irreversible. Although metabolic
regulation via phosphorylation represents an obvious
point of downstream control (Christofk et al. 2008) and
is a known regulator of differentiation events (Milne et al.
1998; Morris et al. 2002), glycosomes are predicted to
comprise >200 distinct proteins (Colasante et al. 2006;
Opperdoes and Szikora 2006) associated with ether lipid
biosynthesis, the b oxidation of fatty acids, purine sal-
vage, pyrimidine biosynthesis, gluconeogenesis, and iso-
prenoid biosynthesis, in addition to glycolysis. Several
identified DxDxT phosphatases, including Dullard, a reg-
ulator of mammalian nuclear membrane biogenesis,
exhibit lipid phosphatase activity (Kim et al. 2007; Reddy
et al. 2008), suggesting that these enzymes may have the
potential to regulate second messenger signaling path-
ways. Hence, any one, or several, of the trypanosome
Figure 6. A model depicting the regulatory interactions be-
tween TbPTP1 and TbPIP39 when exposed to the differentiation
triggers citrate or cis-aconitate. The CCA signal is conveyed by
PAD proteins expressed on the surface of stumpy forms. This
inhibits the activation of TbPTP1 by TbPIP39, although
TbPTP1 may also be inactivated indirectly. Upon the inactiva-
tion of TbPTP1, phosphorylated TbPIP39 predominates, this
being generated by an unidentified protein kinase. TbPIP39,
activated by phosphorylation, is directed toward the glycosomes
by its C-terminal PTS1 signal, and therein promotes a differen-
tiation response.
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glycosomal activities may be regulated by TbPIP39 with
consequences independent of, or indirectly linked to
(Chambers et al. 2008), metabolism.
The existence of signaling pathways directed to perox-
isome-like organelles, and specifically glycosomes, has
been proposed previously (Albert et al. 2005; Michels and
Rigden 2006). Our experiments establish that such a path-
way exists, comprising a phosphatase signaling cascade
that drives an early step in cell type differentiation in
African trypanosomes. Moreover, the bistable regulation
of this pathway by the physiological conditions encoun-
tered during stumpy form transmission suggests a new
elegance to trypanosome developmental control, linked
to the biology of their key metabolic organelle, the
glycosome.
Materials and methods
Parasite growth and transfection
Bloodstream form and procyclic form trypanosomes were cul-
tured in vitro in HMI-9 medium (Hirumi and Hirumi 1984) or
SDM-79 medium (Brun and Schonenberger 1979), respectively.
Culturing, differentiation, pleomorphic trasnfection, and cold-
shock assays of parasites were performed as described in Dean
et al. (2009) using the T. brucei AnTat1.1 90:13 cell line (Engstler
and Boshart 2004), transfectants being generated using an
AMAXA nucleofector protocol (T-cell nucleofection buffer, pro-
gram X001) and selected using 0.5 mg mL1 puromycin. Stumpy-
enriched populations were obtained by DEAE cellulose purifi-
cation (Lanham 1968) of parasites 6–7 d after infection into
cyclophosphamide-treated mice.
For ectopic expression, T. brucei Lister 427 bloodstream forms
were used, these being engineered previously to express the
tetracycline repressor protein (Wirtz et al. 1999), enabling reg-
ulated gene expression of wild-type or substrate-trapping forms
of TbPTP1 (Szö}or et al. 2006). Established, cultured procyclic
forms were T. brucei Lister 427.
A transgenic procyclic line expressing an N-terminal GFP
fusion of PEX13, a glycosomal import protein, was created by
transfection of a previously characterized expression plasmid
kindly provided by Paul Michels (Université Catholique de
Louvain, Brussels) (Verplaetse et al. 2009).
DNA cloning
The TbPIP39 coding region was amplified using TbPIP39-specific
primers Primer 1 (see Table 1) and Primer 2, and was integrated
into the pGEX4T1 (GE Heathcare Lifesciences) protein expres-
sion vector for recombinant protein production. Primer 3 and
Primer 4 (see Table 1) were used to insert TbPIP39 into the
pHD451 trypanosome ectopic expression vector (Biebinger et al.
1997). The pGEX4T1TbPIP39 construct was used as a template
for site-directed mutagenesis in order to mutate TbPIP39 Tyr
278 to phenylalanine (abbreviated Y278F TbPIP39). This was
carried out using a commercial site-directed mutagenesis kit
(Stratagene) using the mutagenesis primers Primer 5 and Primer
6 (see Table 1). Recoded synthetic genes (Supplemental Fig. 10)
were synthesized by Geneart (http://www.geneart.com), re-
cloned into pHD451, and transfected into monomorphic cells
already containing the pALC14TbPIP39 RNAi plasmid as a sta-
ble integrant.
Generation of TbPIP39 RNAi cell line
The TbPIP39 reading frame was amplified from genomic DNA
by PCR using Primer 7 and Primer 8 (Table 1), and was integrated
into the HindIII–XbaI and XhoI–NdeI cloning sites of pALC14
(Pusnik et al. 2007) to generate the pALC14TbPIP39 RNAi
plasmid.
Antibody production
Polyclonal antibody was produced in rabbits against full-length
recombinant TbPIP39 by Eurogentec; an anti-peptide phospho-
278YTbPIP39 antibody was raised in rabbits against the se-
quence N-ELDHWRTDE-[phospho]Y-TKC-C from the amino
acid sequence at position 269–281 in TbPIP39 (Eurogentec).
The resulting antibody was affinity-purified against the phos-
phorylated peptide immunogen, and was counterselected against
the nonphosphorylated peptide to maximize specificity.
Substrate trapping with TbPTP1D199A
The production and purification of the substrate-trapping mu-
tant of TbPTP1 (TbPTP1D199A) was described in Szoor et al.
(2006). Purified His-TbPTP1D199A was mixed with His chelat-
ing Ni-NTA Agarose beads (Qiagen) for 30 min at 4°C. The beads
were then collected by centrifugation and washed three times
with ice-cold His purification lysis buffer (20 mM Tris, 250 mM
NaCl, 1% Triton-X, 1 mM b mercaptoethanol, 5 mM Imidazole
at pH 7.5–8) supplemented with complete, and EDTA-free pro-
tease inhibitor cocktail (Roche).
Approximately 5 3 108 DEAE-purified T. brucei stumpy cells
were harvested by centrifugation, and the cell pellet was frozen
in liquid nitrogen. Cells were then lysed in the presence of
150 mM PTP1B inhibitor BZ3 (Calbiochem) by addition of
500 mL of His purification lysis buffer supplemented with com-
plete, and EDTA-free protease inhibitor cocktail (Roche). The
extract was lysed by two freeze/thaw cycles at80°C, centrifuged
for 20 min at 4°C in a microfuge, and then sonicated for 3 min in
a water bath. Quantification of cellular protein was performed by
the Bradford method following the manufacturer’s instructions.
Table 1. Oligonucleotides used in the study
Oligonucleotide name Sequence
Primer 1 (BamHI Fwd) 59-TATGGATCCATGGTGAGGACGACACGCTTTTC-39
Primer 2 (XhoI Rev) 59-ATACTCGAGCTAAAGTCTTGAAGGAGTGTGTC-39
Primer 3 (HindIII Fwd) 59-TATAAGCTTATGGTGAGGACACGCTTTTC-39
Primer 4 (BamHI Rev) 59-ATAGGATCCCTAAAGTCTTGAAGGAGTGTGTC-39
Primer 5 (Y278F Fwd) 59-CCATTGGCGTACGGATGAGTTCACAAAGTGTGACGACTTTCG-39
Primer 6 (Y278F Rev) 59-CGAAAGTCGTCACACTTTGTGAACTCATCCGTACGCCAATGG-39
Primer 7 (HindIIIBamHIFwd) 59-ATAAAGCTTGGATCCGTGAGGACGACACGCTTTTCACG-39
Primer 8 (XhoINdeI Rev) 59-TGCCATATGCTCGAGGGGAGTTGTAACACCTGCACCTCC-39
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Approximately 0.5 mg of fresh cell extract was incubated for
1.5 h on ice with 20–30 mL of Ni-NTA beads coated with His-
tagged protein; nonspecific interactions were removed by wash-
ing the beads three times with 1 mL of 20 mM Tris, 250 mM
NaCl, and 20 mM imidazole (pH: 8.0), and the bound proteins
were eluted by addition of SDS-PAGE sample buffer.
Mass spectrometry
Eluate from substrate-trapping columns was separated by SDS-
PAGE, and Coomassie Blue-stained bands were excised and
washed in 100 mM ammonium bicarbonate with shaking for
1 h at room temperature, followed by a second wash in 50%
acetonitrile/100 mM ammonium bicarbonate. Proteins were
reduced with 3 mM DTT in 100 mM ammonium bicarbonate
for 30 min at 60°C, followed by alkylation with 10 mM
iodoacetamide for 30 min in the dark at room temperature.
The gel pieces were washed with 50% acetonitrile/100 mM
ammonium bicarbonate, shaking for 1 h at room temperature,
and then were dehydrated by incubation with 0.1 mL of ace-
tonitrile for 10 min at room temperature. All liquid was removed
and gel pieces were dried to completion under vacuum, then
rehydrated with a sufficient volume of trypsin (Promega se-
quencing grade, 2 mg/mL in 25 mM ammonium bicarbonate) to
cover the gel pieces. Digestion was performed overnight at 37°C,
the gel pieces washed for 10 min with 0.02 mL of 1% formic acid,
and then 0.02 mL acetonitrile was added. After 10 min of in-
cubation, all liquid was transferred to a fresh tube, and the tryp-
tic peptides were dried to completion.
Tryptic peptides were solubilized in 0.5% formic acid and 2%
acetonitrile, and were fractionated on a nanoflow HPLC system
(Famos/Switchos/Ultimate, LC Packings) before being analyzed
by electrospray ionization (ESI) mass spectrometry on a Q-STAR
Pulsar i hybrid MS/MS System. Peptide separation was per-
formed on a Pepmap C18 reversed-phase column (LC Packings)
using a 5%–85% v/v acetonitrile gradient (in 0.5% v/v formic
acid) run over 45 min. The flow rate was maintained at 0.2 mL per
minute. Mass spectrometric analysis was performed using a 3-sec
survey MS scan, followed by up to four MS/MS analyses of
the most abundant peptides (3 sec per peak) in Information-
Dependent Acquisition (IDA) mode, choosing 2+ to 4+ ions above
threshold of 30 counts, with dynamic exclusion for 120 sec.
Mass spectrometry data was analyzed using Applied Biosys-
tems Analyst QS (version 1.1) software and the automated
Matrix Science Mascot Daemon server (version 2.1.06). Protein
identifications were assigned using the Mascot search engine,
with carbamidomethylation of cysteines and variable methio-
nine oxidation being allowed. An MS tolerance of 1.2 Da for MS
and 0.4 Da for MS/MS analysis was used. Searches were
performed against the T. brucei genome database (version 3) ob-
tained from the Wellcome Trust Sanger Institute and maintained
on a local Mascot server.
Digitonin permeabilization assay
Approximately 5 3 108 procyclic forms were collected to per-
form digitonin permeabilization. The cell suspension was di-
luted to ;1 mg of total protein per milliliter, and increasing
amounts of digitonin (0.01–5 mg/mg total protein) were used in
digitonin assays according to Ferella et al. (2008).
Immunoprecipitation
Transgenic bloodstream form cell lines in which either wild-type
TbPTP1 or TbPTP1-D199A proteins were expressed ectopically
with a C-terminal Ty1 epitope tag sequence (Szö}or et al. 2006)
were treated with 6 mM cis-aconitate for 24 h. Immunoprecip-
itation was carried out using 1 3 108 to 5 3 108 cells as described
in Paterou et al. (2006).
Western and Northern blotting
Western blotting and Northern blotting was performed as de-
scribed in Tasker et al. (2000). For Western blotting, primary
antibodies were diluted 1:1000 and secondary antibodies were
diluted 1:5000. Proteins were detected using the LI-COR Odys-
sey system for quantification against a tubulin or loading con-
trol as described in Dean et al. (2009). For Northern blots, a
digoxygenin-labeled TbPIP39-specific riboprobe (Roche) was
used, hybridization being detected using CDP-star as a reaction
substrate.
Phosphatase and kinase activity assays
Phosphatase activity was measured by monitoring the TbPIP39-
catalyzed and TbPTP1-catalyzed (0.01–1 mg) hydrolysis of pNPP
to p-nitrophenol (Szö}or et al. 2006). Phosphorylation of recombi-
nant TbPIP39 by FGR kinase was performed according to the
manufacturer’s instructions (Calbiochem). The reaction, con-
taining purified TbPIP39 (5 mg), was initiated with the addition of
FGR kinase, and samples were taken at time points after in-
cubation (0, 30, 60, 90, 120, 240 min) at 30°C for Western blots.
After the 240-min time point, the remainder of the phosphory-
lation mixture was loaded on a GSTrap HP column (GE Health-
care Life Sciences) to remove the GST-tagged FGR kinase. After
collection of the flow-through from the column containing the
phosphorylated TbPIP39, the sample was concentrated on Viva-
spin 2 columns with a 10-kDa-molecular-weight cutoff (Sarto-
rius AG) before use in the in vitro TbPTP1 phosphatase assay.
In vitro TbPTP1 phosphatase assay
To monitor phosphatase activity of phosphorylated TbPIP39, the
concentrated phosphorylated TbPIP39 was treated with either
1 mg of active wild-type TbPTP1 or the same amount of inactive
C229S TbPTP1 mutant in a 100-mL phosphatase assay (50 mM
Tris, 50 mM Bis Tris, 100 mM Na acetate, 1mM DTT at pH 5.5).
The phosphatase reaction was started with the addition of
TbPTP1, and, after 30 min of incubation at 37°C, 20-mL samples
were removed for Western blot.
Flow cytometry and immunofluorescence
Differentiating cells (2 3 106 to 5 3 106) were harvested and fixed
in 2% formaldehyde/0.05% glutaraldehyde for a minimum of 1 h
at 4°C. Antibody staining was executed according to Dean et al.
(2009). Flow cytometry analysis was performed using the BD
LSRII Flow cytometer (Becton Dickenson), and flow cytometry
data was analyzed using FlowJO 8.8.6 software (Tree Star, Inc.)
with unstained cells; cells stained with only the secondary
antibody provided negative controls. For immunofluorescence,
air-dried smears of parasites were prepared and fixed in methanol
for at least 30 min at 20°C. Cells were rehydrated in PBS for
30 min before labeling, as described in Dean et al. (2009).
Image acquisition equipment and settings
Phase-contrast and immunofluorescence microscopy images
(Supplemental Fig. 7A) were captured on a Zeiss Axioskop2 (Carl
Zeiss Microimaging) with a Prior Lumen 200 light source using
a QImaging Retiga 2000RCCD camera; objectives were either
Plan Neofluar 363 (1.25 NA) or Plan Neofluar 3100 (1.30 NA).
Szö}or et al.
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Images were captured via QImage (QImaging). Confocal imaging
(Fig. 3D) used a Leica SP5 confocal laser scanning microscope,
using 363 oil immersion objective (NA = 1.4), with 4.2 zoom.
The green channel was imaged using a 488-nm argon laser, and
the red channel was imaged using a 543-nm helium/neon laser.
The final image was acquired using Volocity Software (Improvi-
sion Ltd.) version 4.4.
Acknowledgments
We thank Achim Schnaufer for comments on the manuscript
and for suggesting the use of recoded synthetic genes, Paul
Michels for TbPEX13-GFP construct, and Michael Boshart
and Markus Engstler for the gift of the T. brucei AnTat1.1
90:13 line. We also thank Martin Waterfall for assistance with
FACS analysis. This work was supported by grants from the
Wellcome Trust, the BBSRC (for the provision of confocal
facilities), and by a Strategic Award from the Wellcome Trust
for the Centre for Immunity, Infection, and Evolution.
References
Albert MA, Haanstra JR, Hannaert V, Van Roy J, Opperdoes FR,
Bakker BM, Michels PA. 2005. Experimental and in silico
analyses of glycolytic flux control in bloodstream form
Trypanosoma brucei. J Biol Chem 280: 28306–28315.
Bakker BM, Mensonides FI, Teusink B, van Hoek P, Michels PA,
Westerhoff HV. 2000. Compartmentation protects trypano-
somes from the dangerous design of glycolysis. Proc Natl
Acad Sci 97: 2087–2092.
Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC,
Cazzulo JJ, Krishna S. 2003. The trypanosomiases. Lancet
362: 1469–1480.
Bastin P, Bagherzadeh Z, Matthews KR, Gull K. 1996. A novel
epitope tag system to study protein targeting and organelle
biogenesis in Trypanosoma brucei. Mol Biochem Parasitol
77: 235–239.
Biebinger S, Wirtz LE, Lorenz P, Clayton C. 1997. Vectors for
inducible expression of toxic gene products in bloodstream
and procyclic Trypanosoma brucei. Mol Biochem Parasitol
85: 99–112.
Blanchetot C, Chagnon M, Dubé N, Hallé M, Tremblay ML.
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